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ABSTRACT 
DNA repair plays a critical role in maintaining the integrity of the genome and the 
dysregulation of key DNA repair genes has been implicated in the development, progression 
and chemotherapeutic resistance of different cancer types. Consequently, many studies have 
made attempts to identify and quantify the expression of various DNA repair genes and their 
products in different cancers. It is on a similar note that this research was conceived, to 
evaluate the expression patterns of the base excision repair genes Neil1, Neil2, Neil3, Ogg1, 
and Nthl1, the nucleotide excision repair gene Ercc1 and the mismatch repair gene Mlh1 in 
colorectal cancer (CRC) tumours and matched normal colon tissue. The project was then 
extended to analyse a further sixteen colon samples that focused on Neil3, Nthl1 and Ercc1, 
that encode DNA repair proteins that have been implicated in chemotherapy resitance 
mechanisms. To learn more about mechanisms of genotoxic agent resistance, Neil3 and 
Ercc1 were analysed at the transcriptome and proteome level in DAOY medulloblastoma 
cells and cisplatin – resistant DAOY cells. Additionally, attempts were made to generate 
mesothelioma-derived cancer stem cells and preliminary gene expression analyses were 
undertaken on human embryonic stem cells. Thus, RNA was extracted, complementary 
DNA synthesized, and RT-PCR performed. Gene expression levels were determined by 
quantitative PCR using the Sybr green method and analysed using the comparative Ct 
method and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) as the standard. Of the 
matched samples investigated, 75% showed increased expression of one or more of the DNA 
repair genes analysed, however, there was no clear pattern of expression and a wide range 
of expression levels observed for individual genes in both normal and tumour tissues. For 
example, the gene encoding the DNA glycosylase Nthl1 was the most frequently highly 
expressed in both normal and tumour samples with about 75% showing high expression of 
the Nthl1 gene with expression levels ranging from 3.3 to over 1400-fold higher than Gapdh. 
DAOY cells were grown in cisplatin and gene expression of Neil3 and Ercc1 analysed in 
the resulting cisplatin - resistant cells. Results indicated that the expression of both these 
genes may be increased in the resistant cell line and that NEIL3 protein was also increased. 
Cancer stem cells were derived from parental mesothelioma cells but were still too small a 
fraction of the cell population to be analysed by these methods. The expression of Gapdh, 
Neil3 and Ercc1 was determined in a series of preliminary experiments on human embryonic 
stem cells. 
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1.1. General introduction 
In a multicellular organism, the constituent cells undergo cell division as a reproductive 
mechanism, resulting in the formation of well organised and collaborative entities known as 
tissues. These cells are subject to a strictly regulated form of collaboration, characterized by 
selflessness and apparently devoid of competition. Hence, at any point in time, each cell is 
either, resting, growing, differentiating, dividing, or dying, as needed; and for the benefit of 
the other cells that made up the organism. Thus, a form of social control network oversees 
cellular behaviours, including cell-to-cell communication, such as relay, receipt and 
interpretation of sets of intracellular, as well as extracellular signals in an elaborate manner 
(Tlsty and Coussens, 2006). Disregard to the sense of community or any attempt to evade 
the cell cycle system that controls the timing of cell division by a cell, or group of cells, 
could pose serious problems for the organism. Additionally, molecular disturbances such as 
genetic mutations, may selectively confer undue advantage on a given cell or group of cells 
that may result in the cells growing more rapidly, differentiating and dividing more rapidly 
and evading death signals (Hanahan & Weinberg, 2000). Consequently, the selectively 
advantaged cells may become the progenitor of a vigorously growing mutant clone, 
initiating selfishness and encouraging competition. Through repeated mutations, the mutant 
clones could engage in serious competition, and natural selection could usher in dangerous 
cell population, and subsequent tumour development. This is known as the mutator 
phenotype and is probably the main theory of cancer development (Loeb, 2001). 
From the foregoing, cancers could be defined as heterogeneous multicellular assemblages, 
made up of cells of different origins, interacting with each other and the extracellular signals 
in complex fashions that encourage the dysfunction of cell cycle control. Essentially, cancer 
is a disease that arises from the disruption of cellular and genetic functions. Although, cancer 
development is a multistep process, it ultimately results from changes in the genome, in 
which intrinsic cellular functions including apoptosis, cell differentiation, metabolism, cell 
cycle check-point control and cell adhesion; immunological response, as well as status of 
the vasculature are affected (Hanahan & Weinberg, 2011). In fact, reports from human 
cancer studies and animal models have clearly demonstrated that during the process of 
tumorigenesis, a range of genetic changes take place, each conferring a given type a 
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specialized competitive advantage, resulting in the successive and progressive change of 
normal human cells into cancer cells (Loeb, 2001). The heterogeneous nature of cancer 
accounts for the prevalence of many different types, each displaying different combinations 
of characteristic cellular and genetic changes. Even within a single type of cancer, 
heterogeneity and tumour subsets that are uniquely defined can be identified (De Sousa et 
al., 2013).  
The increasing incidence of cancers is alarming, and cancer has become one of the major 
factors responsible for disease-related deaths globally (Kanavos, 2006). This high death rate 
could be attributed to the inherent abilities of cancer cells to resist chemotherapy, metastatic 
ability and high degree of immortality with concomitant recurrence capacity. Current 
treatments include conventional therapies such as surgery, radiotherapy and chemotherapy 
(Banerjee et al., 2017; Huang et al., 2017). In the past decade, immuno-gene therapy has 
been introduced as the fourth treatment modality, due to its robustness and promises (Parney 
& Chang, 2003). Unfortunately, irrespective of the availability of these variety of options 
for the treatment of cancer, it is still daunting to define an effective treatment regimen to 
cure patients especially those whose cancers have metastized to distant organs. This can be 
linked to resistance to therapy and relapse associated with most cancers (Zahreddine & 
Borden, 2013).  
Nevertheless, studies that target the discovery of molecular pathways that promote tumour 
growth have improved our understanding of this disease and has revolutionized the way 
cancer cells can be targeted (Sinicrope et al., 2016). Today, several mechanisms that 
contribute to the development of cancer have been elucidated, indicating a difference in the 
dynamics and characteristics of normal cells compared to cancer cells (Hanahan & 
Weinberg, 2011; Turkson, 2017). Whereas normal tissues maintain tissue integrity and 
function by balancing the signals that are involved in cell growth and cell division, cancer 
cells exhibit both dysregulated proliferative signalling and replicative immortality, thus 
giving them a growth and survival advantage (Hanahan and Weinberg, 2000, 2011). Unlike 
cells under normal physiological conditions, cancer cells employ several mechanisms to 
achieve uncontrolled proliferation and DNA replication, most of which involve a subset of 
the regulatory instructions transmitted by an activated receptor acting as an oncogene 
(Vogelstein & Kinzler, 2014). Cancer cells up-regulate growth factor ligands and stimulate 
normal cells to release factors that can support cancer growth, up-regulate receptor proteins 
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that render cells hyperresponsive to growth factor ligands and structurally alter receptor 
molecules that facilitate ligand-independent cell division (Cheng et al., 2008). 
In the last decades, evaluation of several human tumours has implicated somatic and 
germline mutations as additional downstream pathways by which cancer cells sustain 
immortality (Stratton et al., 2009; Davies and Samuels, 2010). To contribute to the global 
quest to conquer cancer, this PhD project sought to investigate the expression patterns of 
selected DNA repair genes in different cancer types, including colorectal cancer (CRC) and 
medulloblastoma. However, the thesis begins with a brief review of DNA damage, some of 
which is pre-mutagenic and therefore thought to be a prerequisite for carcinogenesis. This 
is followed by a review of DNA repair mechanisms that are found in mammalian cells. Many 
of the proteins involved in DNA repair are tumour suppressor genes and individuals lacking 
particular DNA repair functions are often more cancer prone. Next, a synopsis of each of 
the cancer types employed in this research is presented, followed by an introduction to stem 
cells. While preliminary experiments presented here were carried out on human embryonic 
stem (ES) cells, the concept of cancer stem cells is the focus of much research to find more 
effective treatments (Dawood et al., 2014). 
1.2. DNA Damage 
DNA is the active molecule of an organism and serves as a repository of genetic information. 
Since DNA plays a major role in replication and transcription, its integrity and stability at 
any time is a prerequisite for evolutionary fitness and for the health of the individual 
organism.  An individual cell can receive up to one million DNA alterations daily. Some of 
these changes are spontaneous, such as the loss of a purine base from the double-stranded 
DNA molecule (depurination) and deamination, where the amino group is lost from cytosine 
and adenine (see Pierce, 2017 for review). However, other DNA damage results from 
exposure to endogenous and environmental genotoxic agents that can cause a multitude of 
chemical alterations to the DNA molecule. Thus, the resultant effect on the DNA molecule 
can range from many different forms of DNA base damage, bulky adducts attached to bases, 
single- and double-strand breaks and intra-strand and inter-strand DNA cross-links. Some 
of these DNA lesions will be pre-mutagenic, leading to permanent changes in the genomic 
DNA sequence, while others will be toxic and cause cell death at the next round of DNA 
replication due to collapse of the replication fork (Friedberg et al., 2005). 
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While the inherent lability of the DNA molecule can be beneficial, such as in the process of 
natural selection in evolution, it can also be deleterious to the cell and organism, resulting 
in altered pathology. Thus, deleterious DNA changes can cause genomic instability and 
challenge the stability and integrity of the organism (Pierce, 2017). 
Several endogenous and exogenous agents responsible for insults on DNA have been 
described. The most common exogenous or environmental DNA-damaging agents are 
ultraviolet (UV) radiation, chemical agents and chemotherapeutic drugs. Some of these will 
result in disease conditions such as cancer. For instance, it is well known that skin cancers 
are the result of exposure to UV light (Seebode et al., 2016) and lung cancer is largely a 
consequence of cigarette smoke inhalation (Doll and Bradford-Hill, 1950). Related to this, 
it has also been reported that colon epithelial cells are also prone to exogenous mutagens, 
many resulting from normal metabolism of ingested material (Greenman et al., 2007). 
Apart from the afore-mentioned exogenous sources of DNA damage, cellular DNA is also 
under constant attack from endogenous agents such as reactive oxygen species (ROS) 
produced as a consequence of normal aerobic metabolism or resulting from inflammatory 
cytokines that leads to a state of oxidative stress (Federico et al., 2007). However, another 
source of DNA damage comes from the replicative DNA polymerases. During DNA 
replication, the enzyme DNA polymerase adds a nucleotide to the strand of the DNA (Pierce, 
2017). However, the DNA polymerase can add incorrect nucleotides during DNA 
replication and although the main replicative DNA polymerases have a 3ʹ - 5ʹ "proofreading" 
exonunclease activity and can recognize and correct many of these errors, inefficient 
corrections could lead to mutations that can in turn result in disease conditions such as cancer 
(Pierce, 2017). 
As mentioned, endogenous agents such as ROS play an important role in reactions resulting 
in DNA damage (Durand & Storz, 2017).  The key ROS that are of importance include the 
superoxide radical (O2
−), hydrogen peroxide (H2O2) and the hydroxyl radical, (
•OH) 
(Beckman & Ames, 1997; Hazra et al., 2007). Although, the physiological role of ROS in 
cells is evident in the maintenance of homoeostasis (Hancock et al., 2001), damage to 
cellular macromolecules such as lipids, protein, and DNA may ensue when cellular 
production overwhelms its antioxidant capacity (Friedberg et al., 2005). Such elevated ROS 
levels leads to increased levels of DNA damage, causing mutations and ultimately genetic 
instability and pathological conditions. It has been reported that several cancer types 
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including, pancreatic (Vaquero et al., 2004) prostate (Kumar et al., 2008) breast (Hecht et 
al., 2016) and colon (Acharya et al., 2010) show an increased level of ROS. Besides its role 
in cancer, ROS has been implicated in several human diseases including the ageing process, 
cardiovascular disease, diabetes, sterility, autoimmune diseases and neurological diseases 
(Sedelnikova et al., 2010). The mechanism of action of ROS is by induction of several 
covalent modifications to DNA including in single base lesions, DNA strand breaks, intra- 
and inter-strand cross-links. 
An example of oxidative DNA damage caused by ROS is 8-oxo-7,8-dihydroguanine (8-
oxoG), which although not toxic, is highly mutagenic (Suzuki & Kamiya, 2016). 8-oxoG is 
known to mismatch with adenine and by so doing results in ‘GC’ to ‘TA’ transversions. 
Several independent reports have confirmed the involvement of this mis-pairing in somatic 
mutations in lung, CRC, breast, gastric, and ovarian cancer (Fortini et al., 2003). Besides 
causing mutation, ROS is involved in activating transcription factors such as NF-kB, 
activator protein-1 (AP-1) and hypoxia inducible factor-1 (HIF-1α), whose role in cancer 
cell growth and survival, angiogenesis, invasion, and metastasis have been well established 
(Gupta et al., 2012). 
 
1.3. DNA Repair Mechanisms 
As mentioned earlier, cells are constantly under attack by agents known to generate genomic 
instability, resulting in structural damage to the DNA molecule (Fortini et al., 2003). 
Mechanistically, living organisms have evolved a plethora of molecular mechanisms to 
detect and repair the various types of damage that can occur to DNA, irrespective of the 
source. This they do by employing one of five distinct DNA repair mechanisms that play a 
critical role in maintaining the integrity of the genome (Friedberg et al., 2005). This, 
however, does not occur in isolation but is linked to cell cycle regulation; before the 
replication of DNA and the eventual division of the cell can take place, cell cycle 
checkpoint mechanisms ensure that a cell's DNA is intact. Therefore, if DNA is damaged, 
the cell has the ability to stop the cell cycle in G1, remove the lesion and restore the original 
base sequence, before passing through the cell cycle restriction point and commencing DNA 
replication, thus maintaining genetic stability (Pierce, 2017). Five DNA repair mechanisms 
have been described (Friedberg et al., 2005) and these are: (i) mismatch repair (MMR), (ii) 
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base excision repair (BER), (iii) nucleotide excision repair (NER), (iv) Non-homologous 
end-joining (NHEJ) and, (v) homologous recombination repair (HRR). Recently, Abbotts et 
al., (2014) reported that loss or truncation of the efficiency of one or more of the DNA repair 
pathways can accelerate the accumulation of additional mutations by up to 1000-fold 
(Abbotts et al., 2014). Thus, unrepaired DNA damage is the major source of potentially 
mutagenic lesions that drive carcinogenesis (Friedberg et al., 2005).  
Loss of any one of these pathways can result in serious consequences for the organism. For 
example, individuals lacking NER are hypersensitive to sunlight and exhibit either 
accelerated ageing or cancer predisposition (Friedberg et al., 2005). Similarly, several 
inherited colorectal cancer (CRC) syndromes are associated with genetic defects in both 
MMR and BER (Weren et al., 2015). On the other hand, high expression of DNA repair 
proteins in cancer cells can confer resistance to certain chemotherapeutic agents used in 
cancer treatment, such as the platinum-based compounds and alkylating agents.Thus, it has 
been reported that the excision repair cross-complementation group 1 (Ercc1) gene is 
upregulated in colon cancer cells treated with oxaliplatin, and that the small interfering RNA 
(siRNA) knockdown of Ercc1 in these cells sensitises them to the chemotherapeutic effects 
of oxaliplatin (Seethram et al., 2010). The BER DNA glycosylase NEIL3 is also highly 
expressed in most cancer cell lines and metastatic melanoma compared to normal tissue 
cells, where its expression is generally restricted to rapidly dividing cells in the thymus and 
testes (Section 1.3.2; Kauffmann et al., 2008; Hildrestrand et al., 2009). As more 
biochemical information becomes available on the activity of this enzyme (Martin et al., 
2017; Albelazi et al., 2019), it is of increasing interest to determine the levels of expression 
of Neil3 in tumour samples and the likely effect this may have on conferring resistance to 
genotoxic chemotherapeutic agents. 
The next three sections review in more detail the mechanisms of MMR, BER and NER. As 
the double-strand break rejoing pathways (NHEJ and HRR) are outwith the aims of the 
project, these are not covered in the following sections. 
 
 
 
7 
 
1.3.1. Mismatch Repair 
DNA mismatch repair proteins function by recognizing base mismatches and other lesions 
(e.g. nucleotide insertion or deletion) that result from DNA polymerase slippage during 
DNA replication (Lodish, 2004). As a result, it is sometimes called, post-replication repair 
and if it fails, the errors induced during DNA replication are fixed in the genome (mutation). 
As mentioned previously, during DNA replication the enzyme DNA polymerase adds a 
nucleotide to the growing strand of DNA at the replication fork. MMR is involved in the 
post-replicative repair of the errors made by DNA polymerases that have escaped 
proofreading (Umar & Kunkel, 1996). The MMR system will recognise base-base 
mismatches, insertions or deletions occurring in the double-stranded DNA (Harfe & Jinks-
Robertson, 2000). Following this recognition, MMR proteins then initiate the process of 
resection and specifically degrade the affected region of the newly synthesised strand. A 
DNA polymerase will then correctly resynthesise the daughter strand of the DNA in a 
template dependent manner (Lodish, 2004). 
Several genes are important in the normal function of MMR including, in human cells: MutS 
homolog 2 and 6 (Msh2 and Msh6), MutL homolog 1 and 3 (Mlh1 and Mlh3) and post-
meiotic segregation increased 1 and 2 (Pms1 and Pms2: Harfe & Jinks-Robertson, 2000). A 
mutation in any of these genes can result in microsatellite instability (MSI) and predisposes 
the individual to certain cancers, including colorectal and ovarian cancers (Abbotts et al., 
2014). 
Thus, germline mutations in Mlh1, Msh2 or Pms2, or even deletions in the epithelial cell 
adhesion molecule (Epcam) gene that cause allele-specific Msh2 inactivation has been 
linked to hereditary nonpolyposis colorectal cancers (HNPCC; Lynch syndrome) that results 
in early onset CRC. It has been reported that inactivating mutations in any of the MMR 
genes can be found in up to 70% of HNPCC and that, of these, over 90% occur in the hMsh2 
or hMlh1 genes and display a high level microsatellite instability (MSI-H) phenotype 
(Wheeler et al., 2000). 
The second major mutation of MMR genes found in human cells are the somatic mutations 
occurring because of promoter methylation of Mlh1. Often this methylation can be seen in 
the context of CpG island methylator phenotype (CIMP). In sporadic cancer, hyper-
methylation of the promoter region is the cause of Mlh1 inactivation especially in CRC with 
MSI-H (Haydon and Jass, 2002). First-degree relatives of CRC patients with hyper-
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methylation of the promoter region are at a higher risk (up to 60%) of developing CRC. In 
order to reverse Mlh1-methylation in colon cancer, the group of Fujita and colleagues (2007) 
demonstrated that the de-methylating agent 5-aza-2ʹ-deoxycytidine (5-aza-dC) can induce 
Mlh1 expression and sensitise cancer cells to 5-fluorouracil (Fujita et al., 2007). 
Consequently, the expression profile of Mlh1 will be analysed in the course of this project, 
particularly in solid colon cancer tumour tissues, with the view to ascertaining the expression 
pattern at the transcriptional level. 
 
1.3.2. Base Excision Repair 
Amongst the DNA repair mechanisms, BER is the most versatile repair mechanism and is 
involved in repairing the majority of DNA damage arising from both endogenous and 
exogenous sources (Svilar et al., 2011). These include single-strand breaks (SSB), 
depurination and deamination, alkylation and oxidation derived base damage. DNA base 
damage resulting from exposure to environmental factors, ROS as well as alkylation-
induced damage especially those from alkylating agents including chemotherapy and 
radiotherapy are also repaired by BER (Maynard et al., 2009; Whitaker et al., 2017). The 
broad functionality of BER results mainly from a group of enzymes called DNA 
glycosylases that recognise and excise a plethora of chemically modified bases from DNA 
(Mullins et al., 2019). Thus, DNA glycosylases recognize and initiate BER by removing an 
overlapping subset of damaged bases, leaving an abasic site that is further processed by 
short-patch BER or long-patch BER that uses different proteins to complete the repair 
process (Whitaker et al., 2017). Additionally, poly (ADP-ribose) polymerase 1 (PARP-1) 
and PARP-2 are known to facilitate BER by binding to DNA ends at SSBs and synthesizing 
poly (ADP-ribose) polymers on acceptor proteins and the DNA itself (Dantzer et al., 1999; 
Talhaoui et al., 2016). The poly(ADP-ribose) destabilizes the nucleosome structure allowing 
BER proteins access to the damage site. The role of BER in protecting the colorectal tissue 
against oxidative DNA damage, caused by high levels of oxygen radicals either generated 
by bacteria or dietary carcinogens cannot be overemphasized. Steps involved in BER are 
described in Figure 1.1. 
DNA glycosylases are important enzymes in BER (Mullins et al., 2019). These enzymes 
have been well studied and eleven different proteins have been identified in mammalian 
cells (Jacobs & Schär, 2012). These eleven enzymes can be subdivided into four structurally 
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distincy superfamilies, (i) the uracil DNA glycosylases (UDG), (ii) the helix-hairpin-helix 
DNA glycosylases (HhH), (iii) the alkylpurine DNA glycosylases (APNG or MPG) and, (iv) 
the endonuclease VIII – like DNA glycosylases (NEIL). These enzymes can be further 
divided into two classes, depending on whether they are monofunctional (UDG and 
APNG/MPG), or bi-functional (HhH and NEIL) (Jacobs & Schär, 2012). The 
monofunctional DNA glycosylases (UDG and APNG/MPG) have only DNA glycosylase 
activity, catalysing the breakage of the glycosylic bond between the deoxyribose sugar and 
the damaged base, while bifunctional DNA glycosylases also have an associated 
apurinic/apyrimidinic (AP) lyase activity (Jacobs & Schär, 2012). The five bifunctional 
DNA glycosylases in mammalian cells, 8-oxoguanine DNA glycosylase (Ogg1), 
endonuclease III homolog (Nthl1), and the three endonuclease VIII paralogs (NEIL1, NEIL2 
and NEIL3) all recognise and excise oxidised bases from either double-stranded or single-
stranded DNA (Jacobs & Schär, 2012). 
 
Figure 1.1. A current model for BER in mammalian cells. (Elder, unpublished). 
 
The DNA glycosylases NEIL1, NEIL2 and NEIL3 are mammalian homologs of the 
Escherichia coli Nei protein and have been shown to excise oxidised purine and pyrimidine 
bases from both single- and double-stranded DNA (Liu et al., 2013; Albelazi et al., 2019). 
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Amongst these enzymes, NEIL3 is the largest, uniquely containing a long C-terminal region 
ending with tandem GRF-zinc finger domains (Albelazi et al., 2019). Both NEIL1 and 
NEIL3 are reported to be cell cycle regulated, with expression peaking in S-phase and S/G2-
phase respectively, while NEIL2 is constitutively expressed throughout the different stages 
of cell cycle (Neurauter et al., 2012; Hazra & Mitra, 2006; Chakraborty et al., 2015). Thus, 
while evidence from biochemical studies and knockout mice support the idea of an 
involvement of NEIL2 in transcription-coupled BER (Chakraborty et al., 2015), recent 
biochemical evidence reinforces previous reports supporting the involvement of Neil1 and 
NEIL3 at the replication fork (Albelazi et al., 2019; Neurauter et al., 2012). Furthermore, 
NEIL3 also shows a unique restricted expression pattern in normal cells, being expressed 
only in highly dividing cells such as those in the developing brain, the thymus and testes 
(Hildrestrand et al., 2009; Morland et al., 2002). However, high levels of NEIL3 have been 
observed in metastatic melanoma (Kauffmann et al., 2008) and in cancer cells generally 
(Hildrestrand et al., 2009; Duweb, 2015). Recently, it was demonstrated that abnormal 
expression of the Neil DNA glycosylase genes is associated with somatic mutation in several 
human cancers (Shinmura et al., 2016). 
An ongoing study in our laboratory reported that Neil3 is highly expressed in the CRC cell 
line HCT116. However, following siRNA treatment, this expression can be substantially 
reduced. Further knockdown of Neil3 can sensitize tumour cells to oxaliplatin treatment 
(Taylor et al., 2015). These results reveal a potentially novel activity for Neil3 and indicate 
that it could be a major resistance mechanism to certain chemotherapeutic DNA damaging 
agents in solid tumours. Consequently, it is one of the objectives of this thesis, to investigate 
the expression profiles of Neil3 gene in solid tumours derived from different colorectal 
cancer patients. 
Besides the DNA glycosylases, mutations in the BER genes are associated with several 
cancer types. Moreover, the observation that mutations in the gene coding for MUTYH, a 
DNA glycosylase that releases adenine base paired with 8-oxoG predispose to CRC has 
provided strong evidence that dysregulation of the BER pathway contributes to disease 
susceptibility (Hazra et al., 2007). Furthermore, a report by Weren et al. (2015) showed that 
a germline homozygous mutation in the Nthl1 gene that codes for a DNA glycosylase that 
removes oxidized pyrimidines causes adenomatous polyposis and therefore, predisposes to 
colorectal cancer (Weren et al., 2015). More recently, Grolleman et al., (2019) have reported 
that biallelic germline mutations in the Nthl1 gene predispose carriers to tumours at multiple 
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sites, again reinforcing the importance of unrepaired oxidative base damage in 
carcinogenesis and of the DNA glycosylases and BER in maintaining genetic integrity. 
 
1.3.3. Nucleotide Excision Repair. 
Mammalian nucleotide excision repair (NER) is a constitutive DNA repair mechanism and 
its impairment can result in several disease conditions including cancer and premature 
ageing (Marteijn et al., 2014). It is usually involved in the repair of DNA lesions usually 
bulky adducts that destroy the normal double-helical conformation of duplex DNA, 
irrespective of whether the insult is induced by endogenous or exogenous agents (Friedberg 
et al., 2005). Bulky adducts are products of different DNA damaging agents including UV 
radiation and chemicals including alkylating agents. It has been extensively documented that 
exposing DNA to UV radiation typically results in cyclobutane pyrimidine dimers (CPD) 
and pyrimidine-(6,4)-pyrimidone products (6-4PP) that are known to be helix distorting 
lesions (Rastogi et al., 2010). When DNA is exposed to chemicals or alkylating agents such 
as polycyclic aromatic hydrocarbons that are common in cigarette smoke or charcoaled 
meat, bulky adducts can also be formed (Melis et al., 2013). When bulky alterations happen, 
it typically arrests polymerase progression during DNA replication and transcription 
resulting in a damaged replication fork or stalled transcription bubble (Gillet and Scharer, 
2006). Our understanding of the cellular mechanisms of NER and its relationship with 
several cellular processes during DNA repair process indicates that NER employs four 
mechanisms to repair damaged DNA: (i) NER recognizes the extent and location of the 
damage, (ii) Upon this recognition, NER incises both ends of the damaged strand and 
removes an oligonucleotide containing the damaged nucleotides, (iii) This is followed by 
the synthesis of a new DNA strand to fill the gap and restore the DNA duplex that is devoid 
of damage, and (iv) ligation by DNA ligase to seal the nick at the end of the newly 
synthesized DNA strand (Pierce, 2017). Functionally, NER can be divided into two related 
pathways; global genome repair (GG-NER) and transcription-coupled repair (TC-NER). 
These pathways are known to occur in a divergent manner but can proceed along the same 
part when they have recognized the damage on the DNA (Melis et al., 2013). They both 
involve complex mechanisms to initiate the repair response, adopting several reaction-
reversal steps before incision (Luijsterburg et al., 2010). Such a process is necessary to avoid 
undesirable and irreversible DNA modification and to ensure re-start of transcription. 
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GC-NER and TC-NER function in a coordinated manner, involving about thirty proteins, to 
achieve efficient DNA repair (Figure 1.2). The first step in GG-NER is to scan the entire 
genome for helix distortions; this is done through the recruitment of several damage sensor 
proteins (Pierce, 2017). In damage caused by UV radiation, recruitment of xeroderma 
pigmentosum group C protein (XPC) results in a complex with the human homolog of yeast 
RAD23 (XPC–RAD23B) and centrin 2 (CETN2) (Masutani et al., 1994). The principal role 
of XPC-RAD23B-CETN2 complex is to probe for distorting lesions and to recognize the 
structural damage in DNA by the activities of the ultraviolet (UV) radiation DNA damage 
binding protein complex (UV-DDB). Following recognition of this structural damage, XPC 
will bind to strand opposite to the lesion resulting in the dissociation of RAD23B (Schärer, 
2007). 
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Figure 1.2. A representation of nucleotide excision repair (de Laat et al., 1999) 
 
In contrast to GG-NER where damage is recognized directly, recognition of damage in TC-
NER takes an indirect approach. During transcription elongation, the stalling of RNA 
polymerase II is an indication that there is a lesion in the DNA. When this happens, NER 
recruits several proteins to remove the lesions. These include UV-stimulated scaffold protein 
A and ubiquitin-specific-processing protease 7 (Schwertman et al., 2012) and Cockayne 
syndrome complementation group A (CSA) and B (CSB). The purpose of recruitment of 
these proteins is to promote DNA repair as well as restart of the transcription elongation 
process. While CSA is implicated in the elongation process itself, CSB is known for its role 
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in the displacement of the stalled RNA polymerase via a transient interaction (Kamiuchi et 
al., 2002). Upon stalling at a lesion, it has been documented that the affinity of CSB for 
RNA polymerase II increases, leading to the formation of CSA-CSB complex. The formed 
complex is then involved in the reversal of the translocation (backtracking) of RNA 
polymerase II, thus rendering the DNA lesion accessible for repair. After this step, the GG-
NER and the TC-NER converge to continue the repair process of the damaged DNA (Figure 
1.2; de Laat et al., 1999). 
The dissociation of RAD23B in the GG-NER mechanism and the backtracking step in the 
TC-NER mechanism will trigger the deployment of the transcription factor II H (TFIIH) 
complex, that is known to have helicase activities. The presence of two TFIIH basal helicase 
subunits including XPB and XPD results in the opening of the DNA duplex site where 
damage has occurred. However, if XPD fails to detect any damage, the DNA repair process 
can be aborted. This is because the major role of XPD is for damage verification. If there is 
successful verification of damage by XPD, the helicase activities will proceed successfully. 
This process will result in a bubble formation, allowing the engagement of XPA and RPA 
(replication protein A), as well as the assembly of the complexes necessary to initiate 
incision (Compe & Egly, 2012). 
The XPF-ERCC1 complex is a structure activated endonuclease that incises the DNA strand 
on the 5ʹ side of the helix distorting lesion. Similarly, XPG performs a similar function 3ʹ to 
the lesion (Figure 1.2). This step leaves a single strand gap of 22-30 nucleotides and it has 
been suggested that this step is necessary in triggering, a DNA damage signalling reaction 
(Marteijn  et al., 2014).  
In cancer, several studies have shown that the ERCC1-XPF complex is responsible for 
conferring resistance to platinum based drugs (Seetharam et al., 2010; Baba et al., 2012) and 
in particular it has been demonstrated that the over expression of the Ercc1 gene is associated 
with oxaliplatin resistance in metastatic colon cancer (Choueiri et al., 2015). Thus, it has 
been shown that its knock down by siRNA-mediated gene silencing can sensitize the CRC 
cell lines to oxaliplatin, thereby implicating the role of Ercc1 in conferring resistance to this 
crosslinking agent (Seetharam et al., 2010). 
It is based on the above premise that this PhD thesis seeks to profile the expression of Ercc1 
in different solid tumours derived from CRC with a view to establishing the expression 
pattern in tumour versus normal colon tissue. 
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1.4. Colorectal Cancer 
Colorectal cancer (CRC) or colorectal adenocarcinoma is one of the most predominant 
malignant neoplasms and it contributes significantly to cancer-related deaths worldwide 
(Ferlay et al., 2015). In 2014, the number of newly diagnosed patients in the United States 
alone reached nearly 140,000, ranking this disease in second place as a cause of death due 
to cancer in adults (Siegel et al., 2014). Worldwide, it occupies third place and second place 
respectively, as the leading cause of deaths relating to cancer in men and women (Ferlay et 
al., 2015). Although 55% of the cases are found across the industrialized world, Australia 
and New Zealand record the highest rates of CRC with Africa showing the lowest rates (Ries 
et al., 2017). The discrepancy in the documented incidences and death rate can be attributed 
to poor diagnosis or improper data registry (Ferlay et al., 2015). Diagnosis of CRC at the 
stage when it has not metastized to distant organ usually signals a good prognosis and about 
50% of patients have a 5-year survival. However, patients at the metastatic stage have only 
12% survival rate at 5 years (Ferlay et al., 2015). CRC may be asymptomatic for several 
years and the American Cancer Society has recently recommended screening from 45 years 
of age (Mannucci et al., 2019). Detecting blood in the stool and unexplained weight loss 
have previously been reported to be the only symptoms warranting further exploration for 
polyps and CRC (Adelstein et al., 2011).  
While there is no single, distinct cause of CRC, several risk factors leading to its 
development have been described (Kupfer & Ellis, 2017). This neoplasm is sporadic with 
the majority caused by diet, lifestyle, age and only about 15% to 35% linked to hereditary 
factors (Burt, 2007; Mishra & Hall, 2012). Evidence shows that patients with history of 
genetic instability have a greater chance of getting the disease and such patients are 
especially likely to show germline mutations relative to the patients that have spontaneous 
CRC (Gallagher et al., 2010). 
Based on their origin, CRC has been traditionally categorized into two biological subgroups, 
namely a minority (15%) that show microsatellite instability (MSI), which is primarily 
predominant at the right colon and known to be frequently linked to the CpG island 
methylator phenotype (CIMP; Popat et al., 2005). Additionally, predictive and prognostic 
information indicate that they exhibit hyper-mutation including mutation at both the KRAS 
and BRAF oncogenes. On the other hand, the second group comprising 85% of patients is 
made up of a subgroup considered to be microsatellite stable but chromosomally unstable 
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(Marisa et al., 2013; Roepman et al., 2014). It is worthwhile to mention that the above 
classifications are largely based on gene expression profiling; thus, might solely focus on 
single mutations or epigenetic alterations. Therefore, with the advances in genomic 
technology, scientists are now focussing on whole exome and genome sequencing to cover 
a wide range of genome analysis. This technique can sequence the entire human coding 
DNA looking at both the coding and non-coding regions. This will help to provide additional 
information on all the alterations that might have occurred at a single nucleotide including 
copy number and structural variants. Recently, screening with high-throughput gene 
expression profiling including next generation sequencing or expression arrays (microarray) 
has demonstrated that some CRC types overlap with the above-mentioned groups and cannot 
be established only by single mutations or epigenetic profiling (Sinicrope et al., 2016). 
The development of CRC is seen to be a multistep process that involves the development of 
benign polyps that have the capability to evolve into carcinoma in situ by the accumulation 
of somatic mutations (Shussman and Wexner, 2014). Factors such as age, diet, lifestyle, and 
family history are associated with the development of polyps and CRC (Rasool et al., 2013). 
Even though there is a good correlation between polyps and CRC development, three 
different subtypes of polyps have been described, distinguished on the basis of histology, 
such as tubular/villous adenoma, hyperplastic polyps and sessile/traditional serrated 
adenomas (Kalimuthu et al., 2016). Similarly, there is a suggested correlation between the 
risk of cancer development with the number and size of previously developed polyps 
(Shussman & Wexner, 2014). This means that multiple colonic polyp development with 
malignant potential will amount to an increased lifetime risk of developing CRC. 
 
1.4.1. Genetic Predisposition to Colorectal Cancer 
Knowledge of the genetics that defines cancer development is critically important in the 
discovery and development of corresponding therapies for the treatment of any particular 
cancer. In recent years, cancer research scientists have fully become aware to the reality that 
genetic mutation is one of the hallmarks of cancer development including CRC (Hanahan 
and Weinberg, 2000; 2011; Loeb, 2001). Like other cancers, CRC is heterogenous in nature 
and genome sequencing has identified 24 genes that are predominantly subject to mutation 
including APC, TP53, SMAD4, PIK3CA, and KRAS (Cancer Genome Atlas Network, 2012). 
The overall classification of CRC is categorised into three important tumour subtypes 
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including hyper-mutated, non-mutated and CIMP subtypes (Rodriguez-Salas et al., 2017). 
The hyper-mutated tumours have been reported to account for up to 16% of all CRC 
(Dienstmann et al., 2017). While only one-quarter display somatic mismatch repair (MMR) 
gene and DNA polymerase  alterations, three-quarters of them show high-frequency MSI 
(MSI-H) (Cancer Genome Atlas Network., 2012). Mutations in the germline account for 2 - 
5% of CRC and may be as a result of autosomal dominant syndrome (Gatalica et al., 2017). 
The most prevalent and most studied is termed hereditary non-polyposis colorectal cancer 
(HNPCC) or Lynch syndrome (Lynch et al., 2015). When compared to the age of the 
patients, evidence shows that most patients with sporadic CRC are older patients, while 
patients with Lynch syndrome and other genetic predispositions are usually younger (Mauri 
et al., 2019). This can be due to loss of Mlh1 expression, the increase of which is directly 
proportional with age (Kakar et al., 2003). Moreover, sporadic colorectal tumours are also 
characterized by high BRAF (V600E) mutation with loss of MLH1 and PMS2 proteins 
(Kakar et al., 2003).  
Furthermore, microsatellite instability (MSI) positive CRC can be found at the proximal 
bowel exhibiting poor differentiation. This can be due to the presence of dense lymphocytic 
infiltration, suggesting strong anti-tumoural immune responses. Moreover, this is an 
indicative of positive prognosis (Nosho et al., 2010). On the other hand, the non-mutated 
subtype accounts for 84% of CRC; with the majority characterised by many somatic copy 
number changes and aneuploidy; exhibiting genetic alterations at the KRAS and PIK3CA 
genes. This subtype is also known to possess loss of heterozygosity of several tumour-
suppressor genes including APC and TP53 (Cancer Genome Atlas Network, 2012).  
The third subtype as mentioned above is the CIMP characterised predominantly by DNA 
methylation of CPG islands (Hawkins et al., 2002; Weisenberger et al., 2006). This results 
in gene silencing and the subtype exhibits deficient MMR, resulting in MSI-H. Moreover, 
CRC with an MMR/MS-IH phenotype is said to result in a higher proportion of sporadic 
tumours, accounting for up to two-thirds, while the remaining one-third are linked to a 
germline mutation in the MMR genes including Mlh1, Msh2, Msh6 and Pms2 (Buchanan et 
al., 2014). Furthermore, evidence has shown that BRAF/V600E mutations can be another 
consequence of the MMR/MS-IH phenotype as well as CIMP. Thus, MSI-H is suggested to 
be caused by aberrant hyper-methylation that inactivates, principally, Mlh1 (Domingo et al., 
2004). 
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Additionally, two recessive cancer - predisposing genes MUTYH and Nthl1 that both code 
for proteins that act in base excision repair (BER) have been confirmed to be associated with 
increased polyposis and adenomatous polyposis with a high risk of CRC respectively 
(Weren et al., 2018). Indeed, carriers of biallelic mutations in Nthl1 have been shown to 
have an increaseed risk of other cancer types, including breast cancer (Kuiper & 
Hoogerbrugge, 2015). 
 
1.4.2. Colorectal Cancer Treatment and Oxaliplatin 
 
  
 
 
 
Systemic chemotherapy has been used to control cancer and alleviate its related symptoms 
at the metastatic stage. For metastatic CRC, it has been reported that a combination of the 
antimetabolite fluoropyrimidines (intravenous 5-fluorouracil and oral capecitabine), the 
DNA topoisomerase I inhibitor, irinotecan and the genotoxic platinum – based agent 
oxaliplatin (FOLFOXIRI) showed an improved survival of these patients (Leal, 2017). 
However, achieving complete remission at this stage is still daunting, as resistance 
accounting for nearly 30-50% is still a major obstacle (O’Connell et al., 2008). 
Oxaliplatin (Figure 1.3B) is a third-generation platinum – based alkylating agent forming 
primarily N-alkylation products at the N7 of guanine. Similar to cisplatin (cis-
diamminedichloroplatinum (II); Figure 1.3A), this leads to both intra- and inter-strand cross 
links (ICLs) in the DNA molecule, effectively disrupting DNA replication and transcription 
and leading to cell death. For cisplatin, the high extracellular chloride ion concentration 
maintains the molecule in an inactive state and only when it is transported inside the cell, 
where the chloride ion concentration is 5 to 30 times lower, are the chloride groups displaced 
by water molecules to create an effective alkylating agent. The most prevalent products are 
1,2-d(GpG) intrastrand crosslinks that make up 90% of the DNA adducts, 1,2-d(ApG) 
intrastrand crosslinks and ICLs. In the cell, the activated cisplatin has a half-life of around 
two hours, while the protecting chelating ligands of oxaliplatin give this agent a much longer 
A B 
Figure 1.3. Molecular structures of (A) cisplatin and (B) oxaliplatin. 
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half-life, with solutions of oxaliplatin and the related carboplatin being stable in water for a 
period of weeks to months (Johnstone et al., 2016). 
The repair of cisplatin – induced intrastrand crosslinks is thought to be completed by NER 
and the resistance to DNA repair, and therefore the cytotoxic effectiveness of this agent, is 
due to the bending of the DNA at the adduct and the resulting binding of the DNA by high-
mobility group box proteins that have a great affinity for cisplatin modified DNA and thus 
shield the lesion from the NER proteins (Awuah et al., 2017). In CRC, increased expression 
of Ercc1, which encodes one half of the ERCC1/XPF lesion specific endonuclease, has been 
correlated with oxaliplatin resistance (Galluzzi et al., 2012). However, mouse cells lacking 
the BER DNA glycosylase NEIL3 also showed resistance to cisplatin (Rolseth et al., 2013). 
Further evidence of a role for DNA glycosylases in ICL repair came from biochemical 
studies by Couvé and colleagues (2009), which indicated that NEIL1 could excise psoralen 
– induced ICLs from DNA and more recent work has shown that both NEIL1 and NEIL3 
can resolve psoralen - induced ICLs in three- and four-stranded DNA structures (Martin et 
al., 2017) and also that NEIL3 can release ICLs at DNA replication forks (Semlow et al., 
2016). Therefore, as NEIL3 has been reported to be highly expressed in cancer cells and 
metastatic tumours (Kauffmann et al., 2008; Hildrestrand et al., 2009) and recent work from 
my laboratory at the University of Salford had also indicated a role of NEIL3 in the 
resistance to oxaliplatin (Taylor et al., 2015), it was important to determine the levels of 
NEIL3 in the CRC tissues and cell lines analysed in this work. 
 
1.4.3. Colorectal Cancer Treatment and Development of Targeted Therapy 
The use of conventional therapies for cancer patients is long standing, with the treatment 
modalities recording substantial improvements over the years. Patients with CRC can 
benefit from radiotherapy, surgery, chemotherapy or a mixture of surgery and 
chemotherapeutic agents depending on the stage of the disease (Mishra et al., 2013). Surgery 
has been successful when diagnosis and therapeutic interventions happen at the initial stages 
with the tumour displaying adequate surgical margins and no invasive characteristics. 
Although, there are no curative options for most metastatic CRC, Kopetz and colleagues 
(2009) reported that an improvement in the median overall survival can be realised through 
surgical resection of both primary CRC and metastases (Kopetz et al., 2009). 
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Due to the shortcoming of conventional therapies, scientists are focusing on targeting 
metastatic CRC at the molecular level. Cancers including CRC can be characterized based 
on the biomarkers they present. This means that profiling tumours can be a watershed event 
in optimizing therapy to suit an individual patient’s need. The key is in identifying reliable 
biomarkers by performing baseline assessment of tumour gene expression and/or immune 
profile for the best chance of therapeutic success. With the recent innovations in molecular 
testing techniques that allow for high throughput genomic analysis, patients can be selected 
for targeted therapy based on their tumour biology and dispositions (Ohhara et al., 2016). 
So far, techniques involving next generation sequencing and even a much newer technology 
for detecting a mutation in circulating tumour DNA have been described (Perakis et al., 
2017). Since these technologies can detect somatic modifications and mutations such as 
insertions/deletions, copy number variation and rearrangement and base substitutions, 
molecular intervention strategies can be tailored to target the key molecules involved in CRC 
proliferation, envasion and metastasis (Diaz & Bardelli, 2014; Sinicrope et al., 2016). By 
implication, targeted therapy directed against the wrong mutation or given to a patient with 
tumour of unrelated characteristics will not benefit the patient.  
Several biomarkers for CRC including KRAS, NRAS, BRAF mutation, DNA mismatch repair 
(MMR), MSI, and CpG island hypermethylation have been evaluated (Sinicrope et al., 
2016). Consequent upon reports emanating from such findings, treatment modalities such 
as the use of small molecule inhibitors, antibodies (Baudino, 2015), immunotherapy (Lynch 
& Murphy, 2016) and RNA-based technologies such as siRNA or small hairpin RNA 
(Seetharam et al., 2010) have been evaluated. Although some of these techniques are still at 
the preclinical stage, the majority have made their way to the clinic, recording some 
promising outcomes. 
Recent reports show that better patient survival can be achieved by recombinant humanized 
monoclonal IgG antibody targeting either the EGFR or VEGF pathway. The result of the 
clinical trial using the above antibodies as summarized by Ohhara et al., (2016) indicated 
that one anti VEGF antibody; bevacizumab, and two EGFR targeting antibodies; cetuximab 
and panitumumab resulted in significant anti-CRC metastatic control in combination with 
cytotoxic therapy (Ohhara et al., 2016). The clinical trial report showed that they can be 
used in first line, second line or even in salvage settings to enhance overall patient survival 
beyond 40 months from the period of initial diagnosis (Van Cutsem et al., 2011; Heinemann 
et al., 2014). However, this treatment is not suitable for everyone as only those in a healthy 
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state can benefit from it due to inherent toxicity associated with chemotherapy. Additionally, 
patients that have KRAS/NRAS mutations are not subject to this therapy as this mutation lies 
downstream of EGFR. In such instance, mutation at the KRAS/NRAS triggers the 
transcription of the ligand for EGFR; transforming growth factor-alpha (TGF-α). This will 
in turn create an autocrine signaling loop that contributes to tumoural resistance to anti-
EGFR monoclonal antibodies (mAbs) including cetuximab and panitumuab (Lièvre et al., 
2006). 
Immunotherapy for the treatment of cancer has come a long way and has been accepted as 
the fourth treatment modality besides surgery, chemotherapy and radiotherapy. This 
treatment modality is currently approved for many solid tumours due to its efficacy in 
controlling cancer with minimal overall toxicity. The functions of immune cells in the 
development and progression of tumour has been well documented (Hanahan & Weinberg, 
2011) indicating that several cancer types show phenotypic immune cell characteristics. It 
has been demonstrated that CRC with MSI can be characterized by the presence of a 
particular immunogenic phenotype. It was further established that this subtype has 
increasing lymphocytic infiltration which can possibly be due to the creation of tumour-
specific neo-antigens during accumulation of mutations (Schwitalle et al., 2008). When 
primary tumour tissues from patients were further characterized an increasing presence of 
Th1 transcription factors was recorded. This is translated to the presence of activated 
cytotoxic CD8T cells, Th1 cells producing high levels of IFN-y as well as T-BET expressing 
T cells (Llosa et al., 2015). The presence of immune cell infiltration in the CRC is indicative 
of a positive prognosis. However, the immune microenvironment of CRC is composed of 
immune checkpoints that are cytotoxic to activated T cells. In a similar vein, the presence 
of apoptotic cell death ligands, such as programmed cell death ligand 1 (PD-L1), 
programmed cell death 1 (PD-1), T lymphocyte associated antigen 4 (CTLA4), lymphocyte 
activation gene 3 (LAG3) and indoleamine 2, 3-dioxygenses (IDO) have been shown to be 
the hallmark characteristic of several cancers including CRC (Llosa et al., 2015). 
Targeting immune checkpoints has been the major focus of immunotherapy. The 
engagement PD-L1 on the surface of the tumour cells with PD-1 present on the immune 
cells including T cells, B-cells and natural killer cells produces inhibitory signals that result 
in T cell exhaustion and energy (Llosa et al., 2015). Inhibition of this pathway resulted 
tumour regression and reversal of T cell exhaustion in majority of cancer types including 
melanoma, non-small lung cancer and renal carcinoma.  This is a pointer to the fact that the 
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mechanism of tumour regression using this strategy lies in activation of tumour infiltration 
lymphocyte around the tumour border. Recently, Brahmer and colleagues (2009) showed in 
their phase II clinical trial that, blocking PD1/PD-L1 interaction in CRC patients with MDX-
1106 resulted in complete response for a period more than 21 months (Sui et al., 2015). 
Looking at the individual treatment modalities, one can see their strengths and weaknesses. 
Since long-term clinical benefit to more patients is the ultimate goal, future cancer therapy 
is likely to focus on combinatorial approaches involving targeted inhibitors, 
immunotherapy, chemotherapy, surgery, radiation as well as novel therapies to achieve 
success. 
 
1.5. Medulloblastoma 
Medulloblastoma is a malignant, embryonal, heterogeneous, and highly aggressive tumour 
of the central nervous system with a preferential manifestation in children and a marked 
metastatic tendency via the cerebrospinal fluid (CSF) (Louis et al., 2007; Gibson et al., 2010; 
Robinson et al., 2012; Gajjar and Robinson, 2014). The development of medulloblastoma is 
mostly sporadic, originating from the interior fossa because of aberrant cerebellar 
development (Marino, 2005). In very rare cases, medulloblastoma has been reported to be 
associated with heritable disorders like LiFraumeni, Turcot or Gorlin syndrome (Parsons et 
al., 2011; Johansson et al., 2016). More than 70% of reported cases of medulloblastoma 
occur in patients under the age of 15 years, with the incidence peak being 3 to 6 years (Peris-
Bonet et al., 2006). However, medulloblastoma is much less frequent in adults, accounting 
for less than 3% of primary tumours of the central nervous system (Smoll and Drummond, 
2012).  
From a US registry analysis obtained from the Surveillance, Epidemiology, and End-
Results (SEER) database, it was found that medulloblastoma incidence was 1.5 cases per 
million in the general population, and children were reported to show over 10 times more 
likelihood of developing the disease than adults (Rutkowski et al., 2010; Smoll and 
Drummond, 2012). For the period 2000 to 2007, the European annual incidence rate 
reported 6.8 per million children within the age range of 0 – 14 years, with highest rates 
recorded in Southern and Central Europe (Massimino et al., 2016). In males, the occurrence 
was sign more relative to females; and the prevalence rate per annum was reported to be 
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higher in children that are not more than 9 years of age, indicating a frequency of less than 
8 in every million. On the other hand, 6 persons per million was reported in infants, an 
indication of a reduction in the rate of incidence, whereas, in children whose age range is 
between 10 to 14 years, the incidence rate was reportedly lowest, represented by 4 persons 
in every million (Peris-Bonet et al., 2006). In the case of individuals that were above the 
age of 14 years but not more than 19 years of age, higher incidence rate was reported at an 
annual frequency of 2.33 persons per million; with incidence rate declining beyond 19 
years of age up to the age of 40 years, depicting an alignment with the embryonal origin of 
medulloblastoma (Giordana et al., 1999). Between 1978 and 1997, the incidence of 
medulloblastoma was on the rise, with a record 1.3% increase during this period (Peris-
Bonet et al., 2006). In parts of North-America, the occurrence of medulloblastoma was 
reported to be 5.07 per million children aged 0 to 19 years (Kohler et al., 2011). 
Comparatively, from 1114 diagnosis of brain tumours at the Egyptian Children’s Cancer 
Hospital from 2007 to 2013, medulloblastoma represented 23.2% of the overall number of 
diagnosed cases; this shows an agreement with the reported cases of medulloblastoma in 
North America and Europe (Ezzat et al., 2016). 
Children diagnosed with medulloblastoma in Europe, between the years 2000 – 2007, 
showed 81% survival for 1 year, 63% for 3 years and 56% survival was reported for 5 
years. Essentially, worst prognosis was found among infants, where 5-year survival was 
reported to be 33%, but for children aged 1 to 4 years, a relatively improved survival of 
47%; whereas, marked prognosis was reported for children aged 5 to 14 years of age, at 
survival rate of 67% (Kohler et al., 2011). From year 1999 and 2007, survival of patients 
with medulloblastoma remained stable (Gatta et al., 2009), while in the nineties, survival 
significantly improved and the possibility of the patients dying dropped by 30% (Gatta et 
al., 2014).  
For children aged above 5 years, the standard of care requires surgical resection, irradiation 
of the craniospinal region, and CT that have amounted to an enhanced general survival rate, 
which accounted for approximately 70–75% in clinical setting (Lannering et al., 2012). 
The variation in the results reported across European countries are indicative of the fact 
that there are challenges in harnessing of effective treatment and/or reach effectively, 
timely and accurately consistent diagnosis. In Northern Europe, an improved 5-year 
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survival rate at 64% was reported, while it was relatively lowest in countries within Eastern 
Europe at 53% (Gatta et al., 2014). 
Because the highest incidence of medulloblastoma occurs during childhood; it is rational 
to assert that certain factors operating at very early stage of life might play a key role in 
determining the disease development (Massimino et al., 2016). Birth weight is frequently 
suggested as an easy but rough indicator of medulloblastoma prenatal exposures. On this 
note, Harder et al. (2008) systematically reviewed the relationships between patients’ birth 
weights and the localisation of primary brain tumours of specific histological features. 
Interestingly, they observed that high birth weight was significantly associated with 
increased risk of medulloblastoma. Similarly, other studies have made attempts to 
speculate on a possible aetiology that is considered infectious. For instance, a study 
conducted in England, investigated a variety of perinatal factors and their respective 
impacts on brain tumours in children (Fear et al., 2001). The researchers observed that 
children whose mothers had a documented case of viral infection during pregnancy had 
over 11 times increased risk of development of malignant tumours of the central nervous 
system (CNS) (Fear et al., 2001). However, this finding was not supported by recently and 
widely updated reviews (Johnson et al., 2014, Crump et al., 2015). In a large population-
based control-case study, Harding et al. (2009) evaluated the profile of day care and social 
contacts in the first year of life, alongside other indicators of infectious exposure. The 
authors reported elevated risk of medulloblastoma development in children that have had 
no social contact with other infants in the first year of life. However, they interestingly 
noted that analysis of other related hallmarks of infectious exposure such as joint use of 
bedroom, domestic exposure to school-age children, and sequence of birth; failed to concur 
with the proposition of a protective effect of infectious exposure (Harding et al., 2009). 
Diet is another player in medulloblastoma and other tumours of the nervous system, and its 
implications as risk factor and a positive factor, have been reported in multiple studies. The 
hypothesis that maternal dietary intake of N-nitroso compounds (NOC) and NOC 
precursors in the course of pregnancy increases the risk of brain tumour development in 
offspring, is known to be one of the most comprehensively investigated hypotheses 
(Dietrich et al., 2005; Massimino et al., 2016). Based on this premise, a large international 
collaborative case-control study on childhood brain tumours was conducted to ascertain the 
relationships between histology-specific risk and consumption of specific food groups 
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during pregnancy (Pogoda et al., 2009). The researchers observed that cured meats, 
eggs/dairy, and oil products were the main foods regularly linked with increased risk; 
whereas, foods that are mostly associated with lowered risk were fresh fish, yellow-orange 
vegetables, and grains (Pogoda et al., 2009). 
Another risk factor that has been under serious investigation is the maternal occupational 
exposure. Li et al. (2009), while studying the causal relationship between maternal 
occupational exposure and the incidence of childhood brain tumours, evaluated the 
implications of extremely low frequency magnetic fields (ELF-MF) just prior to and during 
pregnancy. They reported a seriously elevated risk for astroglial tumours and for the entire 
childhood brain tumours investigated (Li et al., 2009). Similarly, several epidemiological 
studies have investigated the correlation between parental exposure to pesticide and 
childhood brain tumours, and many of the research outcomes were suggestive of 
affirmative correlation (Massimino et al., 2016). It was based on this rationale that Shim et 
al., (2009), conducted a population- based case-control study to evaluate that association 
between the occurrence of brain cancer in children and parental exposure to pesticides in 
occupational and residential settings. They reported negligible relationship with 
medulloblastoma for any of the pesticide subtype or the sources exposure investigated 
(Shim et al., 2009). Additionally, Rosso et al., (2008), evaluated the relationship between 
the hobbies of fathers and medulloblastoma; and they observed an increased risk of 
medulloblastoma development in children whose fathers’ hobbies are linked to household 
use of chemicals, particularly pesticides. When parental occupation was considered, 
Cordier et al., (1997), reported an increased risk of PNET with parental exposure to 
polycyclic aromatic hydrocarbons and high maternal exposure to solvent during the five-
year period before birth. In another vein, certain genetic abnormalities such as Gorlin, 
Turcot, and Li-Fraumeni syndromes have been reported as cancer-predisposition 
syndromes that are known to be defining risk factors of medulloblastoma (Villani et al., 
2012). 
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1.5.1. Histology and Pathobiology of Medulloblastoma 
To date, the actual cellular origin of medulloblastoma remains subject to debate (Gibson et 
al., 2010). Several reports have shown that the origin of medulloblastoma could be from two 
different embryonal cell groups: cells from the ventricular zone, which differentiate into 
various cells of the cerebellum; and cells from the external germinal layer (EGL), which 
differentiate into cerebella granule cells (Kuzan-Fischer et al., 2018). These cell groups are 
related to different molecular subtypes of medulloblastoma and it has been established that 
ventricular zone cells give rise to the wingless (WNT) subtype, whereas sonic hedgehog 
(SHH) medulloblastoma is produced from the EGL cells (Fan and Eberhart, 2008; Rusert et 
al., 2014; Kuzan-Fischer et al., 2018). In the subsequent sections, these molecular subtypes 
will be reviewed in a more elaborate manner.  
The 2007 WHO classification of tumours of the central nervous system recognises five 
major variants of medulloblastoma, including the classic medulloblastoma, 
desmoplastic/nodular, medulloblastoma with extensive nodularity (MBEN), anaplastic and 
large cell (Giangaspero et al., 2007; Massimino et al., 2016; Kuzan-Fischer et al., 2018). 
From these five forms, large-cell medulloblastoma as well as anaplastic variant of the 
disease have significant overlapping characteristics; consequently, several studies have 
attempted to group them into large cell/anaplastic (LC/A) medulloblastoma (Gilbertson and 
Ellison, 2008). The incidence rate of the combined LC/A type of medulloblastoma has been 
reported to oscillate between 10% and 22%; whereas, anaplastic medulloblastoma is 
established only in event of severe and diffuse anaplasia, comprising up to 50% of reported 
cases (Giangaspero et al., 2007). Nodular/desmoplastic medulloblastoma constitute about 
7%, while MBEN comprises up to 3% of the entire reported cases of the disease, while 
classic subtype of medulloblastoma make up the remaining (Gilbertson and Ellison, 2008; 
Massimino et al., 2016). 
Histologically, the classic subtype of medulloblastoma is made up of tightly packed cells 
with characteristic oval, round, or carrot-shaped hyperchromatic nuclei encircled by 
minimal cytoplasm (Massimino et al., 2013). The Desmoplastic/nodular form of 
medulloblastoma is known to have nodular, reticulin-free zones, which are neuronal 
maturation zones. It is characterised by a small nuclear cytoplasmic ratio, a fibrillary matrix, 
and homogenous cells with a neurocytic appearance (Eberhart et al., 2002a). The densely-
packed cells at very active mitotic state surround the constituent nodules, which results in 
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the production of a dense intercellular reticulin-positive network of fibres (McManamy et 
al., 2007). 
Medulloblastoma with extensive nodularity (MBEN) is known to be predominant in infants 
and it has characteristic better prognosis (Eberhart et al., 2002a); and it is distinct from the 
closely-related nodular/desmoplastic subtype by possessing an expansive lobular 
conformation because of the unusual elongation of the reticulin-free zones and enriched with 
neuropil-like tissue (McManamy et al., 2003). Such zones are filled with small cells that 
have characteristic spherical nuclei that bear close semblance to the cells of a central 
neurocytoma and exhibit a streaming pattern; coupled with the marked reduction of the 
internodular component in some areas (McManamy et al., 2007). Structurally, the large cell 
medulloblastoma is made up of monomorphic cells with large, round, vesicular nuclei, 
prominent nucleoli and variably abundant eosinophilic cytoplasm. Groups of these large 
cells tend to combine with morphologically different cells with characteristic nuclear 
polymorphism and nuclear conformation; this morphological variant has been termed 
anaplastic (Massimino et al., 2016). Large cell and anaplastic histological forms of 
medulloblastoma have been reported to show considerable cytological overlap and many 
studies have attempted to describe the histological alternation between non-anaplastic to 
anaplastic subtypes over time. However, some studies have reported alternated transition 
intra-tumour, as deduced from the presence of varying degrees of cytological atypia or 
anaplasia in any given tumour (Eberhart et al., 2002a; Massimino et al., 2016). 
Clinically, different reports have significantly shown good prognosis for the 
nodular/desmoplastic medulloblastoma at least in certain age groups as well as risk groups, 
particularly in children at younger age (Rutkowski et al., 2005; McManamy et al., 2007). 
Additionally, classic form of medulloblastoma has been reported to show significantly better 
prognostic outcome relative to the LC/A histological variant (Massimino et al., 2013). 
 
1.5.2. Molecular Subgroups of Medulloblastoma 
Increased understanding of the molecular characteristics of medulloblastoma and the advent 
of molecular diagnostics have resulted in the classification of the disease into distinctive 
subgroups (Kool et al., 2012). From the currently established global understanding, there 
are four distinct subgroups of tumours of the medulla, including WNT (wingless), SHH 
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(sonic hedgehog), Group 3 medulloblastoma, and Group 4 medulloblastoma (Taylor et al., 
2012), as represented in Table 1.1. These four molecular subgroups of medulloblastoma 
were isolated using series of genomics and molecular studies They are known and identified 
by properly defined genetic, molecular, clinical, histopathological, and prognostic features 
(Northcott et al., 2012; Ramaswamy et al., 2014; Schneider et al., 2105; Ramaswamy and 
Taylor, 2017; Kuzan-Fischer et al., 2018). From recent research findings derived from 
genetic, transcriptional and epigenetic data, it has been suggested the need to further 
categorise medulloblastoma into subtypes based on molecularly characteristics and such 
sub-classification is most likely to have positive impact on patient stratification in future 
clinical trials (Northcott et al., 2017; Schwalbe et al., 2017; Cavalli et al., 2017). 
 
Table 1.1. Molecular Subgroups of Medolloblastoma. 
 WNT SHH GROUP 3 GROUP 4 
Age Group Children 
& Adults 
Infants, Children & 
Adults 
Infants & 
Children 
Infants, Children 
& Adults 
Metastasis Rarely 
M+ 
Uncommonly M+ Very frequently 
M+ 
Frequently M+ 
Prognosis Very 
good 
Infants good, others 
intermediate 
Poor Intermediate 
Genetics CTNNB
1 
mutation 
PTCH1/EMO/SUFU 
mutation / 
GL12 amplification / 
MYCN 
amplification 
MYC 
amplification 
CDK6 
amplification 
Gene 
Expression 
WNT 
signallin
g 
MYC+ 
SHH signalling 
MYCN+ 
Photoreceptor / 
GABAergic 
MYCN+++ 
Neuronal/Gluta
matergic 
minimal 
MYC/MYCN 
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1.5.2.1. WNT (Wingless) Medulloblastoma  
This is the least prevalent medulloblastoma molecular subgroup, constituting approximately 
11% of the total reported incidences of medulloblastoma (Kool et al., 2012). Though, 
wingless form of medulloblastoma has been reported to occur at all ages, children are 
predominantly affected, with the highest frequency of occurrence recorded in children of 10 
to 12 years (Taylor et al., 2012). Unlike other molecular subgroups of medulloblastoma, 
WNT forms have been reported to have a female preponderance, based on gender ratio. 
Typically, WNT tumours are known to occur in the mid region of the brain, affecting the IV 
ventricle and extending to the brain stem (Gajjar and Robinson, 2014). 
Based on their histological features, most WNT forms of medulloblastoma belong to the 
classic histological subgroup; although, instances of wingless medulloblastoma with LC/A 
histology have been rarely reported (Gajjar and Robinson, 2014). IHC expression of 
DKK1, Filamin-A, YAP-1, and beta-catenin, particularly the nuclear +/− cytoplasmic 
expression, have been demonstrated as a very reliable method for the identification of 
medulloblastoma that have characteristic wingless pathway (Ellison et al., 2011). On a 
positive note, WNT medulloblastoma show much lower metastatic diffusion than other 
molecular subgroups and they have best prognosis, with reported survival rates of about 
95-100% (Salaroli et al., 2015). The reason behind the characteristic improved survival 
rates associated with WNT is still unknown, though, it has been attributed to its increased 
susceptibility to radiation therapy (Gajjar and Robinson, 2014; Salaroli et al., 2015). 
More than 75% of tumours in the WNT molecular subgroup of medulloblastoma habour 
an exon 3 mutation, and in particular a point mutation of the CTNNB1 gene, which encodes 
beta-catenin (Gilbertson, 2004), resulting in the increased excitation of the wingless 
pathway through beta-catenin resistant to breakdown and resulting in nuclear localisation 
of the gene products (proteins) with elevated transcription of genes such as cyclin D1 and 
MYC, that are concerned with cellular proliferation (Massimino et al., 2016; Kuzan-
Fischer et al., 2018). Cytogenetically, WNT pathway tumours have been reported to show 
a characteristic monosomy 6 in more than 79% of patients (Shih et al., 2014). Besides 
monosomy 6, the genomic composition of WNT medulloblastoma is comparatively silent 
and only associated with scarce chromosomal deletion and/or insertion across the genome 
(Gilbertson, 2004). However, in addition to monosomy 6, other genetic alterations such as 
copy number variation (CNV) and/or single nucleotide variants (SNV) include mutations 
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in the gene that promotes cellular proliferation through the increased activating capacity of 
beta-catenin, SMARCB4, p53 gene alteration, tetraploidy, and MLL2 alterations 
(Northcott et al., 2012; Jones et al., 2012). In a clinical trial that assessed medulloblastoma 
patients with characteristic WNT molecular features, Clifford et al. (2015) revealed new 
insights into the clinical features and further demonstrated that relapses occur at higher 
frequency in patients of 16 years at diagnosis. This report agrees with the earlier reports 
from a series of retrospective studies, in which bimodal distribution of age and very poor 
prognosis were demonstrated in adults with WNT medulloblastoma relative to children 
(Korshunov et al., 2010; Kool et al., 2012; Clifford et al., 2015). 
 
1.5.2.2.  Sonic Hedgehog Medulloblastoma  
In normal cerebellar physiology and development, the sonic hedgehog (SHH) pathway plays 
a significant role, where it is responsible for the initiation of the rapid growth of primordial 
cells of the neuron, and its proliferation in the growing cerebellum and other brain tissues 
alike (Massimino et al., 2016). The formation and growth of the external germinal layer 
from the cells of the granule and precursor cells is facilitated by the SHH ligand 
(McManamy et al., 2007). Additionally, paracrine signalling emanating from SHH or the 
activation resulting from PTCH1 mutations leads to the breakdown of some molecular 
regulators, especially the serpentine G-protein coupled receptor SMO from PTCH, and its 
subsequent translocation into the apical section of the cilium, releasing GLI2 from its 
original repressor called suppressor of fused homolog (Archer et al., 2012). From thence, 
the GLI2 localises to the nucleus, where it modulates genes that are responsible for the 
excessive growth of the granule cell precursor cells of the cerebellum, resulting in tumour 
development (Jones et al., 2012; Archer et al., 2012).  
The SHH molecular subgroup of medulloblastoma has been reported to account for 
approximately 30% of all reported cases of medulloblastoma (Taylor et al., 2012). Relative 
to age, its localisation is bimodal, occurring more frequently in children of less than 3 years 
of age and adults of 16 years of age and above; and less frequently reported in patients who 
are 3 years to 16 years old (Gibson et al., 2010). The gender ratio has been shown to be 1:1, 
though incidence rate has been shown to be slightly higher in males (Gajjar and Robinson, 
2014). The SHH subgroup of medulloblastoma predominantly occurs in the hemispheric 
region of the cerebellum; however, some tumours of the SHH pathway have been reported 
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to originate in the mid vermis (Jones et al., 2012). Histologically, SHH medulloblastoma 
have characteristic nodular cum desmoplastic form with MBEN being exclusively added 
into this group; though, there have been reports other forms of SHH medulloblastoma which 
are known to be either of classic or LC/A histology (Ellison et al., 2011). Molecular 
biomarkers like GAB1, SFRP, and GLI1 protein have been reported as the key hallmarks 
for the identification of SHH medulloblastoma using tumour IHC expression for such 
molecular features; but diagnosis of the disease at metastatic stage rarely occurs (Ellison et 
al., 2011; Taylor et al., 2012).  
SHH medulloblastoma has characteristic PTCH1 mutations and approximately 36–54% 
cases of SHH medulloblastoma have been reported to show PTCH1 mutations (Kool et al., 
2014). The characterisation of somatic mutations of PTCH1 in patients devoid of Gorlin 
syndrome has deepened the already established correlation between medulloblastoma and 
sonic hedgehog signalling, including molecular alterations in SUFU and SMO, elevated 
expression of SHH, GLI2, and increased expression of MYCN genes (Massimino et al., 
2016). Previous reports have associated the expression of MYC or MYCN with histological 
features that are large-cell/anaplastic and poor prognostic features of medulloblastoma. 
Similarly, tumours with characteristic MYC or MYCN over-expression and tumours 
harbouring 6q insertion make up subgroups of medulloblastoma which are especially 
characterised by poor prognosis (Eberhart et al., 2002b). Kool et al., (2014) observed that 
mutations affecting PTCH1 gene occurred at an approximate percentage frequency of 36% 
in infants, 42% in children, and 54% in adults. In their work, which was a large-scale 
genomic study of sonic hedgehog subgroup of medulloblastoma, they further observed that 
SUFU mutations were characteristically predominant in infant medulloblastoma patients, 
and SMO mutations were more frequent in adult medulloblastoma patients (Kool et al., 
2014). 
The SHH subgroup of medulloblastoma has a broader molecular heterogeneity in older 
children, where they show increased expression of MYCN and GLI2 genes; TP53 mutations 
predominant in cancers of older children with sonic hedgehog medulloblastoma have also 
been reported (Zhukova et al., 2013). Similarly, over 50% of such children were reported to 
have Li- Fraumeni syndrome and mutations of genes in germline cells that conferred SHH 
medulloblastoma in individuals with very poor prognosis (Jones et al., 2012). They also 
reported tetraploidy in about 29% of investigated samples and it was associated with p53 
mutations. In the same vein, alterations affecting copy number such as the increased 
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expression of protein phosphatase, PIK3C2G, IRS2, YAP-1, and PIK3C2B coupled with the 
deletion of PTEN which are localised on chromosome 10q23.31 and mutations in other 
related genes, was reported by Northcott et al. (2012b).  
At the point of diagnosis, patients within the SHH molecular subgroup of medulloblastoma 
rarely show a disseminated tumour because they are tenable to immediate prognostic 
propensity, with overall survival of over 75% across a 5-year period, particularly when 
standard therapy is employed in the treatment (Taylor et al., 2012). Although, in a relatively 
recent study, Min et al. (2013) reported that a complete deletion of chromosome 14, 
increased expression of GLI2, loss of q10, MYCN upregulation, anaplastic and metastatic 
medulloblastoma at the diagnostic stage identify, have aided the characterisation of further 
subgroups in sonic hedgehog medulloblastoma patients, worsening their prognostic 
propensities. 
 
1.5.2.3.  Group 3 Molecular Subgroup of Medulloblastoma 
This molecular subgroup of medulloblastoma is roughly responsible for 25-28% of the entire 
diagnosed cases of medulloblastoma and it is predominantly found in children, 
characteristically affecting more males, increased frequency of metastasis at the point of 
diagnosis and high incidence of LC/A histology (Northcott et al., 2012). In children, 
medulloblastoma Group 3 has not been shown to be a defining factor and the molecular 
pathogenesis of the disease remains largely unknown. However, some scientists have 
identified expression for NPR3 (Natriuretic Peptide Receptor 3) as a confirmatory feature 
of Group 3 medulloblastoma, however, the validity of this biomarker is in doubt (Taylor et 
al., 2012). 
Almost all cases of Group 3 medulloblastoma have aberrant MYC expression, sometimes 
associated with high-level expression (Northcott et al., 2012). Group 3 medulloblastoma 
also shows characteristic genomic instability with frequent gains due to the insertion at 
chromosomes 1q, 7q, and 17q along with loss of 10q, 11, 16, and 17p (Northcott et al., 
2012). At an early stage in the development of Group 3 medulloblastoma there is a 
significant occurrence of tetraploidy in up to 54% of all cases of the disease (Jones et al., 
2102). When there are no p53 mutations, chromothripsis is a frequent event in Group 3 
medulloblastoma, resulting in aberrant chromosomal rearrangement or fusions due to 
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inefficient DNA repair. Similarly, TGF-β signalling appears to be increased because of 
dysregulation of the genes that are implicated in this signalling pathway and association with 
downstream target genes including OTX-2 (Northcott et al., 2012).  
Amongst all the four molecular subgroups of medulloblastoma, Group 3 is known to be 
associated with the worst prognosis, with less than 50% survival and no survivor exceeding 
10 years of follow-up in evaluation of retrospective studies (Kool et al., 2012; Massimino 
et al., 2016). This agrees with the findings of the study conducted by Shih et al. (2014) that 
revealed that the existence of i17q, MYC upregulation, and the presence of metastatic 
medulloblastoma that are responsible for poor prognosis of Group 3 medulloblastoma, and 
patients without these markers show a relatively better survival. 
 
1.5.2.4. Group 4 Molecular Subgroup of Medulloblastoma  
Group 4 medulloblastoma has been reported to be the most predominant subtype, 
constituting approximately 35% of all diagnosed medulloblastoma. Group 4 
medulloblastoma affects patients of all age groups, with male predominance, but it is rarer 
in infants (Kool et al., 2012; Northcott et al., 2012). Although, Group 4 medulloblastoma is 
the commonest of all the molecular subtypes, its molecular pathogenesis is poorly 
understood (Kuzan-Fischer et al., 2018). Histologically, most of the Group 4 
medulloblastoma have characteristic classic histology; however, some instances of LC/A 
have been reported (Massimino et al., 2016). Group 4 medulloblastoma have been linked 
with KCNA1 as its IHC marker but no other report has validated such claim (Ellison et al., 
2011). 
Group 4 medulloblastoma patients have been reported to have a moderate prognosis with 
standard cytotoxicity regimen. Shih et al. (2014) observed that excellent prognostic 
features are on subset of patients with Group 4 medulloblastoma following the loss of 
chromosome 11 and the presence of i17q, regardless of the attainment of metastatic stage 
by the disease at the point of diagnosis. Like Group 3 tumours, Group 4 medulloblastoma 
is characterised by tetraploidy in at least 40% of cases, as an initial transformation (Jones 
et al., 2012). In over 80% cases of medulloblastoma, the occurrence of isochromosome 17q 
has been reported in addition to 17p deletion, and MYCN and CDK6 genes are reported to 
be commonly amplified (Skowron et al., 2015). Female patients of Group 4 
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medulloblastoma predominantly lose one copy of the X chromosome, implying that one or 
more tumour suppressor genes might be present on this chromosome (Jones et al., 2012). 
Also, in Group 4 medulloblastoma, neural stem cells are kept undifferentiated state due to 
the excessive amplification of EZH2 (enhancer of Zeste homologue 2) and mutations 
affecting chromatin-remodelling genes such as KDM6A, which codes for a H3K27 
methylase and located on chromosome Xp11.3., ZYMYM3, and CHD7; thus, sustaining 
tumorigenesis (Massimino et al., 2016). In Table 1.2, a synopsis of the key genomic and 
clinical features of the four molecular subgroups of medulloblastoma is given.  
 
Table 1.2. A synopsis of the key genomic and clinical features of the medulloblastoma 
molecular subgroups. 
 
WNT SHH GROUP 3 GROUP 4 
Histological 
Feature 
Classic, Rarely 
LCA 
Desmoplastic, 
Classic, LCA 
Classic, LCA Classic, LCA 
Rate of 
Metastasis 
Low Low High High 
Prognostic 
State 
Excellent Intermediate Poor Intermediate 
Alterations 
Somatic 
Copy 
Number 
– MYCN (12%) 
GLI2 (8%) 
MYC (17%) 
PVT1 (12%) 
OTX2 (8%) 
SNCAIP (10%) 
MYCN (6%) 
CDK6 (5%) 
Single-
Nucleotide 
Variants 
CTNNB1 (91%) 
DDX3X (50%) 
SMARCA4 (26%) 
MLL2 (13%) 
TPS3 (13%) 
TERT (60%) 
PTCH1 (46%) 
SUFU (24%) 
MLL2 (16%) 
SMQ (14%) 
TP53 (13%) 
SMARCA4 (11%) 
MLL2 (4%) 
KDM6A (13%) 
MLL (5%) 
Broad 
Events 
6 Loss 3q Gain 
 
9q, 10q, 14q 
Loss 
1q, 7, 17q, 18q 
Gain 
 
8, 10q, 11, 16p, 
17p Loss 
7, 17q, 18q Gain 
 
8,11p, X Loss 
Expression WNT Signaling SHH Signaling MYC/Retinal 
Signature 
Neuronal 
Signature 
Recurrence – Local Metastatic Metastatic 
Adapted from: (Massimino et al., 2016). 
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1.5.3. Risk-Based Classification of Medulloblastoma Patients 
Medulloblastoma patients are traditionally categorized into two key risk strata, namely, the 
average risk and the high risk medulloblastoma patients. This classification is based on three 
clinical factors, which includes the patients’ age during diagnosis, whether there is 
leptomeningeal dissemination or not, and extent of residual tumour post-resection (Kuzan-
Fischer et al., 2018). Patients are classified as average risk if they are older than 3 years of 
age at the point of diagnosis, with residual tumour size less than 1.5 cm2, in addition to 
negative results for macroscopic metastasis on imaging scans as well as CSF analysis for 
microscopic tumour cells (Massimino et al., 2016; Kuzan-Fischer et al., 2018). High risk 
medulloblastoma patients are characterised by the presence of metastasis and/or a 
postoperative tumour size greater than 1.5 cm2. Medulloblastoma patients that are infants 
below the age of 3 years are generally referred to as high risk patients (Northcott et al., 
2011). 
At the 2015 meeting held in Heidelberg, a new medulloblastoma patient risk classification 
protocol premised on the molecular and prognostic features of the disease was suggested for 
patients of medulloblastoma that are within the age range of 3 and 17 years (Ramaswamy et 
al., 2016a, b). This proposed reclassification protocol is made up of four risk groups, mainly 
defined by outcome; and considers the heterogeneous nature of the disease and detailed 
information of the molecular subgroup (Kuzan-Fischer et al., 2018). Based on survival 
outcome, the protocol considers as very high risk if the patients’ survival is less than 50%, 
high risk patients show 50-75% survival, standard risk patients have survival outcome of 
75-90%, and low risk patients have over 90% survival outcome (Ramaswamy et al., 2016b). 
The protocol also opined that individuals suffering from metastatic group 3 
medulloblastoma and patients that have sonic hedgehog tumours with characteristic p53 
mutations, show appalling prognosis and are to be accorded the class of very high risk 
(Ramaswamy et al., 2016a; Kuzan-Fischer et al., 2018). Medulloblastoma patients are also 
considered high risk if they are diagnosed with metastatic or MYCN amplified SHH tumour; 
same is applicable to group 4 medulloblastoma patients with leptomeningeal dissemination 
(Ramaswamy et al., 2016b). On the other hand, medulloblastoma patients are considered 
standard risk if they have unamplified MYCN, unmutated p53 SHH medulloblastoma, group 
3 medulloblastoma with unamplified MYCN, and group 4 tumours devoid of chromosome 
11 loss, as shown in Table 1.3 (Ramaswamy et al., 2016b; Kuzan-Fischer et al., 2018). 
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Importantly, the recently proposed patient risk classification gives room for the assessment 
of treatment reduction for patients whose outcomes are favourable and facilitates the 
possibility of identifying as well as testing recent rationale for target-specific therapies in 
medulloblastoma patients within the range of high risk to very high-risk categories 
(Ramaswamy et al., 2016b; Kuzan-Fischer et al., 2018). 
 
Table 1.3. Medulloblastoma patient risk stratification using molecular and survival 
outcome as criteria. 
 Low risk 
(>90% 
survival) 
Standard risk 
(survival rate 
of 75-90%) 
High risk (survival 
of 50-75%) 
Very high risk 
(survival = 
<50%) 
WNT Non-metastatic    
SHH  Non-metastatic 
AND 
TP53WT 
AND 
No MYCN 
amplification 
Metastatic 
AND 
TP53 WT 
OR 
Non-metastatic 
AND 
MYCN 
amplification 
TP53 mutation 
Group 
3 
 Non-metastatic 
AND 
No MYC 
amplification  
 Metastatic 
AND 
MYC 
amplification 
Group 
4 
Non-metastatic 
AND 
Chromosome 11 
loss 
Non-metastatic 
AND 
No 
chromosome 
11 loss 
Metastatic  
Adapted from: Kuzan-Fischer et al. (2018). 
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1.5.4. Current Medulloblastoma Therapies 
Currently, the treatment protocols for medulloblastoma patients are mostly hinged on the 
conventional risk categorisation and patient’s age at the point diagnosis (Ramaswamy and 
Taylor, 2017). Irrespective of the risk group, patients are firstly subjected to tumour 
resection during diagnosis (Kuzan-Fischer et al., 2017). Recently, Thompson et al., (2016) 
conducted a re-evaluation of the prognostic value of the extent of medulloblastoma 
resection, taking the different subgroups into consideration. Their findings revealed that 
regardless of molecular subgroup, gross total resection has no benefit subtotal resection in 
overall survival for patients, but for patients that were subjected to near-total in lieu of gross-
total resection, no overall survival or progression-free survival advantage was recorded 
(Thompson et al., 2016). Consequently, it is rational to suggest that maximal removal by 
surgery stands as the benchmark of care for patients of medulloblastoma. Additionally, there 
were no obvious practical benefits of surgical resection of minimal residual 
medulloblastoma that embodies an increased risk of morbidity neurologically (Thompson et 
al., 2016; Kuzan-Fischer et al., 2018). 
Though, cut-off age varies from one clinical trial to another, Lafay-Cousin et al. (2016) 
reported that patients designated as average risk patients between the age of 3 to 5 years are 
exposed to the irradiation of craniospinal region at the of 23.4 Gy boosted with an additional 
dose of 55 Gy to the tumour microenvironment in the posterior fossa followed by a 
chemotherapeutic regimen that is characteristically cytotoxic. For individuals at the “high 
risk” category, Holgado et al., (2017) suggested craniospinal irradiation of 36-39 Gy dosage, 
boosted with a further dose of 55 Gy to the bed of the tumour, supported with cytotoxic 
chemotherapeutic regimen. In this case, cisplatin/carboplatin-vincristine-cyclophosphamide 
combination regimens constitute the typical chemotherapeutic intervention (Kuzan-Fischer 
et al., 2018).  
Due to the debilitating side effects of craniospinal radiation on the neuro-cognitive ability 
of developing nervous system, infant patients of medulloblastoma that are not up to the age 
of 3 to 5 years are now treated through approaches devoid of irradiation (Grill et al., 2005; 
Cohen et al., 2015; Holgado et al., 2017). For such non-radiation medulloblastoma therapies 
targeting infants within the age group of 3-5 years, a variety of chemotherapy regimens have 
been under intense research, including etoposide, cisplatin, vincristine, and 
cyclophosphamide, and a further administration of autologous hematopoietic cell rescue and 
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methotrexate administered intravenously and intraventricularly, cyclophosphamide, 
cisplatin analogue (carboplatin), and vincristine (Rutkowski et al., 2005; Cohen et al., 2017; 
Kuzan-Fischer et al., 2018). Unfortunately, for patients in this age group that are diagnosed 
with non-desmoplastic histology and macroscopic metastatic medulloblastoma, survival 
rates and general outcomes have been abysmally poor (Ramaswamy and Taylor, 2017). 
 
1.5.5. Biologically-Informed Medulloblastoma Treatment Strategies: Targeted 
Therapies 
Because of the current knowledge of the fact that medulloblastoma is an aggregation of 
highly heterogenous tumours, molecularly stratified clinical trials have been executed, with 
focal interest in molecular subgroups of the disease and a defined knowledge of patient risk 
stratum (Ramaswamy et al., 2016 a; b; Northcott et al., 2012b). Owing to the advanced 
understanding of major molecular and genetic changes within various medulloblastoma 
subgroups and histological subtypes, researchers have continued to strive to develop novel 
targeted therapies specific to molecular pathways and risk-adapted treatment protocols that 
are patient-specific and suitable to a patient’s tumour (Triscott et al., 2013; Gajjar et al., 
2014; Holgado et al., 2017; Ramaswamy and Taylor, 2017). Recent research efforts are 
geared towards many scientific trials to develop and experiment and establish small 
molecular inhibitors, immunotherapies and other therapies that are based on antibodies, with 
potentials of taking advantage of the molecular vulnerabilities of different molecular 
subgroups as well as histological subtypes of medulloblastoma (Faria et al., 2015; Badodi 
et al., 2017; Holgado et al., 2017). 
For low risk, non-metastatic WNT medulloblastoma, de-escalation of first-line treatment is 
one of the key strategies that are introduced in majority of active clinical trials (Holgado et 
al., 2017). These clinical trials are designed with the intent of craniospinal irradiation 
reduction or elimination and implement reduced dosage of chemotherapeutic regimes 
(Ramaswamy and Taylor, 2017). Owing to the excellent overall patients’ survival that have 
reported for this class of medulloblastoma, these clinical pre-clinical studies are primarily 
aimed at reducing deaths emanating from side effects of treatments in patients with survival 
outcomes that are biologically favourable (Ramaswamy et al., 2011; Henrich et al., 2014; 
Ramaswamy et al., 2016b). 
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For more than a decade now, action-specific molecular targeted therapies against SHH 
medulloblastoma have been under serious investigation; hence, the activation of Hedgehog 
signalling pathway in medulloblastoma has been identified and established in many 
preclinical studies and the efficacy of inhibitors of hedgehog pathways in medulloblastoma 
has been proven in different in vitro studies (Berman et al., 2002; Taipale et al., 2002; 
Robinson et al., 2015). Some of the first action-specific therapies to advance to first stage 
trials in individuals suffering from medulloblastoma were the competitive antagonists of the 
smoothened receptor, vismodegib and sonidegib (Robinson et al., 2015). Interestingly, 
whether paediatric or adult, all medulloblastoma patients treated with vismodegib recorded 
an improvement in the survival of patients with persistent sonic hedgehog type of 
medulloblastoma, though in other molecular subgroups of medulloblastoma, the survival 
outcomes were dismal (MacDonald et al., 2014; Robinson et al., 2015). One of the major 
determinants of response to SMO (smoothened) inhibition is the defined localisation of 
hedgehog cascade modifications downstream of SMO, such as SUFU mutations, which 
negatively regulates hedgehog signalling and the amplification GLI group zinc finger 2 
(GLI2) or MYCN upregulation, that result in the conferment of resistance to SMO inhibitors 
(Pambid et al., 2014; Kool et al., 2014). Based on these molecular premises, a single therapy 
involving the use of smoothened inhibition has been reportedly linked to the isolation of 
therapy-resistant sub-clones through SMO inhibition mutations or increased expression of 
alternative proteins that are associated with survival (Buonamici et al., 2010; Massimino et 
al., 2016); hence, indicative of the possibility that SMO inhibitors cannot achieve durable 
treatment response independently, but will require the company of additional agents to 
function and guarantee better treatment response (Yauch et al., 2009). Similarly, alternative 
molecular agents that target downstream components of the hedgehog signalling pathway 
have been reported to be made up of the trioxide of arsenic and itraconazole, GLI 
transcription factor inhibitors, that could show effectiveness in a small group of hedgehog-
activated medulloblastoma patients that is not determined by SHH-PTCH1-SMO (Kim et 
al., 2013; Rusert et al., 2014). 
Furthermore, other molecular pathways that may proffer targetable vulnerabilities within the 
SHH subgroup have been identified and established through a series of preclinical studies 
(Mille et al., 2014; Faria et al., 2015). For instance, the significance of the PI3K pathway in 
SHH medulloblastoma metastasis was demonstrated in a genomic analysis of mouse model 
of SHH medulloblastoma, in which tumour populations at the stage of metastasis were 
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enriched for clones through the addition of the PI3K pathway (Wu et al., 2012). Mutations 
affecting TP53 are frequently reported in SHH medulloblastoma subtypes; hence, molecular 
therapies targeting such pathway could provide a reasonable alternative to irradiation and 
help overcome radiation resistance associated with these mutations (Tabori et al., 2010; 
Zhukova et al., 2014). 
For group 3 and group 4 molecular subgroups of medulloblastoma, there are no current 
specific targeted therapies in existing clinical trials (Kuzan-Fischer et al., 2018). However, 
Holgado et al. (2017), while attempting to produce a tailored medulloblastoma therapy 
through genomics and evaluating one molecular subgroup at a time; designed a trial 
containing a treatment regimen for patients that have progressed to metastasis during the 
time of diagnosis, incomplete removal and amplification of MYC or MYCN, that were 
referred to as high risk patients (Holgado et al., 2017). Although patients with Group 3 
medulloblastoma molecular subgroup have been shown to have worst prognosis, no current 
clinical trials are known to be investigating targeted therapies in Group 3 and Group 4 
medulloblastoma patients (Faria et al., 2015). It is therefore, important that such studies are 
prioritised. 
Group 3 and Group 4 molecular subgroups of medulloblastoma have been shown to 
demonstrate high degree of heterogeneity as per activated signalling pathways, with the 
overexpression of MYC being the most predominant cytogenetic marker in Group 3 tumours 
(Venkataraman et al., 2014; Pei et al., 2016). Treatment via the combined use of PI3K and 
molecular inhibitors have shown promising results when preclinical agents in Group 3 
MYC-driven medulloblastoma are targeted (Alimova et al., 2012; Dubuc et al., 2013; 
Hovestadt et al., 2014; MacDonald et al., 2014). 
 
1.5.6. Metastatic Medulloblastoma 
Typically, medulloblastoma metastasis involves tumour cell movement to the 
leptomeninges, and the spread and establishment of the disease within the leptomeningeal 
area constitute the most formidable treatment challenge confronting clinicians (Kuzan-
Fischer et al., 2018). Across all molecular subgroups of medulloblastoma, the incidence of 
metastatic tumours at diagnosis has been reported to be approximately 40%, although the 
frequency of metastasis varies across different subgroups at the point of diagnosis (Wu et 
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al., 2012; Zapotocky et al., 2017). In the non-wingless subgroup of medulloblastoma, 
tumour metastasis during the period of diagnosis is an indicator of bad prognostic feature 
(Ramaswamy et al., 2016b). 
 
Owing to the widely-reported treatment failure that have pervaded the clinical setting of 
relapsed metastatic medulloblastoma, the current key focus of investigation is treatment of 
metastatic compartment (Ramaswamy and Taylor, 2017). Significantly, medulloblastoma 
has been demonstrated to undergo notable clonal selection and evolution during 
tumorigenesis; by implication, tumour cells from metastatic compartment are have 
characteristic genetic and epigenetic changes that are uncommon in the primary tumour cells 
(Wang et al., 2015). This assertion is based on reports from genomic analysis via integrated 
profiling approach such as copy number variation, DNA methylation, and exon sequencing 
analysis of corresponding tumour samples derived from human medulloblastoma at primary 
and metastatic phases; in addition to reports obtained from a murine transposon-driven a 
model of SHH medulloblastoma, where unified transposon insertion locations were shown 
to be glaringly different between the primary and metastatic tumours (Wu et al., 2012). It is 
therefore, rationale to suggest that molecular pathways determine the survival of metastatic 
medulloblastoma cells in the metastatic microenvironment or compartment, and such cells 
are invariably different from the cells of the primary tumours and specialised targeted 
treatment will be likely required to achieve an improved survival outcome. Currently, the 
molecular mechanisms that underlie medulloblastoma metastasis is still poorly understood; 
consequently, preclinical studies that are aimed at identifying such mechanisms, whereas 
future trials are needed to establish the defining genetic and molecular profiles of 
medulloblastoma; and analysis of the metastatic tumour microenvironment via tissue biopsy 
to establish the presence of possible therapeutic target that could help optimize 
medulloblastoma patients selection for further experimental therapies. It is also important to 
delve into the implications of DNA damage repair genes in the development of different 
molecular subgroups of medulloblastoma; given the universal report of frequent mutations 
in of key cancer-critical genes, especially the tumour suppressor TP53 gene in most of the 
medulloblastoma subgroups. This is where this PhD is likely to contribute in improving our 
understanding of the molecular characteristics of medulloblastoma and consequent 
development of possible molecular targeted therapies. 
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1.6. Mesothelioma 
Mesothelioma is a rare but prolifically aggressive, asbestos-related cancer that develops on 
the linings (known as the mesothelium) that cover many internal organs such as the lungs, 
heart and abdomen (Kondola et al., 2016). It is often referred to as a cryptic neoplasm owing 
to its characteristic ability to maintain a prolonged period of latency following contact with 
asbestos, remaining asymptomatic and undetected in the body for up to 40 years in some 
cases (Frank, 2012). It originates from the surfaces of mesothelium tissues in the pleural 
region; though, it is not exclusive to the pleural mesothelium, as it can emerge in the tunica 
vaginalis as well as the peritoneal (Teta et al., 2008). In the US, Surveillance Epidemiology 
and End Results (SEER) registry data indicated that the number of reported new cases of 
mesothelioma per annum is approximately 3,300, compared to about 200,000 lung cancer 
incidences (Frank, 2012). 
The risk of mesothelioma development increases with increased exposure to asbestos and 
disease symptoms could take about 20 years and sometimes, up to 50 years to appear 
following contact with asbestos. Currently, patients suffering from mesothelioma show a 
characteristic poor life expectance, because it has no known cure at present. However, the 
disease stage, histological subtype and the tumour location are the most significant 
determinants the survival patient. Additionally, the overall health of the patient, age and 
whether that cancer has assumed metastatic state, are also of critical prognostic significance 
(Frank, 2012). 
 
1.6.1. Histology and Prognostic Features of Mesothelioma 
Mesothelioma is categorized based on location or cell type. Dependent of the location where 
a tumour first develops, mesothelioma is subdivided into four primary types, namely: pleural 
(lungs), peritoneal (abdomen), pericardial (heart), and testicular (testis) mesothelioma (Teta 
et al., 2008). 
Pleural mesothelioma is the type of cancer that develops in the tissue surfaces of the linings 
the lungs, known as the pleura. It is the most predominant form of mesothelioma, accounting 
for over 80% of reported new cases. Pleural mesothelioma is difficult to diagnose because 
it shows no or very minimal symptoms in the early stages (Kondola et al., 2016). However, 
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at later stages, symptoms tend to worsen significantly; hence, pleural mesothelioma 
prognosis is very poor, with most patients surviving less than 17 months following the 
appearance of initial noticeable symptoms (Barreiro and Katzman, 2006; Kondola et al., 
2016). 
Peritoneal mesothelioma is the form of mesothelioma in which the tumour develops in the 
thin layer of tissues lining the abdomen, the abdominal mesothelium. Because of the 
proximity between the abdominal lining and vital abdominal organs, peritoneal 
mesothelioma frequently spreads to such organs as liver, spleen and bowel. It is 
characterized by severe pain in the abdominal as the most predominant symptom, in addition 
to discomfort associated with abdominal effusion (fluid buildup) (Raza et al., 2014). 
Although, peritoneal mesothelioma has poor prognosis, the use of hyperthermic 
intraperitoneal chemotherapy (HIPEC) in recent years, has somewhat impacted positively 
on prognosis. In this case, outcomes are patient-specific but survivorship, is dependent on 
the patient’s situation and particular diagnostic factors (Barreiro and Katzman, 2006).  
Pericardial mesothelioma is the type of mesothelioma that originates from the tissues lining 
the heart cavity, the pericardium. Pericardial mesothelioma is very rare, accounting for less 
than 1% of the total reported cases of mesothelioma. As the disease progresses, it limits the 
rate of oxygen supply to the heart, resulting in further degeneration of patient’s health. The 
symptoms of pericardial mesothelioma resemble those of heart attack, including severe chest 
pain and breathing difficulty. In most cases, pericardial mesothelioma remains undiagnosed 
until autopsy is carried out (Sardar et al., 2012).  
Testicular mesothelioma is the rarest form of mesothelioma affecting the linings of the 
testicles. Only fewer than 100 cases of testicular mesothelioma have been diagnosed across 
the globe; hence, the mechanisms of development and the course of treatment are poorly 
understood (Frank, 2012). 
Currently, the only effective way to confirm mesothelioma diagnosis is by the analysis of 
cell types in the tissue samples obtained via biopsy. Such histological examination provides 
insight into which types of cell and subset of cells constitute mesothelioma. Consequently, 
mesothelioma is categorized into three forms based on the type of constituent cells, namely: 
epithelioid, sarcomatoid, and biphasic mesothelioma (Frank, 2012).  
Epithelioid mesothelioma is the commonest cell type prevalent in mesothelioma, accounting 
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for over 75% of all diagnosed cases. It is easily distinguishable under high magnification, 
especially with reference to its elongated pattern of shape. Epithelioid mesothelioma is 
mostly predominant in lung cancer and has the best prognosis of all mesothelioma cell types 
(Husain et al., 2009). 
Sarcomatoid mesothelioma cells originate from supportive tissue structures such as bones 
and muscles, accounting for less than 10% of all diagnosed cases of mesothelioma. They 
present the worst prognosis among all the cell types and are usually very difficult to treat. 
Histologically, they appear elongated and spindle-like and arranged in haphazard fashion 
(Wu et al., 2013).  
Biphasic mesothelioma is a mixture of both epithelioid and sarcomatoid cell types, 
coexisting as a single tumour tissue. It constitutes about 40% of all reported cases of 
mesothelioma. In this type of mesothelioma, the constituent cell types are differentiated, and 
by implication, the epithelioid cell types exist in separate area from the sarcomatoid cells. 
Biphasic mesothelioma has better prognosis than sarcomatoid mesothelioma and poorer 
prognosis relative to epithelioid mesothelioma (Husain et al., 2009). 
 
1.6.2. Molecular Pathogenesis of Malignant Mesothelioma 
As reviewed in the preceding sections, malignant mesothelioma is a rare but aggressive 
cancer that essentially develops in the superficial parts of serosal cells of the pleural region, 
peritoneum, and sometimes the surface linings of the pericardium and the tunica vaginalis 
of the testis (Tsao et al., 2009). About 80% of the entire reported cases of malignant 
mesothelioma originated from the pleura and are referred to as pleural mesothelioma or 
malignant pleural mesothelioma (MPM). Malignant mesothelioma development occurs 
latently in patients, and due to the ineffectiveness of radiological tools in detecting the 
disease at early stages, mesothelioma is mostly diagnosed at advanced stage; and biomarkers 
for early stage diagnosis are yet to be established (Sekido, 2013). In malignant 
mesothelioma, the structural localisation and features of the body cavities in which the 
disease originated from, aid the spread and invasion of neighbouring cavities by malignant 
cells (Tsao et al., 2009). 
Histologically, three major subtypes of malignant mesothelioma have been characterized, 
namely, epithelioid, sarcomatoid and biphasic; with rare histological variants also included 
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in this disease entity (Husain et al., 2009). Due to its characteristic unresponsiveness to 
conventional therapy and concomitant poor prognostic features, as indicated by a paltry 9 to 
12 months median survival of patients after diagnosis and considering its recalcitrance to 
recent advances in chemotherapeutic regimens combining cisplatin and pemetrexed 
(Vogelzang et al., 2003), it is therefore, urgent to undertake more studies to understand the 
molecular pathogenesis of mesothelioma. Although, some new molecular target drugs 
against the disease have been developed and occasionally demonstrated stabilization of 
malignant mesothelioma, such treatment modalities have failed to advance to the stage they 
could be recommended as an optimal/standard treatment regimen (Jakobsen et al., 2011). 
Because malignant mesothelioma is a relatively uncommon, research to expose its molecular 
pathogenesis and understand the genetic and epigenetic alterations that aid malignant 
mesothelioma development has lagged relative to other common cancer types (Jean et al., 
2012). In recent times, research findings from global genetic and epigenetic evaluations are 
facilitating the delineation of basic molecular abnormalities of this rare, but extremely 
aggressive cancer. Recently, several reviews of mesothelioma have made attempts to 
describe the myriads of genetic, epigenetic and signalling pathway modifications (Jean et 
al., 2012; Sekido, 2013). Considering the foregoing review, this PhD thesis investigated the 
expression of several DNA repair genes from different DNA repair pathways such as Neil1, 
Neil2, Neil3, (BER), Ercc1, (nucleotide excision repair, NER) and Mlh1 (MMR) in cell lines 
derived from malignant mesothelioma and further, attempted to compare gene expression 
levels in these cells with cancer stem cells derived from the cell line. 
 
1.6.3. Asbestos-Induced Molecular and Genetic Damage  
Exposure to asbestos has been shown to be the major cause of malignant mesothelioma and 
more than 80% of individuals that have this cancer have reportedly had contact with asbestos 
at one point in their lifetime (Pass et al., 2004). Asbestos represents a group of six mineral 
fibres, categorised into two subcategories, (a) a collection of fibres that are rod-like, known 
as the amphiboles, with five constituent members, namely, brown asbestos also called 
amosite, blue asbestos also known as crocidolite, tremolite, actinolite, and anthophyllite and, 
(b) the serpentine subcategory, made up of white asbestos, which is also known as chrysotile, 
as the only member of the category (Baumann et al., 2013). The correlation between the 
asbestos of the amphibole category and the tumorigenesis of malignant mesothelioma has 
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been extensively documented; particularly the blue asbestos, which has been severally 
reported to be the type of asbestos with the highest carcinogenic propensity (Mossman et 
al., 1990). An asbestos-like mineral known as erionite has also been implicated as a major 
cause of malignant mesothelioma (Sekido, 2013). 
After the inhalation of asbestos fibres deep into the lungs and their subsequent penetration 
into the pleural space, the interaction between the asbestos fibres with the cells of the 
mesothelium and inflammatory cells results in the initiation of prolonged cascade and 
repeated of tissue damage, tissue inflammation and repair, and the eventual development of 
malignant mesothelioma in a yet to be established mechanism (Liu et al., 2000; Pass et al., 
2004). It is still unknown why parietal pleura is the initial site of development of asbestos-
induced malignant mesothelioma, rather than the visceral pleura. Relative to other cell types, 
cells of the human mesothelium show very high susceptibility to asbestos toxicity; hence, 
there is a paradoxical question of how asbestos leads to the development of malignant 
mesothelioma given that the exposure of human cells derived from the mesothelium to 
asbestos is expected to lead to the death of the cells (Liu et al., 2000; Sekido, 2013). 
Many possible mechanisms that define the involvement of asbestos fibres in the 
development of malignant mesothelioma have been suggested (Toyokuni, 2009; Heintz et 
al., 2010). As represented in Figure 1.1, there are four proposed routes by which asbestos 
fibres initiate molecular and cytological destructions of cells of the mesothelium and severe 
inflammation that characterize malignant mesothelioma, namely: 
(i) Generation of reactive oxygen species: DNA damage including DNA strand 
breaks are caused by reactive oxygen species (ROS) emanating from the asbestos 
fibres and their exposed surfaces. Macrophages, while attempting to defend the 
organism phagocytose the asbestos fibres, however, they are unable to digest 
them, resulting in further production of abundant ROS (Toyokuni, 2009; Sekido, 
2013). 
(ii) Engulfment of asbestos fibres by mesothelial cells: the uptake of asbestos 
fibres by the cells of the mesothelium can result in its physical interference with 
the process of mitosis through the disruption of the mitotic spindles. 
Chromosomal structural aberrations and mesothelial aneuploidy could result 
from the entanglement of the asbestos fibres with mitotic spindles or 
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chromosomes (Toyokuni, 2009). 
(iii) Uptake of chemicals and binding of proteins by asbestos fibres: a variety of 
chemicals and proteins are adsorbed by the asbestos fibres to the extensive 
surface of asbestos leading to the accumulation of hazardous molecules including 
those capable of causing neoplasm of the mesothelium. Additionally, some 
important proteins have high affinity for asbestos fibres and when such proteins 
are deficient, mesothelial cells may be negatively affected (Toyokuni, 2009). 
(iv) Release of cytokines and growth factors: mesothelial cells and macrophages 
exposed to asbestos release myriads of cytokines and growth factors such as 
tumour necrosis factor-α (TNFα), interleukin-1β (IL-1β), transforming growth 
factor-β (TGFβ), and platelet-derived growth factor (PDGF), which induce 
inflammation and promote tumour development and cellular proliferation (As 
reviewed by Sekido, 2013). For instance, it has been demonstrated that TNFα 
activates nuclear factor-кB (NF-кB), resulting in mesothelial cell survival and 
inhibition of asbestos-induced cytotoxicity (Yang et al., 2006). It has also been 
shown that following the exposure of mesothelial cells to asbestos, they release 
high-mobility group box 1 protein and then, undergo necrosis, promoting 
inflammatory response (Yang et al., 2010). From the foregoing models of 
asbestos-induced pathogenesis of mesothelioma, it is rational to suggest that the 
aberrantly activated molecular signalling network among mesothelial cells, 
inflammatory cells, fibroblasts and other stromal cells that were exposed to 
asbestos, may result in a congregation of mutant clones of mesothelial cells, 
which harbour DNA damage and aneuploidy, and aggregate as cancer cells, 
forming a tumour microenvironment of mesothelioma as shown in Figure 1.4 
(Sekido, 2013) 
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Figure 1.4. A schematic representation of the molecular mechanisms underlying the 
process of tumour development due to asbestos fibres. High-mobility group box 1 
(HMGB1) protein; reactive oxygen species (ROS); transforming growth factor-β 
(TGF-β), and vascular endothelial growth factor (VEGF) (Sekido, 2013). 
 
Asbestos-induced DNA damage in cells of the mesothelium or DNA damage emanating 
from other factors must be correctly and timely repaired to ensure that DNA integrity in 
the cells is maintained. Base excision repair (BER), NER, MMR and homologous 
recombination and non-homologous end-joining (for the repair of double strand breaks) 
have been reported as the key DNA damage repair mechanisms in mammalian cells 
(Toumpanakis et al., 2011). Each of these DNA repair routes have been variously shown 
to be significantly overexpressed in malignant mesothelioma, and most prominent of them 
are genes related to the repair of double-strand breaks (Røe et al., 2010). Similarly, genetic 
polymorphisms in genes that encode BER proteins such as X-ray cross complementing 
group 1 (XRCC1) have been reported to be overexpressed in malignant mesothelioma (Røe 
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et al., 2010). It is therefore, rational to hypothesize that the increased expression of some 
genes involved in DNA repair and their products could be responsible for the observed 
resistance of mesothelioma to chemotherapy and radiotherapy; hence, the focus of this 
research. In later sections of this chapter, a detailed review of DNA repair genes and their 
implications in cancer development and therapy will be presented. 
Besides the asbestos-dependent molecular pathogenesis of malignant mesothelioma 
reviewed above and the models of mesothelioma development represented in Figure 1.4, 
there are several other molecular events and signalling pathways that determine the 
development of malignant tumours. These asbestos-independent molecular pathogenetic 
pathways of malignant mesothelioma are predicated on DNA damage affecting the proto-
oncogenes and tumour suppressor genes, resulting in their activation and inactivation 
respectively. The next sections will attempt to review the molecular pathogenesis of 
malignant mesothelioma on the basis of oncogenic activation and tumour suppressor gene 
inactivation. 
 
1.6.4. Activation of Oncogenic Cascades 
In malignant cells of most cancer types, there is a characteristic activation of receptor 
tyrosine kinases (RTK) (Baselga, 2006). Activation of RTKs results in the concomitant 
overexpression of two major oncogene-dependent cell signalling pathways, the 
phosphoinositide-3 kinase (PI3K)-AKT pathway and Raf-MEK-extracellular signal-
regulated kinase, which are known to regulate the growth, proliferation and survival of 
malignant cells (Sekido, 2013). The RTK oncogenes such as epidermal growth factor 
receptor (EGFR) and MET have been shown to be constitutively and simultaneously 
activated in many cultured malignant mesothelioma cells (Brevet et al., 2011). There have 
also been reports of other receptors of RTK such as AXL, which were suggested to be 
associated with more malignant phenotypes of mesothelioma (Laurie et al., 2011). 
In a similar vein, the activation of the mammalian target of rapamycin (mTOR) signalling 
pathway has been reported to significantly contribute to the pathogenesis of many cancer 
types, including malignant mesothelioma (Hartman et al., 2010). In a related event, 
Varghese et al. (2011) demonstrated that the upregulation of PI3K and mTOR signalling 
pathways in patients with malignant peritoneal mesothelioma resulted in shortened survival. 
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In addition to the pathways of mitogen-activated protein kinase (MAPK) and PI3K-AKT, 
reports have also indicated the aberrant activation and overexpression of the signal 
transducer and activator of transcription 1 (STAT1) in malignant mesothelioma using a 
phosphotyrosine proteomic screen (Menges et al., 2010). Besides the frequent activation of 
STAT1, the Src group of kinases have as well, been suggested to be required in the 
development of malignant mesothelioma (Menges et al., 2010). 
 
1.6.5. Inactivation of Tumour Suppressor Genes 
In human malignant mesothelioma, three major tumour suppressor genes, including the 
cyclin-dependent kinase inhibitor 2A (CDKN2A), neurofibromatosis type 2 (NF2), and 
BRCA1-associated protein-1 (BAP1) genes, are frequently altered, resulting in their 
inactivation and the aberrant expression of their respective gene product and concomitant 
dysfunctional substrate interaction; culminating in cancer cell proliferation, survival and 
resistance to therapy. In this section, the attendant implications of the inactivation of these 
key tumour suppressor genes will be reviewed, with emphasis on the type of mutation events 
that produce the DNA damage. 
(i) The cyclin-dependent kinase inhibitor 2A/alternative reading frame genes: 
In malignant mesothelioma, the CDKN2A gene is known to be prone to mutation 
and has been reported as the most frequently mutated and inactivated tumour 
suppressor gene (Foulkes et al., 1997; Guo et al., 2015). The gene is localised on 
chromosome 9p21.3 and encodes two proteins, p16INK4a and p14ARF. Cell 
cycle fate is determined by p16INK4a through the combined pathways of cyclin-
dependent retinoblastoma protein and cyclin-dependent kinase 4 (CDK4). On the 
other hand, p14ARF modulates the Tp53 pathway by inactivating MDM2 that in 
turn, controls p53 function (Musti et al., 2006). Hence, when CDKN2A is deleted 
in a homozygous fashion, two main tumour-suppressing pathways of 
retinoblastoma and p53 are deactivated in malignant mesothelioma cells. Over 
the past decade, several reports have shown that the analysis of malignant 
mesothelioma tissues or cell lines via fluorescent in situ hybridization (FISH) 
revealed that more than 70% of the analysed samples showed uniform loss of the 
CDKN2A locus (Chiosea et al., 2008; Matsumoto et al., 2013; Wu et al., 2013). 
Based on histological sub-categorization, malignant mesothelioma that belongs 
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to the epithelioid type showed approximately 70% of CDKN2A homozygous 
deletions, while sarcomatoid malignant mesothelioma cases displayed 
approximately 100% homozygous deletion of the CDKN2A gene (Matsumoto et 
al., 2013). 
(ii) Neurofibromatosis type 2 inactivation: the NF2 gene encodes moesin-ezrin-
radixin-like protein (Merlin), a tumour suppressor protein, belonging to the band 
4.1 family of cytoskeletal linker proteins (Bianchi et al., 1995). Tumorigenesis 
of the nervous system such as bilateral vestibular schwannomas at the eighth 
cranial nerve, spinal schwannomas and meningiomas, are a defining 
characteristic of NF2 cancer syndrome; and bi-allelic mutations of NF2 are also 
reported to occur frequently in sporadic cases of these tumours (Thurneysen et 
al., 2009). In malignant mesothelioma, the NF2 gene has been variously reported 
to be the key tumour suppressor gene most affected by the loss of the 
chromosomal locus 22q12 (Bianchi et al., 1995), with 40 – 50% of malignant 
mesothelioma cases shown to be harboring an inactivation mutation (Murakami 
et al., 2011). The tumour suppression role of Merlin has been reported to be 
modulated by the E3 ubiquitin ligase CRL4 (DCAF1) in a study that employed 
malignant mesothelioma cells and immortalized mesothelial cells (Li et al., 
2010). 
(iii) Deactivation of BRCA1-associated protein-1 (BAP1): The BAP1 gene has 
been shown to be a very important tumour suppressor gene in malignant 
mesothelioma, where 23% of 53 cases were shown to have somatic mutationsin 
BAP1 (Bott et al., 2011). Similarly, a study conducted by Yoshikawa et al. 
(2012), using malignant mesothelioma patients of Japanese origin, showed that 
BAP1 is frequently mutated. BAP1 is localized to chromosome 3p21.1, where it 
is responsible for the production of a nuclear ubiquitin C-terminal hydrolase, 
which is a member of the deubiquitinating enzymes. The substrate specificity of 
BAP1 is characteristically broad and it is known for its affinity for several 
substrates including the host cell factor 1 transcriptional scaffolding subunit, 
which is an N -acetyl-glucosamine transferase that is O-linked, human orthologs 
of additional sex combs (ASXL1/ASXL2), and fork-head transcription factors 
(FOXK1/FOXK2). BAP1 has been reported to have a role in a variety of cellular 
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processes such as, cell growth control, response to DNA damage, chromatin 
dynamics, and modulation of the cell cycle (Eletr & Wilkinson, 2011). 
Additionally, it has also been reported that BAP1 is involved in modulating 
polycomb target proteins in malignant mesothelioma tissues (Murali et al., 2013). 
Interestingly, two families with phylogenetic history of high incidence of 
mesothelioma were shown to have germline mutations of the BAP1 gene and 
some carriers of BAP1 gene mutations in the two families developed other types 
of cancer (Testa et al., 2011). 
 
1.6.6. Chemotherapeutic Treatment of Mesothelioma 
Over many years, research has strived to establish the best chemotherapeutic treatment 
regimen for mesothelioma, however, the results have been disappointing, partly due to the 
ability of mesothelioma to resist chemotherapy and the non-availability of effective 
chemotherapeutic agents with minimal cytotoxicity (Frank, 2012). Single anticancer agents 
such as antimetabolites, anthracyclines, and platinum-based agents have been studied but 
only show an approximate response rate of 10% (Su, 2009). Oncologists and scientists were 
previously concerned that chemotherapeutic treatment of mesothelioma failed to produce 
better patient outcome relative to the lone implementation of best supportive care (BSC). 
Consequently, the UK Medical Research Council (MRC) tried to develop the key 
advantages of chemotherapeutic use, when compared to supportive care in a clinical trial 
in individuals suffering from mesothelioma, who were not previously treated (Muers et al., 
2008). The research design employed was a three-arm design and participants were 
randomized to best supportive care with the inclusion or exclusion of one out of two 
chemotherapeutic regimens: vinorelbine as a single agent or a combination regimen 
comprising mitomycin, vinblastine, and cisplatin. Upon combination and comparison, the 
results of the two arms of chemotherapy relative to BSC alone, showed median survival 
for patients at 8.5 months and 7.6 months respectively; which showed statistical 
insignificance. Further statistical exploration of the two chemotherapy arms independently 
showed that patients treated with vinorelbine had a median survival of 9.4 months, but 
patients in the MVP arm had no significant survival advantage (Muers et al., 2008; Frank, 
2012).  
As a monotherapy, vinorelbine was further tested in a second-line or salvage setting, in 
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which 63 patients with relapsed or refractory mesothelioma were given the drug weekly. 
The results produced 16% rate of susceptibility and 9.6 months median survival rate 
(Stebbing et al., 2009). However, a combination therapy regimen of vinorelbine and 
cisplatin as first-line of treatment in patients with non-resectable malignant pleural 
mesothelioma, achieved a 30% response rate, median survival rate of 16.8 months and 
median period of progression of 7.2 months (Sørensen et al., 2008). 
In 23 patients with untreated cases of malignant pleural mesothelioma, the use of 
gemcitabine monotherapy achieved a 31% rate of response and improved symptoms were 
recorded in over 40% of the participants, (Bischoff et al., 1998). However, the sample size 
employed by the researchers was too small and the patients in the trial were all at the early-
stage of the disease and promising epithelial histology (Frank, 2012). In other clinical trials, 
where gemcitabine was used as a monotherapy, the response rates were disappointing, 
ranging from 0 to 7% and median survival of 4.7 months to 8 months (Kindler et al., 2001). 
Interestingly, clinical trials employing a combination therapy regimen of gemcitabine and 
cisplatin or carboplatin resulted in response rates of 12% to 48% and median time to 
progression of 6 months to 9 months (Jackman, 2009). 
Berghmans et al. (2002) reported that cisplatin was the potent monotherapy to which, un-
resectable malignant pleural mesothelioma is susceptible; hence, serves as a standard 
chemotherapy for the disease. The reliability and potency of cisplatin as a single therapy 
has made it the backbone of most doublet regimens, over the years. On this note, Vogelzang 
et al. (2003) reported that the dual therapy of cisplatin and pemetrexed is considered the 
optimal treatment option and opined that it should be regarded as a standard first-line 
chemotherapy for the treatment of unresectable mesothelioma that has assumed 
malignancy; and indeed, it has become a treatment benchmark which is recommended as 
the combination therapy regimen to resectable mesothelioma (Frank, 2012). 
Regardless of the improvement recorded with the use of cisplatin and pemetrexed 
combination therapy regimen against mesothelioma; the treatment of the disease, like most 
cancer types, is still gravely challenged by chemotherapeutic resistance. Consequently, 
approximately 67% of the investigated patients failed to demonstrate positive response to 
the cisplatin - pemetrexed combined therapy approach, and majority of the subjects will 
progress after first-line therapy and usually die no later than one year after diagnosis (Green 
et al., 2007). On this note, scientists have been gearing efforts towards finding and 
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developing better chemotherapeutic regimen by exploiting the activities of molecular 
markers that promote mesothelioma response to cisplatin-pemetrexed combination therapy 
(Castagneto et al., 2007). 
Interestingly, one of the genes that formed the focus of this PhD work, the excision repair 
cross-complementing 1 (Ercc1) gene, has been variously shown to enhance cisplatin 
activity against different cancer types. For instance, Ercc1, which is primarily known for 
the repair of helix-distorting DNA adducts, has been shown to also repair DNA strand 
damage caused by cisplatin and the expression of Ercc1 gene correlates with favourable 
prognosis in ovarian cancer and non-small cell lung cancer patients treated with 
chemotherapeutic regimen containing cisplatin (Simon et al., 2005). Zucali and colleagues 
(2011) in a similar vein, reported that there is a positive interrelationship between the 
upregulation of thymidine synthetase (TS) protein and prolonged progression-free survival, 
and mesothelioma patients’ overall survival, in a carboplatin-pemetrexed treatment 
regimen. 
 
1.6.7. New Approaches to Mesothelioma Treatment: Targeted Therapy 
Like most cancer types, successful treatment of patients with malignant mesothelioma 
remains a challenge, due to the usual chemotherapeutic resistance that bedevils most 
cancers. In addition to its characteristic resistance to therapy, mesothelioma treatment is 
further hampered by its inherent latency and consequent late diagnosis and poor prognosis. 
Currently, treatment approaches are: chemotherapy, and multimodal treatment including 
surgical resection combined with chemotherapy and/or radiotherapy, photodynamic therapy 
(PDT), and hyperthermic perfusion of the pleura followed by resection (Zervos et al., 2008; 
Bononi et al., 2015). These treatment regimens may positively affect the patient’s quality of 
life; however, only modest effects have been recorded with same treatment modalities in 
improving overall survival. Increased understanding of the molecular pathogenesis and 
characteristics of mesothelioma, and the rationale behind investigating novel targeted 
approaches have resulted in development of novel potential therapeutic strategies aimed at 
exploiting the molecular features of mesothelioma to produce action-specificity; hence, the 
name targeted therapy. In the recent past, the identification and characterization of many 
different forms of mutation, a variety of enzymatic catalases, myriads of growth factors, and 
glycoproteins that contribute to the inherent refractory and poor prognostic features of 
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malignant mesothelioma led to the development of targeted therapies including (i) molecular 
therapies, (ii) immunotherapy, (iii) targeting asbestos-induced inflammation (Bononi et al., 
2015). However, for the purpose of this thesis, only molecular therapies will be reviewed. 
 
1.6.7.1. Molecular Therapies 
Few years ago, it was reported that malignant mesothelioma are polyclonal tumours, formed 
by the aggregation of different independent subclones, which may account for a high degree 
of cellular heterogeneity within the tumour microenvironment and contribute to the 
development of chemo-resistant subpopulations in various in vitro experiments conducted 
(Comertpay et al., 2014). The characteristic heterogeneity of cell subpopulation in malignant 
mesothelioma highlights the importance of simultaneously attacking several different 
molecular targets to obliterate the different clones, given that each clone may be defined by 
distinct set of molecular alterations (Bononi et al., 2015). 
From the foregoing review, the importance of BAP1 gene as a major tumour suppressor 
gene, its physiological role in biological processes, as well as its importance in the molecular 
pathogenesis of malignant mesothelioma cannot be overemphasized. It is therefore, not 
surprising that BAP1 gene and its gene products are of key interest in the quest of researchers 
to develop molecular-based target therapies that are action-specific. For instance, it has been 
reported that the somatic loss of BAP1 is associated to a slightly longer survival (Arzt et al., 
2014). This finding is probably rationalized by the fact that most somatic mutations are 
frequently detected in epithelioid malignant mesothelioma, which have a better prognosis 
than sarcomatoid and biphasic malignant mesothelioma (Farzin et al., 2015). When 
malignant mesothelioma occurs in a setting of germline BAP1 gene mutations, their 
prognosis is markedly better with survival of over 5 – 10 years (Baumann et al., 2015). 
However, it is surprising that germline BAP1 mutations promotes malignant mesothelioma 
on one hand, while they are on the other hand, reported to reduce the disease aggressiveness. 
The mechanistic underpinnings of this dual role of double-edged sword activity are yet to 
be elucidated.   
BAP1 functions as a tumour suppressor have been ascribed to (i) BAP1 deubiquitination of 
histone H2A, leading to transcriptional activation of genes that regulate cell growth 
(Scheuermann et al., 2010); (ii) BAP1 functions as a transcriptional coregulator by 
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interaction to host cell factor-1 (HCF1), Ying Yang 1 (YY1), and E2F1, to induce 
transcription of genes involved in cell cycle regulation (Yu et al., 2010); and (iii) BAP1 
contribution to DNA repair (Ismail et al., 2014; Yu et al., 2014), as depicted in Figure 1.5. 
Owing to the implication of BAP1 in chromatin re-modelling and its inherent ability to 
deubiquitinate H2A, it is very likely that BAP1 mutations promote cellular sensitivity to 
epigenetic modulators. The epigenetic regulation of tumour suppressor genes via chromatin 
condensation and de-condensation has been reported to be of mechanistic significance in the 
development of mesothelioma and most cancers (Bononi et al., 2015). For instance, the 
homeostasis of the acetylated and deacetylated forms of histone proteins is regulated by 
histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation is 
increased by HATs, facilitating greater accessibility of chromatin for gene expression. On 
the other hand, HDACs inhibitors alter the wrapping of DNA strands around histones, 
modifying the access of transcription factors and affecting the expression of different genes 
(Landreville et al., 2012). 
The therapeutic effect of four different HDAC inhibitors, valproic acid, trichostatin A, LBH-
589, and suberoylanilide hydroxamic acid (vorinostat), has been investigated using primary 
UVM cells and in UVM cell lines. Interestingly, these compounds were shown to reverse 
H2A hyper-ubiquitination due to BAP1 loss, and initiated differentiation, cell cycle exit, a 
shift to a differentiated, melanocytic gene expression profile in cultured UVM cells. 
However, valproic acid inhibited UVM tumour growth in vivo (Landreville et al., 2012). In 
various In vitro experiments to understand the role of HDAC inhibition in malignant 
mesothelioma, increased apoptosis was predominantly reported in malignant mesothelioma 
cell lines following treatment with HDAC inhibitors alone or in combination with 
chemotherapy (Neuzil et al., 2004; Bolden et al., 2006; Symanowski et al., 2009). 
Germline mutations resulting in the loss of BAP1 has been shown to alter the sensitivity of 
malignant pleural mesothelioma cells to HDAC inhibitors through the regulation of HDAC2 
transcription. However, established malignant mesothelioma cell lines with low endogenous 
HDAC2 were found to be resistant to HDAC inhibition (Sacco et al., 2015). These reports 
are indicative of the fact that HDAC inhibitors might be effective in the adjuvant therapy of 
patients with BAP1 mutated malignant mesothelioma.   
Vorinostat is approved by the FDA for the treatment of cutaneous T-cell lymphoma. In a 
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Phase I clinical trial using patients with advanced malignant pleural mesothelioma, 30% of 
patients that received vorinostat had a stabilization of their disease lasting more than 4 
months (Kelly et al., 2005). However, negative results have been reported in phase II and 
phase III clinical trials of vorinostat and belinostat respectively, in patients with advanced 
pre-treated malignant pleural mesothelioma (Ramalingam et al., 2009; Krug et al., 2015) as 
shown in Figure 1.5. 
 
Figure 1.5. Schematic representation of the key molecular and genetic alterations 
involved in the development of malignant mesothelioma and possible strategies for 
therapeutic intervention (Bononi et al., 2015). 
 
Besides BAP1, the role of NF2 gene, another tumour suppressor gene, in the pathogenesis 
of malignant mesothelioma was originally reported by data showing that asbestos-
treated NF2+/− mice exhibit a significantly accelerated malignant mesothelioma tumour 
formation relative to wild-type littermates (Altomare et al., 2005). Merlin, which is the gene 
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product encoded by NF2 gene, interacts with multiple substrates thereby, modulating 
multiple signal transduction cascades including mTOR, focal adhesion kinase (FAK) and 
Hippo signalling pathways (Bianchi et al., 1995) as shown in Figure 1.5. 
Cellular proliferation is mediated by merlin through the inhibition of mTOR, in an AKT-
independent manner (Ladanyi et al., 2012). Loss of merlin has been shown to result in the 
activation of mTOR signalling in malignant mesothelioma cells; hence, in merlin silenced 
tumours, mitogenic signalling is highly upregulated and cellular proliferation is markedly 
increased. Expectedly, merlin-negative malignant mesothelioma cells were shown to be 
more sensitive to the mTOR inhibitor rapamycin, relative to merlin-positive cells (Lopez-
Lago et al., 2009). Owing to this significant observation, mTOR has been identified as a 
therapeutic target in the large fraction of malignant mesotheliomas that carry NF2 mutations 
and provided the rationale for the further study of mTOR inhibitors as possible molecular 
target therapy in malignant mesothelioma. However, it was unfortunate that the oral form of 
mTOR inhibitor known as everolimus, when tested in a phase II clinical trial as second- and 
third-line of treatment in unselected pre-treated malignant pleural mesothelioma patients, 
showed limited clinical activity. 
It is imperative to note that mTOR inhibition alone results in compensatory upregulation of 
PI3K, consequently permitting the restoration of the downstream AKT signalling 
(Carracedo et al., 2008). To address this mechanism of mTOR resistance, GDC-0980, a 
potent and selective oral dual inhibitor of class I PI3K and mTOR were tested. GDC-0980 
demonstrated broad activity in various xenograft cancer models, including malignant pleural 
mesothelioma (Kanteti et al., 2014), but pulmonary toxicity of this class of agents limits 
their application in a clinical setting. Other molecular alterations that are targeted for 
therapeutic use against malignant mesothelioma include cyclin-dependent kinase inhibitor 
2A (CDKN2A) / alternative reading frame (ARF) and neurofibromatosis type 2 (NF2), 
VEGF, etc.  
From the forgoing review, it is evident that scientists are more interested in the molecular 
alterations that bring about the development of malignant mesothelioma, without recourse 
to the implication of correctional events that physiologically repair these alterations. 
Consequently, this PhD thesis places emphasis on the involvement of DNA repair genes and 
their products in the treatment of malignant mesothelioma; with the view to providing 
insights into the possible therapeutic significance. 
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1.7. Stem Cells 
Embryonic stem (ES) cells are obtained from the inner cell mass of an embryo, typically 
during the developmental stage known as a blastocyst (Ramalho-Santos and Willenbring, 
2007). They are characterised by two distinguishing features: pluripotency, which is the 
capacity of embryonic stem cells to generate all the other cell types that constitute the 
histology of adult organisms (Kim and Orkin, 2011; Takahashi and Yamanaka, 2015); and 
self-renewal ability, which defines the ability of embryonic stem cells to retain its cellular 
characteristics whilst maintaining a proliferative state (Choumerianou et al., 2008). The 
realisation of the full potential of ES cells in basic biology, biomedicine and regenerative 
medicine is critically dependent on understanding these two keys defining characteristics 
(Kim and Orkin, 2011). Additionally, the applicability of ES cells in regenerative medicine 
and related fields of science is further determined by knowledge of the molecular and 
genetic underpinnings of ES cells (Roeder and Radtke, 2009). 
For the past two decades, research has been ongoing to decipher the molecular 
characteristic of ES cells and enhance their usefulness to mankind. Consequently, a group 
of transcription factors, including the homeodomain protein Oct4, Sox2, and Nanog (Tai 
and Ying, 2013), were identified and demonstrated in different studies, as major regulatory 
factors responsible for the control of the pluripotent feature of embryonic stem cells (Mitsui 
et al., 2003; Chambers et al., 2003; Avilion et al., 2003). This cadre of regulatory 
transcription factors are known as ES cell core factors (Kim and Orkin, 2011). The 
relevance of transcriptional regulatory mechanisms to cell fate control and pluripotency 
(Graf et al., 2009) cannot be overemphasised. Interestingly, Yamanaka and Takahashi 
(2015) reported that the introduction of the transcription factors Oct4, Sox2, Klf4, and Myc 
(Tan et al., 2013), into somatic cells can result in the reprogramming of the somatic cells 
into ES cell-like cells known as induced pluripotent stem (iPS) cells (Yamanaka and 
Takahashi, 2006; Takahashi et al., 2007; Wernig et al., 2007; Yu et al., 2007; Park et al., 
2008a). 
Owing to the attendant advancements in high-throughput technologies over the past 
decade, enormous databases of proteomic and genomic information have been assembled 
through such technologies like gene expression profiling, microarrays or sequencing 
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(Hawkins et al., 2010), the study of the interactions between and within proteins, the use 
of affinity purification and mass spectrometry for the identification of members of protein 
complexes (Gavin et al., 2011), and the  downregulation of genes by RNA interference 
(Dykxhoorn and Lieberman, 2005). These new tools have been employed in the dissection 
of pluripotency and self-renewal control in embryonic stem cells (MacArthur et al., 2009; 
Roeder and Radtke, 2009) and further deepened the comprehensibility of our understanding 
of cell states at system level (Marks et al., 2012). 
Delineation of the cells that sustain cancer has been a very critical goal in the context of 
cancer biology. Consequently, researchers have proposed that upon transplantation, a small 
population of cells have characteristic ability of re-initiation of tumour formation; and 
responsible for maintenance of the tumours and their resistance to anticancer therapies 
(Kim and Orkin, 2011). These tumour-initiating cells otherwise known as cancer stem cells 
might originate from progenitor cells or adult stem cells or from somatic cells 
dedifferentiation (Reya et al., 2001; Boroviak et al., 2014). Scientists have proposed the 
hypothesis that ES cells and cancer cells share commonalities relating to the regulation of 
gene expression, which has likely implications and linkage to the embryonic state of 
tumour initiating cells prevalent in tumour microenvironment (Kim et al., 2010). 
Additionally, evidence deduced from research works that employed somatic cell 
reprogramming has further underscored key similarities between tumour cell and induced-
pluripotent stem cells. Pluripotency acquisition during reprogramming, typically represents 
a reversal of differentiation suggested for certain cancer types (Daley, 2008; Papatsenko et 
al., 2015). Several researchers have made concerted efforts to explain the inherent 
characteristic of cancer stem cells to renew self, and as a result, specific expression 
signatures of embryonic stem cells have been defined, which have also been analysed in 
diverse cancers (Wong et al., 2008; Somervaille et al., 2009; Schoenhals et al., 2009; 
Mizuno et al., 2010; Shats et al., 2011; Radzisheuskaya and Silva, 2014).  
In the experimental segments of this PhD, the expression profiles of some key DNA repair 
genes in ES cells are investigated with the views to gain insights into the shared similarities 
between ES cells and tumour initiating cells and contributing to the repository of 
information about the molecular definition of the stem cell like state of tumour initiating 
cells. Based on this rationale, this part of the Introduction will attempt to critically review 
the molecular signatures and gene regulations in ES cells, with emphasis on transcriptional 
factors, regulation of somatic cell reprogramming, and the activities of different genes 
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encoding DNA repair proteins within the different DNA repair mechanisms. These will be 
aimed at gaining more insights into the molecular and cellular similarities between 
embryonic stem cells and cancer cell and furthering our understating of the role of acquired 
self-renewal ability of cancer cells in development of drug resistance capabilities by tumour 
cells. 
 
1.7.1. Molecular Signatures and Genomic Regulations in Embryonic Stem Cells 
To understand the molecular signature of embryonic stem cells, it is important to present a 
synopsis of the key modulators of the self-renewal and pluripotent characteristics of 
embryonic stem cells, and the acquisition of pluripotent features during somatic cell 
reprogramming. Consequently, Table 1.4 captures these key modulators of pluripotency in 
stem cells, their physiological relevance, and the molecular techniques employed in the 
methods of their investigation (Kim and Orkin, 2011). 
 
Table 1.4. Presentation of the genomic studies of self-renewal and pluripotency 
characteristics of embryonic stem cells. 
Regulators Function Methods Reference(s) 
Core factors 
   
Oct4 
(Pou5f1) 
ES cell core 
factor 
ChIP, MS Loh et al., 2006; Kim et al., 2008; van 
den Berg et al 2010; Pardo et al., 2010; 
Radzisheuskaya and Silva, 2014; Dunn 
et al., 2014; Xu et al., 2014. 
Sox2 ES cell core 
factor 
ChIP, MS Chen et al., 2008; Kim et al., 2008; 
Lopez-Bertoni et al., 2014; Wu et al., 
2014. 
Nanog ES cell core 
factor 
ChIP, MS Loh et al., 2006; Chen et al., 2008; Kim 
et al., 2008; Costa et al., 2013; Do et al., 
2013; Gingold et al., 2014. 
Tcf3 (Tcf7l1) Wnt signalling ChIP Cole et al., 2008; Martello et al., 2012 
Klf4 LIF signalling ChIP Chen et al., 2008; Kim et al., 2008 
Stat3 LIF signalling ChIP Chen et al., 2008; van Oosten et al., 
2012 
Dax1 (Nr0b1) Negative 
regulation of 
transcription 
ChIP, MS Wang et al., 2006; Kim et al., 2008 
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Sall4 Self-renewal and 
pluripotency 
ChIP, MS Wang et al., 2006; Yang et al., 2008; 
Lim et al., 2008; Rao et al., 2010 
Polycomb-
related factors 
   
Ezh2 PRC2, repressor ChIP, MS Shen et al., 2009; Peng et al., 2009 
Jarid2 Fine-tuning of 
PRC2 
ChIP, MS Shen et al., 2009; Peng et al., 2009 
Mtf2 Polycomb-like 
protein 
ChIP, MS Shen et al., 2009 
Suz12 PRC2, repressor ChIP, MS Boyer et al., 2006; Lee et al., 2006; 
Shen et al., 2009; Peng et al., 2009. 
Eed PRC2, repressor ChIP Boyer et al., 2006; Lee et al., 2006. 
Rnf2 PRC1, repressor ChIP Boyer et al., 2006. 
Phc1 PRC1, repressor ChIP Boyer et al., 2006. 
Myc-related 
factors 
   
Myc Proliferation ChIP, MS Chen et al., 2008; Kim et al., 2010. 
Max Myc-
interACTINg 
ChIP, MS Kim et al., 2010. 
Zfx Self-renewal ChIP Chen et al., 2008. 
Trrap Histone 
acetylation 
RNAi Fazzio et al., 2008. 
Tip60 (Kat5) Histone 
acetylation 
ChIP, MS, 
RNAi 
Fazzio et al., 2008; Kim et al., 2010. 
Ep400 Histone 
acetylation 
MS, RNAi Fazzio et al., 2008. 
Dmap1 Histone 
acetylation 
ChIP, MS, 
RNAi 
Fazzio et al., 2008; Kim et al., 2010. 
E2F1 Regulator of cell 
cycle 
ChIP Chen et al., 2008. 
E2F4 Transcription 
activator 
ChIP, MS Kim et al., 2010. 
Cnot3 General 
transcription 
regulator 
ChIP, 
RNAi 
Hu et al., 2009. 
Trim28 
(Tif1b) 
Transcription co-
activator 
ChIP, 
RNAi 
Hu et al., 2009 
LIF = leukaemia inhibitory factor. 
Adapted from: (Kim and Orkin, 2011; Morgani et al., 2017). 
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1.7.2. Core Transcriptional Regulators in Embryonic Stem Cells  
The availability cytokines in conjunction with many other factors regulate pluripotency and 
self-renewal characteristics of embryonic stem cells in the cell culture environment (Morey 
et al., 2015). An aggregation of regulatory networks called the pluripotency gene regulatory 
network (PGRN) is responsible for maintaining ES cell pluripotency (Morgani et al., 2017); 
and pluripotency is believed to exists in many different states, dependent on the stage of the 
progenitor cells (Davidson et al., 2015). 
Pluripotency exists transiently in mouse embryo, from the onset of cleavage cycles until late 
stages of blastocyst (Boroviak et al., 2014). This is contrary to the human embryonic stem 
cells cultivated in vitro, where differentiation requires that the cells become non-pluripotent, 
whereas conversion of somatic cells to induced-pluripotent cells needs reversal to 
pluripotent state (Takahashi and Yamanaka, 2015). Embryonic stem cells and induced-
pluripotent cells are likely to be subject to the same basic PGRN network; hence, controlling 
reprogramming and differentiation is dependent on the knowledge of the various network of 
genes that transcriptionally regulate cell fate transition and lineage determination (Morgani 
et al., 2017).   
Genome-wide studies have in recent years, expanded the list of regulatory factors in the 
embryonic stem cell pluripotency network (Marks et al., 2012). For instance, reconstructed 
networks of transcriptional regulators that demonstrated many similar features were 
independently produced by Dunn et al. (2014) and Xu et al. (2014). Multiple positive 
correlations between the differently reconstructed transcriptional networks were identified 
when the two constructs were merged as shown in Figure 1.6.  
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Figure 1.6. A comparative representation of published regulatory networks for 
embryonic stem cells, showing pluripotency network reconstructions with respect to 
published reports (A & B) and a combination of both networks to reveal areas of 
negative and positive interactions (C; Papatsenko et al., 2018). 
 
Although, intracellular signalling cascades may intersect and diverge, activation and 
regulation of specific transcription are typically affected by an inherent effector protein of 
each pathway, originating from the nucleus (Itoh et al., 2014; Lakatos et al., 2014). Hence, 
besides the set of core transcriptional factors represented in Figure 1.6, the next of 
transcriptional factors are represented by regulatory factors like Stat3, Smads, β-catenin, 
and ERK, which are correspondingly effectors of LIF, BMP, WNT and FGF signalling 
routes (Tai and Ying, 2013; Itoh et al., 2014; Lakatos et al., 2014), as shown in Figure 1.7. 
Essentially, regulatory signals originating the effectors are relayed to several downstream 
receptors, inclusive of pluripotency network, which is made up of transcription factors like 
Oct4, Sox2, Nanog, Esrrb, Tbx3, and c-Myc (Boyer et al., 2006). These core transcription 
factors are responsible for processing inputs from signalling systems and deciding the self-
renewal and differentiation propensities of embryonic stem cells (Dunn et al., 2014; Xu et 
al., 2014). 
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Figure 1.7. A representation of the organization of pluripotency gene regulatory 
networks in hierarchical fashion. showing signalling pathways (green coloured), the 
mediators of signalling pathway (yellow colouration), constituents of the 
transcriptional pluripotency networks (in red shades), and lowest levels of the 
pluripotency network (shown in violet shades) (Papatsenko et al., 2018). 
  
Scientists are of the view that transcription factors constituted by CPN represent a third 
hierarchical level, downstream of the signalling modulators like Stat3, Smads, etc., and in 
the embryo several key pluripotency transcription factors are expressed maternally (Zuccotti 
et al., 2011). These set of maternally expressed genes are involved in the regulation of 
arrangement of the inner mass of the cells and epiblast and are critically important in further 
embryonic development (Le Bin et al., 2014; Radzisheuskaya and Silva, 2014). The 
upregulation of a simple combination of these embryonic stem cell transcriptional core 
factors in vitro has been shown to possess the capability of inducing the reprogramming of 
somatic cells to induced pluripotent stem cells (Takahashi and Yamanaka, 2006). It has been 
reported that cells re-enter pluripotency state and pluripotency network is re-established 
during this process (Buganim et al., 2012; Takahashi and Yamanaka, 2015). Many of the 
pluripotent transcription core factors within the CPN are likely to serve as targets of the key 
signalling effectors either directly or indirectly (Babaie et al., 2007). For instance, a core 
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pluripotency factor Nanog is targeted by Tfcp2l1, which on the other hand, is targeted by 
Stat3 that emanates from the leukaemia inhibitory factor (LIF) signalling; this is in addition 
to Nanog which is targeted by Tcf3 repressor, downstream of β-catenin that is part of the 
WNT signalling (Ye et al., 2013). In fact, various studies have shown that thousands of 
genes within the genome of embryonic stem cells is targeted by the core pluripotency factors 
(Ivanova et al., 2006; Chen et al., 2008; Ye et al., 2013). 
 
1.7.3. Regulation of Somatic Cell Reprogramming 
In the initial report where Yamanaka and colleagues (2006) demonstrated somatic cell 
reprogramming, terminally differentiated cells represented by mouse fibroblasts, were 
changed to stem-cell-like cells with pluripotent features via four key pluripotent modulators, 
comprising two core ES cell transcriptional factors, Klf4 and Myc, and Oct4 and Sox2 
(Yamanaka and Takahashi, 2006; Takahashi et al., 2007). The eventual success recorded in 
the reprogramming of human fibroblasts to pluripotent-stem-cell-like cells (Takahashi et al., 
2007; Yu et al., 2007; Park et al., 2008a), in addition to the production of pluripotent-stem-
cell-like cell lines that are disease-specific with cells derived from genetic disorder patients, 
gives an avenue for in vitro investigations of various diseases in humans (Dimos et al., 2008; 
Park et al., 2008b). Interestingly, as demonstrated by the initial studies conducted by 
Yamanaka and Takahashi (2006), the four modulators of reprogramming show elevated 
expression in ES cells; and reprogramming modulators have been variously suggested to 
play distinctive roles in the initiation and development of different cancer types 
(Werbowetski-Ogilvie and Bhatia, 2008; Daley, 2008). Drawing inference from these 
interesting observations, it is rational to hypothesize that there might be common 
denominators between in the pathways of reprogramming of somatic cells, regulation of 
pluripotent characteristics in embryonic stem cells, and transformation of the cells 
(Werbowetski-Ogilvie and Bhatia, 2008). 
Another important regulatory factor in embryonic stem cells, which have also been 
implicated to have essential roles in early development are the polycomb-group (PcG) 
proteins. Following their initial discovery in Drosophila melanogaster, PcG proteins have 
been shown to contribute to repression of crucial developmental or lineage-specific 
regulators through the generation of a repressive histone mark (Margueron and Reinberg, 
2011). In both mouse and human embryonic stem cells, interrogating PcG-repressive protein 
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complex (PRC)1 and PRC2 targets by ChiP revealed that several commonly repressed genes 
are linked to PRC proteins, including lineage-specific transcription factors (Boyer et al., 
2006; Lee et al., 2006). These studies demonstrated that PRC proteins are responsible for 
the maintenance of the undifferentiated state of embryonic stem cells through the repression 
of critically relevant genes that are involved in the regulation of embryonic development. 
Similarly, in some studies where RNA immunoprecipitation and sequencing were 
employed, non-coding RNA molecules interactions with the PRC complexes has been 
shown to be involved in the regulation of target genes (Zhao et al., 2010); and PRC proteins 
have also been reported to play roles in the somatic cell reprogramming process (Pereira et 
al., 2010; Zhang et al., 2011). 
One of the most frequently reported oncogenes is the activation of Myc, which has been 
reported in over 70% cases of human cancers (Nilsson and Cleveland, 2003). Myc has been 
implicated in numerous cellular physiological processes and has been shown to be involved 
in myriad of important biochemical pathways, of which the regulation of self-renewal 
capability in embryonic stem cells is inclusive (Meyer and Penn, 2008). In embryonic stem 
cells, interrogation of the targets of Myc demonstrated that the role of Myc in the 
maintenance of the pluripotency of embryonic stem cells is independent of and totally 
different from that of the core factors (Kim et al., 2008; Chen et al., 2008). Relative to the 
core factors of embryonic stem cells, Myc has many more chromatin targets, and genes 
targeted by Myc are enriched in pathways that are involved in protein synthesis and cellular 
metabolic processes (Chen et al., 2008). In contrast, the target genes of the core factors of 
embryonic stem cells are implicated in transcription and developmental processes (Kim et 
al., 2008; Chen et al., 2008). In somatic cell reprogramming, the role of Myc is considered 
dispensable (Wernig et al., 2008; Nakagawa et al., 2008); however, the effectiveness and 
speed of reprogramming by Myc are indicative of the possibility of its involvement in 
providing a favourable the reprogramming process with the conducive atmosphere via the 
regulation of chromosome structural alterations (Knoepfler et al., 2006; Knoepfler, 2008; 
Gaspar-Maia et al., 2011). In ES cells, proteins that interact with Myc and their target 
substrates have been identified; where the Myc network has been revealed to be different 
from the ES cell key survival network or the PRC network (Kim et al., 2010). Notably, 
histone acetyltransferase (HAT) complex proteins, which is known to interact with Myc in 
embryonic stem cells (Fazzio et al 2008; Kim et al., 2010), have been reported to play critical 
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role in the definition of embryonic stem cell identity, control its pluripotent characteristic 
and somatic cell reprogramming (Fazzio et al., 2008). 
 
1.7.4. Embryonic Stem Cell Signatures in Cancer 
Because of the commonalities in the characteristics embryonic stem cells and tumour cells, 
researchers were compelled to investigate the gene whose products are responsible for the 
regulation of these common denominators (Reya et al., 2001). From the foregoing review, 
it is a common knowledge that one of the key factors that has been shown to aid the 
reprogramming of somatic cells, Myc, a known oncogene, and p53 pathways deactivation, 
which has also been demonstrated as a predominant characteristic of numerous cancers, 
facilitates the efficiency of the reprogramming process (Yamanaka and Takahashi, 2006; 
Hanna et al., 2009; Krizhanovsky and Lowe, 2009; Utika et al., 2009). From these findings, 
the evidence is further glaring that unifying pathways could serve both in the acquisition of 
pluripotent characteristic and in the process of tumour development. Consequent upon the 
above premise, it is safe to propose that understanding of the pluripotent characteristic of 
embryonic stem cells and somatic cell reprogramming could deepen our knowledge of the 
important shared characteristics of ES cells and cancer cells. This therefore, rationalizes the 
fact that many ES cell -specific gene sets that have been reported in the investigations of the 
pluripotent stem cells could serve as important analytic instruments for the analysis of the 
expression patterns genes in various tumours; hence a key part of the objectives of this PhD 
is to analyse the expression patterns of DNA damage repair genes in embryonic stem cells 
as well as in tumours of the colon, central nervous system and mesothelium. On this note, 
the DNA repair genes of the key DNA repair pathways that are prevalent in ES cells are 
reviewed in the following section. 
1.7.5. DNA Repair in Embryonic Stem Cells 
The survival, self-renewal and pluripotent potential of both ES cells and adult stem cells 
could be limited by endogenous DNA damage due to oxidative metabolism and 
environmental pollution, and all DNA alterations inclusive of base and backbone 
modifications, single strand break, and double strand break (Frosina, 2010). In ES cells, 
maintenance of genomic stability must be stringent and tightly controlled as any genetic 
alterations affecting the progenitor cells will compromise the functionality and genomic 
stability of the entire cell lineages (Frosina, 2010). Consistent with this assertion, it has been 
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shown that mitotic recombination rate and the frequency of mutations are remarkably less 
in embryonic stem cells than in adult somatic cells (Hong et al., 2007). Additionally, it has 
been shown that mechanisms of mutagenesis also differ in ES cells relative to adult somatic 
cells. Although, the majority of mutations result in loss of heterozygosity (LOH) in ES cells 
as well as mouse embryonic fibroblasts, LOH in ES cells is initiated via chromosomal 
nondisjunction, whereas in mouse embryonic fibroblasts, it occurs through mitotic 
recombination (Tichy and Stambrook, 2008). Similarly, evaluation of spontaneous mutation 
at hprt, an X-linked locus, revealed that it is latent in ES cells (<10) and ~10 in mouse 
embryonic fibroblasts. Consequently, several mechanistic approaches must be executed to 
ensure the robust repression and reversal of spontaneous mutagenesis in embryonic stem 
cells and DNA repair is likely one of them (Maynard et al., 2008; Tichy and Stambrook, 
2008; Frosina, 2009). Furthermore, irrespective of the characteristic finite replicative 
potentials of embryonic stem cells, studies employing murine genetic models have expressly 
indicated that DNA repair is critically important to the life span and the capability of 
embryonic stem cells to respond to stress (Warren and Rossi, 2009).  
In the research conducted by Maynard and colleagues (2008) using single-cell gel 
electrophoresis (SCGE), human embryonic stem cells were observed to have more efficient 
repair of different types of DNA damage than human primary fibroblasts (Maynard et al., 
2008). Similarly, Maynard and colleagues (2008) further reported that the transcriptional 
levels of majority of DNA repair genes, inclusive of those involved in BER and inter-strand 
crosslink repair, were highly upregulated in ES cells relative to human somatic cells 
(Maynard et al., 2008). In agreement with the above findings, the expression of antioxidant 
and DNA repair genes was markedly reduced, and increased DNA damage was recorded 
during spontaneous differentiation of two human ES cell lines (Saretzki et al., 2008). 
In ES cells, replicating chromatin has been shown to be highly vulnerable to strand breaks 
(Banáth et al., 2009). In mammalian cells, including ES cells, two pathways repair double-
strand breaks; non-homologous end joining (NHEJ), which is the key repair pathway and 
homology-directed repair (HDR), which functionally replaces NHEJ in the presence of a 
sister chromatid (Friedberg et al., 2005). During the differentiation of murine ES cells, the 
expression of genes involved in double-strand break repair, such as Rad51 has been reported 
to diminish (Saretzki et al., 2004; Saretzki et al., 2008; Tichy and Stambrook, 2008). 
Regardless of the overexpression of O6-methylguanine-DNA-methyltransferase, murine ES 
cells have been shown to be characterised by a higher apoptotic frequency relative to 
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differentiated cells following N-methyl-N-nitro-N-nitrosoguanidine treatment (Roos et al., 
2007). This is because in ES cells, there is an elevated expression level of the MMR proteins, 
MSH2 and MSH6, that triggers fruitless cycles of O6-methylguanine repair/replication 
(Casorelli et al., 2008). Several reports are consistent with the suggestion that the high 
apoptotic response of murine ES cells may be partly responsible for the reduction of the 
mutational load in these cells (Roos et al., 2007; van der Wees et al., 2007). Therefore, from 
available reports and research evidence, it has been shown that ES cells are characterised by 
elevated DNA repair capacity relative to their differentiated derivatives (Frosina, 2010).  
Bracker and colleagues (2006) investigated the differences in the capabilities of DNA repair 
and the level of the gene products during the hematopoietic stem cell maturation process; 
and they observed that the removal of DNA adducts, the repair of strand breaks and the 
resistance to DNA-reactive drugs were noticeably higher in stem (CD34+ 38−) than in 
mature (CD34−) or progenitor (CD34+ 38+) cells isolated from umbilical cord from the 
same individual (Bracker et al., 2006). It is therefore, rational to assert that sluggishly 
dividing stem cells are likely to be under the protection of extensive DNA repair while more 
differentiated and less valuable cells, in the event of damage, could be removed via apoptosis 
(Frosina, 2010). 
Transcription-coupled NER (TC-NER), has a preference for the repair of the transcribed 
strand of active genes relative the strand that is not transcribed, thereby providing cells with 
a mechanism for repairing DNA damage during, and restarting transcription (Hanawalt and 
Spivak, 2008). Like BER and double-strand break repair, NER genes are under-expressed 
in the majority of human cells that are in the process of differentiation, as reported in the 
monocytic primordial cells during their differentiation to macrophages or neural stem cells 
transformation to neurons (Nouspikel and Hanawalt, 2000; Hsu et al., 2007; Nouspikel, 
2007). During cellular differentiation, authentication of NER occurs due to the non-
ubiquitination of proteins involved in NER, which on the other hand is associated with the 
disparities in phosphorylation of the ubiquitin-activating enzyme (E1) (Nouspikel, 2007). 
To make sure that genes that are active are protected from damage and proficiently repaired 
in the event of any damage, cells are characteristically endowed with a specialised 
mechanism called differentiation-associated repair (DAR), in addition to transcription-
coupled repair (Frosina, 2010). Because of the activities of DAR in differentiated cells, DAR 
could be regarded as a subcategory of GG-NER, with emphasis on the differentiated cells 
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chromatin loci within which transcription takes place (Nouspikel et al., 2006; Nouspikel, 
2007). 
Expression of the 8-oxoguanine DNA glycosylase (Ogg1) gene, one of the genes that formed 
the key focus of this PhD, has been reported to show a characteristic overexpression in 
regions of the neonatal mouse brain containing multiple neural stem cells (Hildrestrand et 
al., 2007). Interestingly, it has been shown that the expression level and activity of Ogg1 are 
elevated in neural stem/primordial cells from new-born mice and fades as the animal grows 
to adulthood and following initiation of cellular differentiation (Hildrestrand et al., 2007; 
Frosina, 2010). It is therefore, safe to assert that elevated expression of Ogg1 and other BER 
proteins may be responsible for the protection of neural stem/progenitor cells from oxidative 
DNA damage (Hildrestrand et al., 2007). Another DNA glycosylase gene, Nei endonuclease 
VIII-like 3 (Neil3), another key gene of interest in thisproject, has also been demonstrated 
to be highly elevated in brain regions harbouring stem cell populations (Rolseth et al., 2008; 
Hildrestrand et al., 2009). 
1.8. Research Aims 
Cancer development involves the complex mechanisms of DNA damage, particularly 
damage that results in the loss of function of tumour suppressor genes and gain of function 
by proto-oncogenes. In this instance, the inability of DNA repair genes to immediately code 
for corrective proteins to restore damaged DNA, probably because of mutation, results in 
development of mutant cell clones (Loeb, 2001). Accordingly, many genes have been 
identified that encode proteins that are directly or indirectly involved in the repair of 
damaged DNA and attempts have been made to classify them into major repair pathways as 
previously reviewed. Additionally, some of the genes that are responsible for the repair of 
damaged DNA have been further implicated in tumour development and drug resistance in 
different cancer types. For instance, high levels of Ercc1 expression have been reported to 
result in CRC resistance to oxaliplatin (Baba et al., 2012; Choueiri et al., 2015). Similarly, 
high levels of Neil3 have been found in metastatic melanoma tumours and various cancer 
cell lines and may also be a resistance factor against cancer chemotherapy (Seetharam et al., 
2010; Elder, pers. commun.). 
 
Though mammalian cells adopt several mechanisms to proofread DNA sequences and 
ensure error-free DNA replication before cell division, impairment in the functions of genes 
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responsible for the repair of DNA damage and correction of replication-associated errors 
could amount to the accumulation of errors with concomitant genetic instability and 
consequent development of aberrant cellular clones (Loeb, 2001). These aberrations may 
occur because of exposure to extrinsic factors such as exposure to carcinogens or mutagens 
and/or intrinsic factors such as endogenously produced ROS (Stratton et al., 2009). Owing 
to the enormity of significance attached to an error-free replication and the vital roles of 
DNA repair genes in ensuring that normal cellular physiology is not compromised, many 
studies have made attempts to identify, characterize and establish various DNA repair genes 
and their products in different cancer types. It is on a similar note, that this research was 
conceived, with the view to mapping the expression patterns of different genes that have 
characteristically been associated with different forms of DNA repair in different cancer 
types including colorectal cancer, medulloblastoma and mesothelioma with a focus on the 
BER DNA glycosylase NEIL3, the NER endonuclease ERCC1 and the mismatch repair 
gene MLH1 (MutL-homolog 1). This will be done with a view to gain insight into the 
involvement of these genes and their products in cancer development and understanding the 
causal relationships between their expression and cancer resistance to chemotherapy. 
 
1.9. Research Objectives 
To achieve the above aims, this research will key into the following objectives: 
1. Extraction of RNA from colon cancer tissues and, where available, matched normal 
colon tissue.  
2. Quantify the expression levels of Neil1, Neil2, Neil3, Ercc11, Nthl1 and Mlh1 in 
colorectal cancer tissues relative to normal colon tissues using quantitative PCR. 
3. Quantify the expression levels of Neil1, Neil2, Neil3, Ercc1 and Mlh1 in 
medulloblastoma cell lines using quantitative PCR. 
4. Extraction of RNA from human embryonic stem cell lines and RT-PCR of DNA 
repair genes of interest. 
5. To determine the growth response of medulloblastoma cell lines following genotoxic 
insult. 
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2.0. MATERIALS AND METHODS 
2.1. Materials 
The RNeasy Fibrous Tissue Mini kit and QuantiNova Reverse Transcription kit were 
obtained from Qiagen Ltd, UK. The ISOLATE II RNA Mini Kit, SensiFast SYBR LO-ROX 
kit and MyTaq RedMix were obtained from Bioline UK. Cisplatin, oxalipatin & tert-butyl 
hydroperoxide were obtained from Sigma-Aldrich. The Aldefluor kit was from Stem Cell 
Technology and the SuperSignal West Femto Maximum Sensitivity Substrate and TRIzol 
RNA isolation Reagent were from ThermoFisher Scientific. Tris base, ammonium persulfate 
and sodium dodecyl sulfate were from Fisher Scientific. 
 
Table 2.1. Agarose Gel Electrophoresis Buffers 
 
 
 
 
 
Material Description 
Tris-Borate-EDTA 
(TBE) 
5x TBE was prepared by dissolving 54 g of Tris base, 27.5 g 
of boric acid and 20 ml of 0.5 M EDTA pH8.0 in 1 L of dH2O. 
The 5x TBE stock solutions was diluted 10-fold to 0.5 x prior 
to use. 
Agarose Gel 
Electrophoresis 
Loading Buffer 
4 g of sucrose, 25 mg of bromophenol blue (0.25% w/v), and 
2.4 ml of 0.5 M EDTA pH 8.0 was mixed and made up to 10 
ml with dH2O. 
DNA Size Marker 2 µl of Hyperladder 1kb or Hyperladder 100 bp (Bioline UK) 
was made up to 10 µl with dH2O 
GelRed  4 μl of GelRed (Biotium) was added to 100 ml of agarose gel 
solution at approximately 50ºC. 
74 
 
 
Table 2.2. Reagents used in Protein Analysis. 
Reagent Description 
Acrylamide  Acrylamide (30% acrylamide, 0.8% bis) obtained 
ready for use (Bio-Rad Laboratories Ltd). 
Ammonium Persulfate (APS)  A 10% (w/v) stock solution of APS was prepared 
by dissolving 1 g of APS in 10 ml dH2O. Aliquots 
were stored at -20°C. 
Tetramethylethylenediamine 
(TEMED) 
TEMED was obtained from Sigma-Aldrich. 
 
 
 
3x SDS-PAGE Loading Buffer 
 
The stock was prepared by mixing, 2.4 ml of 1 M 
Tris-HCl pH6.8, 3 ml 20% (w/v) SDS, 3 ml, 
100% (v/v) glycerol, 1.6 l 2-mercaptoethanol 
and 6 mg bromophenol blue and the final volume 
adjusted to 10 ml with dH2O and stored at 4°C. 
 
 
10x SDS-PAGE Running Buffer 
The 10x stock was prepared by mixing 30.2 g Tris 
base, 10 g of SDS and 144 g of glycine in about 
900 ml of dH2O. The pH was adjusted to pH8.3 if 
required and the volume adjusted to 1 L with 
dH2O. The 10x stock was diluted to 1x buffer just 
before use. 
 
 
10x Western Blot Transfer Buffer 
(WTB) 
 
10x western blot transfer buffer (WTB) was 
prepared by dissolving 144 g glycine and 30.2 g 
Tris base and the final volume made up to 1 L with 
dH2O. A 1x working buffer was prepared by 
adding 100 ml of 10x WTB to 200 ml of methanol 
and made up to 1 L with dH2O and stored at 4°C. 
10x Phosphate Buffered Saline 
(PBS) 
10x PBS was prepared by adding 80 g NaCl, 2 g 
KCl, 7.62 g Na2HPO4 and 0.77 g KH2PO4 to 800 
ml of dH2O. Once fully dissolved, the pH was 
adjusted to pH7.4 with concentrated HCl and the 
total volume made up to 1 L with dH2O. 
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2.1.1. Tissue Samples Collection and Designation  
Frozen human colon tumour and matched normal colon tissues were kindly provided by Dr. 
Andrew Povey, University of Manchester. The tissues were designated as N for normal 
colon tissues and corresponding colon cancer tissues represented by T. In addition, sixteen 
colon tissue samples were collected from the Biobank at the Central Manchester University 
Hospital NHS Foundation Trust and stored at -80oC until used. 
2.2. Methods  
2.2.1. Tissue Preparation and RNA Extraction 
Prior to the start of the RNA extraction, the work environment was cleaned with 70% ethanol 
and DEPC (diethyl pyrocarbonate) water to inactivate RNase enzymes. All equipment and 
plasticware were disinfected in 3% (w/v) Virkon solution before disposal or re-use. 
RNA extraction was carried out from colon cancer and matched normal colon tissue samples 
using the RNeasy Fibrous Tissue Mini kit (Qiagen), following the manufacturer’s 
instructions. Briefly, 30 mg of frozen colon cancer tissue or corresponding normal colon 
tissue was transferred to 300 µl Buffer RLT, disrupted and homogenized using a Tissue 
Lyser (Qiagen). The supernatant was transferred into a sterile 1.5 ml Eppendorf tube for 
RNA isolation.  Subsequently, 590 µl of RNase-free water and 10 µl of proteinase K was 
added, mixed, incubate at 550C for 10 min and centrifuged at 10,000 xg for 3 min. The 
PBS-Tween-20 
 
PBS-Tween-20 contained 100 ml of 10x PBS and 
1 ml of Tween-20 made up to 1 L with dH2O. 
Blocking buffer Blocking buffer was prepared using 5% (w/v) non-
fat milk in PBS-Tween-20. 
Antibody dilution buffer The antibody dilution buffer contained 2.5% (w/v) 
non-fat milk in 1x PBS-Tween-20 
Protein molecular weight (MW) 
Standards  
5 l of PageRuler Plus Prestained Protein Ladder 
(Thermo Scientific) was added to a lane of each 
SDS-PAGE gel. 
RIPA buffer 50 mM Tris-HCl pH8.0, 150 mM sodium chloride, 
1% igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, 0.1% SDS. 
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supernatant was transferred to a new tube and 0.5 volumes of 100% ethanol was added and 
mixed, followed by the transfer of 700 µl of the sample to RNeasy Mini column in a 2ml 
collection tube and its centrifugation for 15 s at 8000 xg. The flow-through was discarded 
and the step was repeated until complete lysate was produced. Then, 350 µl of Buffer RW1 
was added to RNeasy column and centrifuged for 15 s at 8000 xg, and the flow-through was 
discarded. 10 µl of DNase stock solution was mixed with 70 µl Buffer RDD and this was 
added to the RNeasy membrane, and incubated for 15 min at 250C. 350 µl of Buffer RW1 
was added to the RNeasy column and centrifuged for 15 s at 8000 xg and the flow-through 
discarded. Then, 500 µl of Buffer RPE was added to the RNeasy column and centrifuged 
for 15 s at 8000 xg and discarded the flow-through. Another 500 µl of Buffer RPE was added 
to the RNeasy column and centrifuged for 2 min at 8,000 xg. The RNeasy column was placed 
in new 2 ml tube and centrifuged at 8,000 xg for 1 min. Finally, the RNA was eluted by 
placing the RNeasy column in a new 1.5 ml tube and 30 µl of RNase-free water was added 
directly onto the centre of the column followed by centrifugation at 8,000 xg for 1 min. 
 
2.2.2. RNA Extraction from Tissue Using Trizol Reagent 
Fifty milligrams of frozen tissue were homogenized in liquid nitrogen using RNase free 
mortar and pestle until ground into a fine powder. An RNase - free spatula was used to 
transfer the powder to 1 ml of Trizol solution in a 2 ml Eppendorf tube. The mixture was 
vortexed thoroughly and 20% chloroform (200 µl) was added. The mixture was vortexed for 
30 s and incubated at room temperature for 2 min, then centrifuged at 12,000 xg for 15 min 
at 4oC. The clear phase was transferred to a new tube and 200 µl of isopropanol was added 
to precipitate the RNA.  The mixture was vortexed for 30 s and incubated at room 
temperature for 10 min followed by centrifugation at 12,000 xg for 10 min. The supernatant 
was removed by inverting the tubes and the tubes left to dry on absorbent paper. The RNA 
pellet was washed with 1 ml of 75% ethanol and vortex for 30 s and centrifuged at 7,500 xg 
for 5 min at 4oC.  Then, the supernatant was discarded, and the pellet was re-suspended in 
50 µl of RNase-free water and stored at -20oC until required. 
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2.2.3. Determination of the Concentration of RNA 
After purification, the RNA concentration of each sample was determined using a Nanodrop 
2000 spectrophotometer (Thermo Scientific). RNA analysis was carried out by first using 1 
µl of the elution buffer to blank the Nanodrop, after which 1 µl of the RNA sample was 
pipetted onto the pedestal on the Nanodrop and then the concentration measured at 260 nm. 
 
2.2.4. Agarose Gel Electrophoresis of the RNA Product 
The integrity of the extracted RNA was assessed using 1% agarose gel electrophoresis. The 
agarose gel was prepared by mixing 0.5 g of agarose powder with 50 ml of 0.5x TBE (Tris-
borate-EDTA) in a 250 ml Duran bottle and then heating the mixture in a microwave oven 
for 2-3 minutes, until the agarose powder had completely dissolved. Once the agarose had 
cooled sufficiently to be held by hand, 2 µl of GelRed (Biotium) was added and the contents 
poured into a gel tray containing a gel comb to create wells. Subsequently, 10µl of each 
RNA sample was loaded into each well along with 10 µl Hyperladder 1kb DNA ladder 
(prepared by mixing 1 µl Hyperladder 1 kb and 2 µl loading buffer in 7 µl dH2O). The gel 
was subjected to electrophoresis at 100V for 70 min. The bands were imaged and recorded 
by UV-trans illumination and GeneSnap software (Syngene, Geneflow Ltd). 
 
2.2.5. Complementary DNA (cDNA) Synthesis by Reverse Transcription  
The extracted RNA was reverse transcribed into complementary DNA (cDNA) using the 
QuantiNova Reverse Transcription kit (Qiagen) according to the manufacturer’s guidelines. 
Thus, 2 µl of genomic DNA (gDNA) removal mix was mixed with 3 µl of RNA (1.0 ng), 1 
µl internal control RNA and 9 µl RNase-free water to make a final volume of 15 µl and 
incubated at 45°C for 2 min, then placed immediately on ice. The reaction mixture for 
reverse-transcription was prepared by mixing 1 µl Reverse Transcription Enzyme with 4 µl 
Reverse Transcription mix and the 15 µl entire genomic DNA elimination reaction mixture, 
to make a final volume of 20 µl. This was incubated at 25°C for 3 min followed by further 
incubation at 45°C for 10 min. The reverse transcriptase enzyme was inactivated by 
incubating at 85°C for 5 min. The cDNA obtained was amplified by the target gene primers 
using the polymerase chain reaction (PCR) as described in Section 2.2.6. 
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2.2.6. Primer Design 
The primers used to assess the expression of the target DNA repair genes were designed 
using National Centre for Biotechnology Information software (NCBI/Primer BLAST). The 
primer pairs were picked from different exons of the genes. The primers were purchased 
from Eurofins Genomics and reconstituted following the manufacturer’s instructions to 100 
µM with 10 mM Tris-HCl pH8.0 and 1 mM EDTA (TE) buffer and stored at -20°C. The 
forward and reverse primers for the different target genes are tabulated in Table 2.3. 
 
Table 2.3. qPCR Gene Specific Primers. 
Target Gene DNA Sequence Tm (°C) GC-Content 
(%) 
PCR 
product (bp) 
Gapdh 1014 GGTGGTCTCCTCTGACT
TCAACA 
61.8 52.2  
127 
Gapdh 1140 GTTGCTGTAGCCAAATT
CGTTGT 
60.5 43.5 
Ercc1 884S CAAAACGGACAGTCAG
ACCCT  
 59.8 52.4  
146 
Ercc1 1029AS TCAAGAAGGGCTCGTG
CAG  
58.8 57.9 
Neil1 1071S@@ AGAAGATAAGGACCAA
GCTGC 
 57.9 47.6  
212 
Neil1 
1283AS@@ 
GATCCCCCTGGAACCA
GATG 
 61.4 60.0 
Neil1 
1079S 
AGGACCAAGCTGCAGAAT
CC 
60.0 55.0  
125 
Neil1 
1203AS 
GCTCGAAAGGCAGCAAAG
TC 
60.1 55.0 
Mlh1 2276S# AGGAGTCGACCCTCTCA
GG  
61.0 63.2  
66 
Mlh1 2342AS# GTCCACTTCCAGGAGTT
TGG 
59.4 55.0 
Neil2 
631S 
GAAGCTTCCCCGTAGA
AGAGG  
61.8 57.1  
122 
Neil2 
773AS 
TGTAGCTTCTTACTGCT
GCCC 
59.8 52.4 
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Neil2 1291S## GCCTTAGAAGCTCTAGG
CCA  
59.4 55.0  
 
145 Neil2 
1436AS## 
GCACTCAGGACTGAAC
CGAG 
60.2 54.0 
Neil3 1651S CGCCTCTGCATTGTCCG
AGT  
62.3 62.3  
 
147 
Neil3 1798AS TGGAACGCTTGCCATGG
TTG  
61.8 61.8 
Nthl1 679S@ GATGGCACACCTGGCT
ATG 
58.8 57.9  
 
165 
Nthl1 844AS@ CCACAGCTCCCTAGGCA
G 
60.5 66.7 
Ogg1 1020S AGCAGCTACGAGAGTC
CTCA 
59.4 55.0  
137 
Ogg1 1156AS CATATGGACATCCACG
GGCA 
59.4 55.0 
 
@@ Obtained from Shinmura et al., (2004); @Obtained from Goto et al., (2009); #Obtained 
from Jensen et al., (2013); ## Obtained from Mandal et al., (2012). 
 
2.2.7. Amplification of Genes of Interest in Colon Cancer and Normal Colon Tissues 
by Reverse Transcription PCR (RT-PCR). 
Following the conversion of the RNA extracted from the colon tumours and corresponding 
colon tissues to complementary DNA (cDNA) by the reverse transcription reaction, the 
sequences of the target genes were amplified by PCR. The primers were prepared by diluting 
1 µl of 100 µM stock with 9 µl of TE buffer. The cDNA sample was mixed with 2x MyTaq 
RedMix (Bioline UK), forward primer, reverse primer and the total reaction was made up to 
25 µl by adding dH2O (Table 2.4). Denaturation, annealing and extension were run for 30 
cycles. Table 2.5 shows the conditions of the PCR reaction. 
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 Table 2.4. Composition of the PCR reaction mixture. 
Reagent Volume 
Template cDNA (1.0 ng) 1 µl 
2x MyTaq RedMix 12.5 µl 
10 µM Forward primer 0.5 µl 
10 µM Reverse primer 0.5 µl 
dH2O 10.5 µl 
Total 25 µl 
  
Table 2.5. PCR Reaction Conditions. 
PCR conditions Temperature Time 
Pre-denaturation 95°C 1 min 
Denaturation 95°C 10 s 
Annealing 60°C 10 s 
Extension 72°C 10 s 
Final extension 72°C 5 min 
Final Hold 4°C Hold 
 
Upon the completion of the PCR reaction, 5 µl from each PCR reaction was mixed with 2 
µl of gel loading buffer and 3 µl of dH2O, then 10 µl was loaded on a 2% agarose gel 
(prepared by mixing 2.0 g agarose with 100 ml 0.5x TBE and 4 µl of GelRed) along with 
10 µl Hyperladder 100bp DNA marker (prepared by mixing 1 µl Hyperladder 100bp, 2 µl 
loading buffer and 7 µl dH2O). The gel was subjected to electrophoresis at 100V for 70 min. 
The bands were imaged and recorded as previously described in Section 2.2.3. 
 
2.2.8. Amplification of Genes of Interest in the Biobank Tumour Samples by RT-PCR 
Following the conversion of the RNA extracted from the various colon tumours to cDNA, 
the DNA sequences of the target genes were amplified by PCR. The primers were prepared 
by diluting 1 µl with 9 µl TE buffer and the cDNA sample was mixed with OneTaq Hot 
30 cycles 
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Start DNA Polymerase (New England Biolabs) and the total reaction was made up to 25 µl 
by adding nuclease free water as indicated in Table 2.6. Denaturation, annealing and 
extension were run for 35 cycles (Table 2.7). 
 
Table 2.6. One Taq PCR reaction mixture. 
Reagent Volume 
5x OneTaq Standard Reaction Buffer 5 µl 
10 mM dNTPs 0.5 µl  
10 µM Forward Primer 0.5 µl 
10 µM Reverse Primer 0.5 µl 
One Taq Hot Start DNA Polymerase 0.125 µl 
Template DNA (< 1,000 ng) Variable 
Nuclease-free water to 25 µl 
 
 
Table 2.7. PCR Reaction conditions for OneTaq Hot Start Reactions. 
PCR conditions Temperature  Time 
Pre-denaturation 94°C 1 min 
Denaturation 94°C 15 s 
Annealing 60°C 15 s 
Extension 68°C 30 s 
Final extension 68°C 5 min 
Final Hold 4°C Hold 
 
2.2.9. Quantitative PCR (qPCR) 
Quantitative real time PCR (qPCR) was carried out to quantify the expression of the target 
genes on cDNA from colon cancer tissue samples using the SensiFast SYBR Lo-ROX Kit 
(Bioline UK), following the manufacturer’s instructions. The reference gene for 
normalization was glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and melting 
curves were used to confirm the specificity of the PCR primers as well as purity of products. 
35 cycles 
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Accordingly, 5 µl of cDNA from the reverse transcription reaction (20 µl) was added to 45 
µl of TE buffer to obtain a final volume of 50 µl and then a standard curve was obtained 
by a 10-fold serial dilution which was made as follows: 100%, 10%, 1%, 0.1% and 0% 
cDNA by the following steps:  
10%: 8 µl from 100% of cDNA sample was added to 72 µl of RNase-free water. 
1%:   8 µl from 10% of cDNA sample was added to 72 µl of RNase-free water. 
0.1%: 8 µl from 1% of cDNA sample was added to 72 µl of RNase-free water. 
0.01%:   8 µl from 0.1% of cDNA sample was added to 72 µl of RNase-free water.  
 
Subsequently, triplicate aliquots of 5 µl cDNA template were added to the wells of a 96–
well reaction plate as shown in Table 2.8. The PCR primers were prepared by diluting 1 µl 
(100 pmol) with 9 µl TE buffer to give a final concentration of 10 µM. For each PCR 
reaction mix, 18.5 µl of forward primer, 18.5 µl of reverse primer, 230 µl 2x SensiFast 
SYBR Lo-ROX (containing SYBR Green l dye and dNTPs) and 78 µl RNase-free water 
were mixed in a 1.5 ml micro-centrifuge tube and then 15 µl was distributed in each well 
as shown in Table 2.8. Negative control wells had the following: forward primer, reverse 
primer, 2x SensiFast SYBR Lo-ROX and RNase-free water. The qPCR reactions were 
prepared in a 96-well plate and the wells were loaded as shown in Table 2.9. Two-step 
cycling was used for the PCR reaction and the conditions are given in Table 2.10. Melting 
curve from 72oC to 90oC, reading every 1°C, hold at 30 s. 
 
 
 
Table 2.8. Loading of the 10-fold serially diluted cDNA in triplicate in a 96-well plate. 
100% 10% 1% 0.1% 0.01% 
A1 - A12 C1-C12 D1- D12 E1- E12 F1 –F12 
B1 –B12     
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Table 2.9. Sample Loading Pattern for qPCR in a 96-well plate. 
Primer Sample Standard Negative 
Control 
Gapdh A1, A2, A3 B1, B2, B3, C1, C2, C3, D1, D2, 
D3, E1, E2, E3, F1, F2, F3. 
G1, G2, G3. 
Neil1 A4, A5, A6 B4, B5, B6, C4, C5, C6, D4, D5, 
D6, E4, E5, E6, F4, F5, F6. 
G4, G5, G6. 
Neil2 A7, A8, A9 B7, B8, B9, C7, C8, C9, D7, D8, 
D9, E7, E8, E9, F7, F8, F9. 
G7, G8, G9. 
Neil3 A10, A11, A12 B10, B11, B12, C10, C11, C12, 
D10, D11, D12, E10, E11, E12, 
F10, F11, F12. 
G10, G11, 
G12. 
 
 
Table 2.10. qPCR conditions 
Cycles Temperature Time PCR phase 
1 95°C 2 min Denaturation 
40 95°C 5 s Denaturation 
40 60°C 30 s Annealing/ Extension 
 
 
Analysis of the results was conducted through MJ Opticon Monitor Version 3.1 software 
and the relative expression of the target gene in each cell line was calculated by 
normalization of its mRNA quantitative values with the values of Gapdh using the 2(-Delta 
Delta C(T)) method (Livak and Schmittgen, 2001). 
By plotting fluorescence against the cycle number, an amplification plot that represents the 
accumulation of product over the duration of the PCR reaction was generated. Gapdh was 
used as a reference gene and it is assumed that its expression level is constant in the cells 
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from tumour and normal tissues. Each run of qPCR has a standard curve that was generated 
through serial dilution of cDNA. 
2.3. Cell Culture 
2.3.1. Cells 
The medulloblastoma (DAOY) cell lines, including the cisplatin-resistant subtype and the 
conventional medulloblastoma cells were kind gifts from Dr Gianpiero Di Leva, University 
of Salford. The Mero25 mesothelioma cell line was kindly supplied by Professor Luciano 
Mutti, University of Salford. The human embryonic stem (hES) cell pellets were kindly 
supplied by Professor Daniel Brison, Central Manchester University Hospitals NHS 
Foundation Trust, Manchester, UK and were stored at -80˚C until required. 
 
2.3.2. Cell Culture Methods 
The medulloblastoma and mesothelioma cell lines were grown at early passage and working 
stocks were aliquoted in vials and stored in 10% (v/v) dimethyl sulfoxide (DMSO), 90% 
FBS at -80˚C or in liquid nitrogen for short-term storage. For each experiment, the 
medulloblastoma (DAOY) cell lines were routinely cultured in RPMI1640 with 0.2 mM L-
glutamine (Invitrogen), supplemented with 10% heat-inactivated foetal bovine serum (FBS) 
(Invitrogen, UK) and 1% penicillin-streptomycin (Complete medium; Invitrogen, UK) until 
70-80% confluent. Similarly, the mesothelioma (MERO-25) cells were cultured in 
Dulbecco’s modified eagle medium (DMEM) with 0.2 mM L-glutamine, supplemented with 
10% heat-inactivated FBS and 1% penicillin-streptomycin (Complete medium;) until 70-
80% confluent. 
Cells were split 1:10-1:15 when confluency of 70%-80% was reached. The cells were 
washed with phosphate buffered saline (PBS) and then incubated for up to five minutes at 
37°C with 5 ml of 1x trypsin-EDTA (Invitrogen). Once most cells had detached from the 
flask, the trypsin-EDTA was quenched by the addition of double the volume of complete 
cell culture medium. Cells were collected and then pelleted by centrifugation for 3 min at 
1200 rpm. Cells were then re-suspended in medium and seeded in T75 flasks for further 
experiments. 
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2.3.3. Cell Seeding Conditions 
Unless otherwise stated, all experiments were performed in triplicate. Cells from flasks that 
were 70-80% confluent and were seeded in either 96-, 12- or 6-well plates or 10 cm petri 
dishes or T25 flasks, depending on the experiment. The cells were pelleted (as described in 
Section 2.3.2) and re-suspended in fresh medium. To accurately establish the number of 
cells per millilitre, the cells were counted using a haemocytometer and plated at the 
appropriate density depending on cell type, the plate used and the experiment, as detailed 
throughout the corresponding Sections. 
 
2.3.4. Cell Viability Assays (MTT Assay) 
The genotoxic agents, oxaliplatin, cisplatin and tert-butyl hydroperoxide were employed in 
this project to induce DNA damage and to assess cell viability in relation to the gene 
expression of selected DNA repair genes. Normal and cisplatin-resistant DAOY 
medulloblastoma cells were grown in RPMI1640 medium supplemented with 2 mM L-
glutamine, 10% FBS and 1% penicillin-streptomycin. The cells were maintained at 37°C in 
a humidified incubator with an atmosphere of 95% air and 5% CO2. Cell viability was 
determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
Cells were cultured overnight in 96-well plates (2 x 103/well) containing 100 µl complete 
medium prior to incubation with 100 µl of complete medium containing various 
concentrations of either oxaliplatin, cisplatin or tert-butyl hydroperoxide (0.78 µM - 100 
µM) in each well and incubated for 72 h at 37°C in a humidified atmosphere and 5% CO2. 
Once incubation was complete, 40 µl of MTT (3 mg/ml) reagent was added into each well 
using a multi-channel pipette and incubated for 3 h at 370C. (Then purple formazan crystals 
were observed in the wells). The medium was aspirated carefully from each well and 200 µl 
of DMSO was added to each well using a multi-channel pipette and mixed thoroughly until 
the crystals dissolved fully. The plate was read at 540 nm and 690 nm using the multi-scan 
Ascent plate reader (Thermo Scientific) and analysed. 
 
 
86 
 
2.3.5. Gene Expression Analysis in Cell Lines 
RNA extraction was carried out from the stored pellets of the normal & cisplatin-resistant 
DAOY cells, Mero25 and human embryonic stem cell lines using the Isolate II RNA Mini 
kit following the manufacturer’s instructions. Cell pellets were thawed on ice for 5 min. 
Three hundred and fifty microlitres of lysis buffer was added to 3.5 µl of 2-mercaptoethanol 
and mixed on a vortex in 1.5 ml tubes, then added to the cell pellets. The lysate was 
transferred to an Isolate II filter (violet) which was then placed in a 2 ml collection tube and 
centrifuged at 11,000 xg for 1 min. The flow-through was transferred to a 1.5 ml 
microcentrifuge tube, and then 350 µl of 70% ethanol was added and mixed by pipetting up 
and down 5 times. It was transferred to a 2 ml collection tube which was placed in an Isolate 
II RNA mini column (blue) and centrifuged at 11,000 xg for 30 s. After that, the column was 
put in a new 2 ml collection tube and the silica membrane was desalted by adding 350 µl of 
membrane desalting buffer and centrifuging at 11,000 xg for 1 min before the membrane 
was dried through centrifugation at 11,000 xg for 1 min. 
The DNase I reaction mixture was prepared by adding 10 µl of reconstituted DNase I to 90 
µl of reaction buffer for DNase I and mixed by gently flicking the tube. Genomic DNA was 
digested by adding 95 µl DNase I reaction mixture directly on the centre of the silica 
membrane and incubating at room temperature for 15 min. The silica membrane was then 
washed several times, first by adding 200 µl of wash buffer RWI, followed by centrifugation 
at 11,000 xg for 30 s, and then the column was placed into a new collection tube (2 ml). The 
second wash was carried out by adding 600 µl wash buffer RW2, then it was centrifuged at 
11,000 xg for 30 s, the flow- through was discarded and the column was placed back into 
the collection tube. The third wash was carried out by adding 250 µl wash buffer RW2 
followed by centrifugation at 11,000 xg for 2 min, the flow-through discarded and the 
column placed into a nuclease free 1.5 ml collection tube. Finally, the RNA was eluted by 
adding 60 µl of RNase-free water directly onto the centre of the silica membrane and 
incubated for 1 min at room temperature followed by centrifugation at 11,000 xg for 1 min. 
Following the successful extraction, the RNA concentration was measured, and RNA quality 
was assessed, cDNA was synthesised, RT-PCR and qPCR were conducted as previously 
described in Sections 2.2.7 and 2.2.8.  
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2.3.6. Preparation of cancer stem cells. 
2-hydroxyethyl methacrylate (polyHEMA) was prepared by adding 12 g into 1 L of 98% 
(v/v) ethanol and mixed on a magnetic stirrer at 45-50°C for about 8 h to dissolve complete 
dissolution. After this, 1.5 ml of this solution was added into each well of a 6-well tissue 
culture plate and incubated in an oven at 55°C for 5 days. Before seeding of the cells, the 
coated plate, without the lid, was placed in a sterile cabinet under a UV light for 10 – 15 
min. Two millilitres of freshly grown Mero25 mesothelioma cells was mixed with 4 ml of 
cancer stem cell medium (DMEM/F-12) in a 15 ml tube and centrifuged at 1,250 rpm for 5 
min. The supernatant was discarded, and 2 ml of cancer stem cell medium was added to 
resuspend the cells. A sterile syringe with a 25G needle was used to pipette the cells up and 
down once to make a single cell suspension. Then, 5000 cells were seeded in 2 ml of 
DMEM/F-12 medium in each well of the 6-well plate and incubated for 5 days at 37°C in a 
humidified incubator with an atmosphere of 95% air and 5% CO2. Thereafter, the cells were 
harvested for flow cytometry analysis and RNA extraction. 
 
2.3.7. Flow Cytometry Analysis of Cancer Stem Cells Derived from Mesothelioma 
Cell Line Mero-25. 
Cancer stem cells (CSC) were confirmed by flow cytometry analysis of viable cells using 
an Aldefluor kit (Stem Cell Technologies). Cancer stem cells derived from the mesothelioma 
cell line Mero-25 were grown to 80% confluence in DMEM/F-12 medium All the cells were 
transferred to a 1.5 ml tube and centrifuged at 1300 xg for 5 min. The supernatant was 
discarded and 100 µl of 1x trypsin-EDTA was added and incubated for one minute. Two 
hundered microlitres of DMEM/F12 medium was added, pipetted up and down and the cells 
centrifuged at 1200 xg for 5 min, after which the supernatant was discarded. Following this, 
400 µl of DMEM/F12 medium was added, pipetted up and down with a syringe to separate 
the cells.  Then, a “test” and a “control” tube for each sample to be tested were labelled and 
400 µl of the cell suspension was placed into each of the sample tube (test). Five microlitres 
of Aldefluor DEAB reagent was added to the control tube and recapped immediately. 5 µl 
of the activated Aldefluor reagent was added into the tube containing 400 µl of cell 
suspension.  200 µl of the mixture was immediately added to the DEAB tube (control). The 
test and control sample were incubated for 60 min at 37°C. After incubation, all of the tubes 
were centrifuged for 5 min at 250 xg and the supernatant was discarded. The cell pellet was 
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re-suspended in 0.5 ml of Aldefluor Assay Buffer and kept on ice. The cells were analysed 
for viable cancer stem cells following mixing with Adefluor. Analysis of derived cancer 
stem cells was carried out using a FACSCalibur flow cytometer (BD Biosciences). 
 
2.4. Protein Analysis 
2.4.1. Protein extraction and Separation by SDS-PAGE 
Medulloblastoma DAOY cells (Normal & cisplatin-resistant) were grown in T25 flasks up 
to 80% confluence, as previously described in Section 2.3.2. Each cell line was lysed directly 
in flasks with ice-cold RIPA buffer containing 50 mM Tris-HCl pH8.0, 150 mM sodium 
chloride, 1% igepal CA-630 (NP-40), 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate (SDS); and protease inhibitor cocktail (Invitrogen, UK). Protein concentrations were 
determined using the Bradford method (Bradford, 1976), and lysates were snap-frozen in 
liquid nitrogen before storage at -80oC. Cell lysates were thawed on ice and mixed at the 
ratio of 1:1 with Laemmli buffer containing 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 
2-mercaptoethanol, 0.004% (w/v) bromophenol blue, and 0.125 M Tris-HCl pH6.8. The 
mixtures containing 15 µg, 30 µg or 60 µg of total protein were heated for 5 min at 95oC 
before separating the proteins through a 10% SDS-polyacrylamide gel (see Table 2.11) at a 
constant voltage of 80V for 30 min, then at 120V for 1 h.  
Table 2.11. Composition of SDS-polyacrylamide gels. 
Percentage gels 10% 5% 
 Resolving Stacking 
dH2O 10.94 ml 6.73 ml 
30% acrylamide 9.33 ml 1.67 ml 
1.5 M Tris-HCl (pH 8.8) 7 ml - 
0.5 M  
Tris-HCl (pH 6.8) 
- 1.25 ml 
0.2 M EDTA 280 µl 100 µl 
10% SDS 280 µl 100 µl 
10% APS 157 µl 157 µl 
TEMED 17 µl 17 µl 
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2.4.2. Western blotting  
Following separation by SDS-PAGE, the proteins were transferred onto PVDF membranes 
at constant current of 400 mA for two hours, using ice-cold 1x western transfer buffer 
(WTB). The membranes were subsequently blocked for 1 h in blocking buffer (5% non-fat 
milk in PBS-Tween-20). This was followed by overnight incubation at 4oC with primary 
antibody specific for the target protein under investigation in 2.5% non-fat milk in PBS-
Tween-20 at the dilution indicated in the manufacturer’s data sheet. The blots were then 
washed three times with 0.1% PBS-Tween for ten-minute intervals, before further 
incubation with secondary antibody - horseradish peroxidase (HRP) conjugate inantibody 
dilution buffer for 1 h at room temperature, at the dilution specified in the manufacturer’s 
data sheet. Afterwards, the blots were washed three times for 10 min with PBS-Tween-20. 
Finally, the membrane was washed in PBS for 5 min to remove excess Tween-20 and placed 
on a paper towel to drain off excess liquid. Then, the chemiluminescence substrate reagent 
(SuperSignal West Femto Maximum Sensitivity Substrate, Thermos Scientific) was 
prepared with 500 l of each femto reagent and poured over the membrane. Finally, the 
membrane was incubated on a shaker for 1 – 2 min at room temperature and the protein 
bands were viewed on a G-box image analyser (Syngene). 
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RESULTS 
3.1. Preliminary experiments 
To ensure that the RNA extraction procedures and RT-PCR reactions were robust and 
working as expected, preliminary experiments were carried out on two cancer cell lines, 
HCT116, a human colorectal carcinoma cell line and Mero25, a mesothelioma - derived cell 
line. Figure 3.1 shows that the two bands of 28S and 18S rRNA were obtained from both 
cell lines using the Bioline ISOLATE II RNA mini kit. 
 
Figure 3.1 Agarose gel electrophoresis of RNA extracted from HCT116 and Mero25 
Lane H: Hyperladder 1kb; lanes 1, 2 µl; lane 2, 5 µl; lane 3, 7 µl; lane 4, 2 µl; lane 5, 5 
µl; lane 6, 7 µl. 
 
Following this, the PCR primer pairs obtained for each target gene (Table 2.3) were tested 
on cDNA prepared from the two RNA samples. The results are presented in Figure 3.2 - 
Figure 3.3.  
 
 
 
bp 
1000 
10,000 
H                      1           2          3         4          5        6 
28S 
18S 
HCT116 Mero25 
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Figure 3.2 Agarose gel electrophoresis of RT-PCR products of Gapdh, Ercc1, Ogg1, 
Nthl1 and Mlh1 genes for HCT116 and Mero-25 cell lines. 
Lane 1, Gapdh; lane 2, Ercc1 (884S); lane 3, Ercc1 (994S); lane 4, Ogg1 (1020S); lane 5, 
Ogg1 (1258S); lane 6, Nthl1 (349S); lane 7, Nthl1 (679S); lane 8, Mlh1 (1814S); lane 9, 
Mlh1 (2276S); lane 10, Ercc1 (884S); lane 11, Gapdh; lane 12, Ercc1 (994S); lane 13, 
Ogg1 (1020S); lane 14, Ogg1 (1258S); lane 15, Nthl1 (349S); lane 16, Nthl1 (679S); lane 
17, Mlh1 (1814S); lane 18,  Mlh1 (2276). H represents Hyperladder 100bp. 
 
The results of the RT-PCR reactions shown in Figure 3.2 indicate that the majority of gene 
specific primer pairs amplified the target section of cDNA uniquely, resulting in a single 
band in each lane. However, there were exceptions and no PCR product were obtained 
from primer pairs 994S for Ercc1 (lanes 3 and 12), 349S for Nthl1 (lanes 6 and 15) or 
1814S for Mlh1 (lanes 8 and 17) in cDNA prepared from either cell line. Thus, where more 
than one set of primers for a particular gene was used, the primer pair showing the more 
robust activity was chosen. 
Figure 3.3 shows a similar result for the three Neil genes, although this time there is a 
marked difference in expression levels between the two cell lines, with the exception of 
Gapdh (lanes 1 and 7) and Neil3 (lanes 6 and 12) using this qualitative method. 
HCT11
6
Mero-
25
HCT116 Mero25 
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Figure 3.3 Agarose gel electrophoresis of RT-PCR products of Gapdh, Neil1, Neil2 
and Neil3 for HCT116 and Mero-25 cells. 
Lanes 1 – 6, HCT116 and lanes 7-13, Mero-25. Lane 1, Gapdh; lane 2, Neil1 (1079S); lane 
3, Neil1 (1071S); lane 4, Neil2 (631S); lane 5, Neil2 (1291S); lane 6, Neil3 (1651S); lane7, 
Gapdh; lane 8, Neil1 (1079S); lane 9, Neil1 (1071S); lane 10, Neil2 (631S); lane 11, Neil2 
(1291S); lane 12, Neil3 (1651S); lane 13, Neil2 (631S). H: Hyperladder 100 bp. 
 
Following these preliminary experiments to gain experience in working with RNA and to 
confirm the specificity and suitability of the PCR primers, the project could now focus on 
the expression of the selected DNA repair genes in CRC tumour samples (Section 3.2), the 
change in expression of a subset of these genes in response to cisplatin treatment in 
medulloblastoma cells (Section 3.4) and an analysis of gene expression in putative cancer 
stem cells derived from a mesothelioma cell line (Section 3.5) and in human ES cells 
(Section 3.6). 
 
 
 
 
HCT116 Mero-25 
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3.1.1. Colon tissue samples 
In this project, colon tissue samples were obtained from two sources. The first twelve 
samples included matched control tissue (Table 3.1) and were obtained from the laboratory 
of Dr Andrew Povey (University of Manchester, UK), where they had been kept in long-
term storage at -80°C. Despite many attempts and change of protocols the total RNA 
obtained from these samples rarely produced the characteristic double rRNA bands that had 
been expected, indicating that the rRNA, and by inference, the mRNA may have been 
degraded (Figure 3.4). While RT-PCR results were still obtained for these samples and a 
control gene (Gapdh) consistently produced similar results across all samples, it was decided 
to obtain fresh samples from the biobank at the Central Manchester University Hospital NHS 
Foundation Trust and these are listed in Table 3.2. These samples also had the benefit of 
having some basic patient information that may have been useful. However, again, despite 
all efforts to avoid RNA degradation, the two rRNA bands were rarely observed in the total 
RNA samples extracted from these tumour samples (Figure 3.5). The analysis of the gene 
expression of selected DNA repair genes from these samples is described in the following 
sections. 
           Table 3.1 Nomenclature of matched tumour and normal colon samples 
Sample 
Number 
 
Colon Tumour 
Samples 
Matched Normal 
Colon Tissue 
Samples 
Designation 
1 2T 1N Pair 1 
2 4T 3N Pair 2 
3 6T 5N Pair 3 
4 8T 7N Pair 4 
5 10T 10N Pair 5 
6 11T 11N Pair 6 
7 12T 12N Pair 7 
8 13T 13N Pair 8 
9 33T 33N Pair 9 
10 34T 34N Pair 10 
11 35T 35N Pair 11 
12 36T 36N Pair 12 
 
94 
 
 
Table 3.2 Description of the sixteen biobank colon tissue samples 
Sample 
Number 
 
Tissue ID Tissue Sample 
Site 
Gender Age Tissue 
Status 
1 1538 Colon Male 72 Normal 
2 1545 Colon Female 63 Normal 
3 1573 Colon Female 70 Normal 
4 1573T Colon Female 70 Tumour 
5 1580 Not Specified Male 69 Normal 
6 1581 Not Specified Female 62 Normal 
7 1581T Not Specified Female 62 Tumour 
8 1597 Caecum Male 54 Normal 
9 1597T Caecum Male 54 Tumour 
10 1604 Colon Female 79 Normal 
11 1604T Colon Female 79 Tumour 
12 1610 Caecum Male 59 Tumour 
13 1620 Colon Male 65 Tumour 
14 1626 Colon Female 73 Tumour 
15 1627 Colon Male 64 Tumour 
16 1630 Colon Male 64 Tumour 
 
3.1.1.1. Assessment of Yield and Integrity of RNA Extracted from Samples. 
To establish the quality of the RNA purified from the different colon cancer tissue samples 
and their corresponding normal colon tissues, agarose gel electrophoresis was conducted. 
For total RNA extracted from human cells, it was expected that the gels should show two 
distinct bands representing 18S and 28S rRNA. However, as can be seen in Figure 3.4, the 
extracted RNA was often degraded and the rRNA bands were not observed, thus Figure 
3.4 typifies the banding patterns of RNA extracted from the colon cancer and normal colon 
tissues, with the thickness of the bands serving as indicators of RNA yield. A DNA ladder 
was included in all gels solely to confirm that the electrophoresis had occurred correctly. 
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Figure 3.4 Agarose gel electrophoresis of RNA extracted from different colon tumour 
tissue samples and matched normal colon tissue.  
Lane H, Hyperladder 1kb; lane 1N, normal colon tissue from sample 1N; lane 2T, colon 
tumour tissue from sample 2T; lane 3N, normal colon tissue from sample 3N; lane 4T, 
colon tumour tissue from sample 4T; lane 5N, normal colon tissue from sample 5N; lane 
6T colon tumour tissue from sample 6T.  
 
Following many unsuccessful attempts to reduce RNA degradation, sixteen tissue samples 
were obtained from a biobank as described in Section 3.1.1. The source of these sixteen 
samples and available patient information is given in Table 3.2. 
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Figure 3.5. Agarose gel electrophoresis of RNA extracted from the 16 colon tissue 
samples obtained from the biobank (see Table 3.2 for full details). 
A: Lane H,  Hyperladder 1kb; lane 1, Sample 1538; lane 2, Sample 1545; lane 3, Sample 
1604T; lane 4, Sample 1610. B: Lane H, Hyperladder 1kb; lane 1, Sample 1573; lane 2, 
Sample 1573T; lane 3, Sample 1581; lane 4, Sample 1620. C: Lane H, Hyperladder 1kb; 
lane 1, Sample 1580; lane 2, Sample 1581T; lane 3, Sample 1597; lane 4, Sample 1626; lane 
5, Sample 1627; lane 6, Sample 1630. D: Lane H, Hyperladder 1kb; lane 1, Sample 1597T; 
lane 2, Sample 1604. 
 
The results presented in Figure 3.5 again indicate ribosomal RNA degradation in the 
majority of samples, only lane 2 in Figure 3.5A  (sample 1545) and lane 2 in Figure 3.5D 
(sample 1604) showing the expected 28S and 18S rRNA bands. However, there is no 
evidence of a high molecular band in any of the samples that would indicate genomic DNA 
contamination and therefore the DNase step in the RNA extraction procedure appears to 
A 
D C 
B 
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have been successful. As shown in subsequent sections, the lack of intact rRNA did not 
prevent the amplification of specific mRNA sequences from any of the samples, although it 
is acknowledged that there is no way of knowing the effect of the observed rRNA 
degradation on the mRNA component and it is assumed that if degradation occurred, it 
affected all mRNA molecules equally. 
 
3.2. Reverse Transcripion-PCR 
3.2.1. Primer Specificity 
RT-PCR was carried out on cDNA from tissue samples using specific primers of the target 
genes. To confirm the primer specificity and ensure that genes of interest only were 
amplified, agarose gel electrophoresis of the RT-PCR products was conducted, with 
particular attention given to ensuring a unique product of the correct size was obtained. Thus, 
Figure 3.6 is a representative gel from the matched tissue samples listed in Table 3.1, while 
Figure 3.7 to Figure 3.13 show the results for the different genes analysed from each of the 
RNA samples from the different CRC tissue samples listed in Table 3.2. 
 
 
Figure 3.6. Agarose gel electrophoresis of RT-PCR products corresponding to Gapdh 
and Neil3 from tissue samples 10N and 10T. 
Lane H, Hyperladder 100bp; lane 1, Gapdh from sample 10N; lane 2, Neil3 from sample 
10N; lane 3, Gapdh from sample 10T; lane 4, Neil3 from sample 10T.  
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Figure 3.6 shows that a single band of the expected size was obtained when PCR primers 
specific for Gapdh (127 bp) and Neil3 (147 bp) were used. There appears to be little 
observable difference between the RNA sample extracted for the normal tissue (lanes 2 and 
3) and the RNA extracted from the CRC sample (lanes 3 and 4) and for these tissues, and 
in the semi-quantitative nature of the assay, Neil3 expression was less than that of Gapdh. 
 
 
Figure 3.7. Agarose gel electrophoresis of RT-PCR products of tissue samples 1597T 
and 1604. 
Lane H, Hyperladder 100 bp; lanes 1 & 4, Gapdh (127 bp); lanes 2 & 5, Neil3 (147 bp); 
lanes 3 & 6, Ercc1 (146 bp).  
Figure 3.7 is the first of seven gels showing the RT-PCR results from the sixteen biobank 
tissue samples listed in Table 3.2. Sample 1597T was obtained from the tumour of a 54 
year-old male, while 1604 was from a 79 year-old female. The results of the PCR from 
each sample look quite different, with all bands with the exception of Neil3 much stronger 
in 1604. It is worth noting that the Gapdh band is much stronger in 1604 and, if 
reproducible, will have a bearing on the qPCR results, where the amount of PCR product 
was compared with that of Gapdh. However, all reactions again show just a single band of 
the correct size indicating that the PCR primers can be used for qPCR. 
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Figure 3.8. Agarose gel electrophoresis of RT-PCR products of tissue samples 1538 & 
1545 for Gapdh, Neil1, Neil3, Ercc1 and Nthl1. 
 
Lane H, Hyperladder 100 bp; lanes 1 & 6, Gapdh); lanes 2 & 7, Neil1; lanes 3 & 8, Neil3; 
lanes 4 & 9, Ercc1; lanes 5 & 10, Nthl1. 
In Figure 3.8, cDNA prepared from RNA extracted from samples 1538 and 1545 were 
subjected to RT-PCR for Neil1 (212 bp), Neil3 (147 bp), Ercc1 (146 bp) and Nthl1 (165 bp) 
in addition to Gapdh (127 bp). Sample 1538 was obtained from a 72 year-old male and 
sample 1545 from a 63 year-old female. Again a single band was obtained from each 
sample where the PCR produced a band and only the reactions for Neil1 failed to yield a 
product in either sample (Figure 3.8, lanes 2 and 7). Again, the intensity of the band for 
Gapdh varies between the samples (lanes 1 and 6). Only Neil3 is at a similar intensity in 
both samples (lanes 3 and 8). Ercc1 appears more highly expressed in sample 1545 (lanes 
4 and 9) and Nthl1 is also more pronounced in 1545 (lanes 5 and 10). 
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Figure 3.9. Agarose gel electrophoresis of RT-PCR products of tissue samples 1604T 
& 1610 for Gapdh, Neil1, Neil3, Ercc1 and Nthl1. 
Lane H, Hyperladder 100 bp; lanes 1 & 6, Gapdh; lanes 2 & 7, Neil1; lanes 3 & 8, Neil3; 
lanes 4 & 9, Ercc1; lanes 5 & 10, Nthl1. 
 
In Figure 3.9, cDNA prepared from RNA extracted from samples 1604T and 1610 were 
subjected to RT-PCR for Neil1, Neil3, Ercc1 and Nthl1 in addition to Gapdh. Sample 1604T 
was obtained from a 79 year-old female and sample 1610 from a 59 year-old male. The 
results are similar to those presented in Figure 3.8 in that no band was obtained for Neil1 
(lanes 2 and 7) and that the intensity of the band for Gapdh is different between the two 
samples (lanes 1 and 6). Neil3 is again present as a high intensity band in both samples and 
while Ercc1 is only faintly visible in 1604T, it is more intense in 1610. However, no band 
was obtained for Nthl1 from either tumour sample (lanes 5 and 10). 
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Figure 3.10. Agarose gel electrophoresis of RT-PCR products of tissue samples 1573 
& 1573T for Gapdh, Neil1, Neil3, Ercc1 and Nthl1. 
 
Lane H, Hyperladder 100 bp; lanes 1 & 6, Gapdh; lanes 2 & 7, Neil1; lanes 3 & 8, Neil3; 
lanes 4 & 9, Ercc1; lanes 5 & 10, Nthl1. 
 
In Figure 3.10, cDNA prepared from RNA extracted from samples 1573 and 1573T were 
subjected to RT-PCR for Neil1, Neil3, Ercc1 and Nthl1 in addition to Gapdh. Sample 1573 
was obtained from the colon of a 70 year-old female and sample 1573T also from the colon 
of a 70 year-old female. The results again indicate high expression levels of Neil3 (lanes 3 
and 8) and similar levels of expression of the control gene, Gapdh (lanes 1 and 6). While 
Neil1 is again absent in sample 1573 (lane 2), a band is observed for Neil1 in sample 1573T 
(lane 7). Conversely, Ercc1 expression is observed in sample 1573 (lane 5) but not in 1573T 
(lane 10). Expression of Nthl1 was not observed in either sample (lanes 5 and 10). 
1573 1573T 
102 
 
 
Figure 3.11. Agarose gel electrophoresis of RT-PCR products of tissue samples 1581 
and 1620 for Gapdh, Neil1, Neil3, Ercc1 and Nthl1. 
 
Lane H, Hyperladder 100 bp; lanes 1 & 6, Gapdh; lanes 2 & 7, Neil1; lanes 3 & 8, Neil 3; 
lane 4 & 9, Ercc1; lanes 5 & 10, Nthl1. 
  
In Figure 3.11, cDNA prepared from RNA extracted from samples 1581 and 1620 were 
subjected to RT-PCR for Neil1, Neil3, Ercc1 and Nthl1 in addition to Gapdh. Sample 1581 
was obtained from a 62 year-old female and sample 1620 from the colon of a 65 year-old 
male. In both these samples, Gapdh is an intense band, indicating that there was nothing in 
the PCR mixture inhibiting the reaction (lanes 1 and 6). However, the only other intense 
band observed is that for Nthl1 in 1620 (lane 9). Neil3 is again present in both samples but 
the bands are much reduced in intensity with respect to Gapdh as seen previously (lanes 3 
and 8). No bands for Neil1 or Nthl1 were observed in either sample. 
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Figure 3.12. Agarose gel electrophoresis of RT-PCR products of tissue samples 1580, 
1581T & 1597 for Gapdh, Neil1, Neil3, Ercc1 and Nthl1. 
 
Lane H, Hyperladder 100 bp; lanes 1, 6 & 11, Gapdh; lanes 2, 7 & 12, Neil1; lanes 3, 8 & 
13, Neil3; lanes 4, 9 & 14, Ercc1; lanes 5, 10 & 15, Nthl1. 
 
In Figure 3.12, cDNA prepared from RNA extracted from samples 1580, 1581T and 1597 
were subjected to RT-PCR for Neil1, Neil3, Ercc1 and Nthl1 in addition to Gapdh. Sample 
1580 was obtained from a 69 year-old male, sample 1581T from a 62 year-old female and 
sample 1597 from the caecum of a 54 year-old male. The results are strikingly similar for 
all three samples: Gapdh, Neil3 and Ercc1 PCR products all show a similar pattern of 
intensity while no bands arre observed for Neil1 or Nthl1. 
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Figure 3.13. Agarose gel electrophoresis of RT-PCR products of tissue samples 1626, 
1627 & 1630 for Gapdh, Neil1, Neil3, Ercc1 and Nthl1. 
 
Lane H, Hyperladder 100bp; lanes 1, 6 & 11, Gapdh; lanes 2, 7 & 12, Neil1; lanes 3, 8 & 
13, Neil3; lanes 4, 9 & 14, Ercc1; lanes 5, 10 & 15, Nthl1. 
In Figure 3.13, cDNA prepared from RNA extracted from samples 1626, 1627 and 1630 
were subjected to RT-PCR for Neil1, Neil3, Ercc1 and Nthl1 in addition to Gapdh. Sample 
1626 was obtained from the colon of a 73 year-old female, sample 1627 from a 64 year-
old male and sample 1630 from the colon of a 64 year-old male. As in Figure 3.13, the 
pattern of bands is similar across all the tumour samples with Gapdh, Neil3 and Ercc1 
expressed in all three tumour samples. A faint band for Neil1 is observed in sample 1630 
(lane 12), but Nthl1 is absent from all tumour samples (lanes 5, 10, 15). 
 
3.2.2. Quantitative PCR 
Quantitative PCR (qPCR) is one of the most powerful technologies in molecular biology. 
It is a fluorescent based technique used to measure the level of the mRNA of target genes 
with the aid of fluorescent dye such as SYBR Green 1. By plotting fluorescence against the 
cycle number, an amplification plot that represents the accumulation of product over the 
duration of the PCR reaction was generated. Appropriate normalization is required in qPCR 
to sort out experimental errors that may arise from extraction of RNA and generation of 
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cDNA. Gapdh was used as a reference gene, as it is assumed that its expression level is 
constant in cells. Each run of qPCR has a standard curve that was generated through serial 
dilution of the cDNA. The melting curves are indicators of the purity and specificity of 
primers for target genes as shown in Figure 3.14 to Figure 3.17. 
 
Figure 3.14. Analysis of Gapdh expression in tissue sample 10T. 
 
In Figure 3.14A, each coloured line represents a single PCR reaction of a 10-fold serial 
dilution of the cDNA. The threshold cycle (Ct) was set on the graph at a point where the 
Ct and the log quantity became linear. In this example, the sample reaches the Ct value at 
22 cycles (Figure 3.14A). The linear regression curve (the standard curve for use with 
Gapdh) represents the relation between the Ct cycle and the log quantity and r2 showing a 
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value of 0.768 (Figure 3.14B). The melting curve with a single peak shows that a single 
product is amplified (Figure 3.14C).  
 
Figure 3.15. Analysis of Neil3 expression in tissue sample 10T. 
 
Figure 3.15A, each coloured line represents a single PCR reaction of a 10-fold serial 
dilution of the cDNA. The threshold cycle (Ct) was set on the graph at a point where the 
Ct and the log quantity became linear. In this example, the sample reaches the Ct value at 
26 cycles (Figure 3.15A). The linear regression curve (the standard curve for use with 
Gapdh) represents the relation between the Ct cycle and the log quantity and r2 showing a 
value of 0.645 (Figure 3.15B). The melting curve with a single peak indicatess that a single 
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product is amplified (Figure 3.15C). 
 
 
 
Figure 3.16. Analysis of Ercc1 expression in tissue sample 13N. 
 
In Figure 3.16A each coloured line represents a single PCR reaction of a 10-fold serial 
dilution of the cDNA.The threshold cycle (Ct) was set on the graph at a point where the Ct 
and the log quantity became linear. In this example, the sample reaches the Ct value at 26 
cycles (Figure 3.16A). The linear regression curve (the standard curve for use with Gapdh) 
represents the relation between the Ct cycle and the log quantity and r2 showing a value of 
0.834 (Figure 3.16B). The melting curve with a single peak shows that a single product is 
amplified (Figure 3.16C). 
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Figure 3.17. Analysis of Mlh1 expression in tissue sample 34T. 
 
In Figure 3.17A each coloured line represents a single PCR reaction of a 10-fold serial 
dilution of the cDNA. The threshold cycle (Ct) was set on the graph at a point where the 
Ct and the log quantity became linear. In this example, the sample reaches the Ct value at 
26 cycles (Figure 3.17B). The linear regression curve (the standard curve for use with 
Gapdh) represents the relation between the Ct cycle and the log quantity and r2 showing a 
value of 0.921 (Figure 3.17B). The melting curve with a single peak indicates that a single 
product is amplified (Figure 3.17C). 
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3.2.2.1.  Analysis of the Expression Patterns of Selected DNA Repair Genes in 
Different Colon Cancer Tissues Relative to Normal Colon Tissue. 
Following the RT-PCR experiments detailed in Figure 3.6 to Figure 3.13, which confirmed 
that one band of the correct length was obtained for each primer pair, and the control 
experiments detailed in Figure 3.14 to Figure 3.17, qPCR was carried out, firstly to compare 
gene expression between CRC tumour and matched normal colon tissue (Figure 3.18 to 
Figure 3.19; Table 3.3) and then to compare expression of the selected DNA repair genes 
against that of the control Gapdh (Figure 3.20 to Figure 3.26; Table 3.5). Initially, the 
expression patterns of seven different DNA repair genes, Neil1, Neil2, Neil3, Ogg1, Nthl1, 
Ercc1 and Mlh1 were quantified with Gapdh employed as the housekeeping gene (control; 
Figure 3.18), however, this was reduced due to practical considerations to just three CRC 
relevant target genes from three different DNA repair pathways, BER, NER and MMR: 
Neil3, Ercc1 and Mlh1 (Figure 3.19).  
Results are presented as bar graphs and summarized in two tables, where the fold difference 
in expression is clearly assigned. As the range of fold-increase in gene expression varied 
widely, and in order to show the results in a meaningful way, the y-axis range has also been 
varied between graphs, as it was not possible to show all results using just one axis (Figure 
3.20 to Figure 3.22). Furthermore, the results obtained for the sixteen CRC samples are also 
shown based on the target gene of interest in order to give a better visual appreciation of the 
spread of results obtained (Figure 3.23 to Figure 3.26). 
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Figure 3.18. Gene expression levels of six DNA repair genes in colon tumour tissue 
compared to matched normal tissue 
 
Figure 3.18 shows the gene expression of the DNA glycosylase genes, Neil1, Neil2, Neil3, 
Ogg1 and Nthl1 and the NER gene Ercc1 in colon tumour samples when compared with 
matched normal colon tissue. Overall, there is no clear pattern of expression in the different 
tumour samples, with different genes being most highly expressed in each of the four paired 
samples. For example, in tissue sample pair 1, the expression of Ogg1 was the only gene to 
be induced in the tumour sample with a 14-fold increase. In the other tumour samples 
increased expression of one or more genes was more modest. In tissue pair 2, the expression 
of Neil3 and Ogg1 were induced 2.3- and 3.3-fold respectively, while in tissue pair 3, Neil2 
(4.3-fold) and Ercc1 (3.3-fold) were induced in the tumour sample. In tissue pair 4, Neil2 
(4.3-fold) and Nthl1 (3.0-fold) expression was induced, with Neil1 and Ogg1 just below the 
2.0-fold induction level. 
Following analysis of these results it was decided to focus on the expression of Ercc1, which 
is thought to be a contributing factor in the resistance of colon tumours to oxaliplatin 
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(Sheetharam et al., 2010) and Neil3, as there is increasing evidence from our laboratory and 
others that it too may be involved in the repair of ICLs and therefore resistance to oxaliplatin 
treatment (Martin et al., 2017; Semlow et al., 2016). Finally, the expression of the MMR 
gene Mlh1 was also studied because a lack of MMR and Mlh1 in particular, is often 
associated with CRC (Kheirelseid et al., 2013). 
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Figure 3.19 Gene expression levels of three DNA repair genes in colon tumour tissue 
compared to matched normal tissue 
 
Similar to the results obtained in Figure 3.18, Figure 3.19 shows no clear pattern of gene 
expression in the eight tissue pairs analysed. Neil3 was induced in only two of the sample 
pairs (Pair 11, 8.8-fold; Pair 12 2.7-fold), while expression of Ercc1 was induced in four 
of the eight samples, ranging from 2.1-fold (Pair 12) to 4.3-fold (Pair 9). Mlh1 also showed 
highly variable expression levels with an induction of 27.8-fold observed in Pair 11. None 
of the genes analysed were induced in tissue pairs 8 and 10. 
As no obvious pattern was emerging form these samples, it was decided to obtain fresh 
samples from a biobank in Manchester. For this study, the expression of genes encoding 
proteins likely to be involved in the repair of ICLs (Neil, Neil3, and Ercc1) was studied, 
along with Nthl1, which encodes a DNA glycosylase, the lack of which is known to be a 
risk factor in early onset CRC (Weren et al., 2018). 
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Table 3.3. Summary of the expression patterns of selected DNA repair genes in colon 
tumours versus matched normal colon tissue. 
Samples ≤ 1-fold 1-2 fold 2-10 fold ≥ 10-fold 
Pair 1 Neil1, Neil2, Neil3, Ercc1 & 
Nthl1 
  Ogg1 
Pair 2 Neil1, Neil 2, Ercc1 & Nthl1  Neil3 & Ogg1  
Pair 3 Neil1, Neil3, Ogg1 & Nthl1  Neil2 & Ercc1  
Pair 4 Neil3 & Ercc1 Neil1 & 
Ogg1 
Neil2 & Nthl1  
Pair 5 Neil3 & Mlh1  Ercc1  
Pair 6 Neil3 & Ercc1  Mlh1  
Pair 7 Neil3, Ercc1 & Mlh1    
Pair 8 Neil3, Ercc1 & Mlh1    
Pair 9 Neil3 & Mlh1  Ercc1  
Pair 10 Neil3, Ercc1 & Mlh1    
Pair 11   Neil3 & Ercc1 Mlh1 
Pair 12 Mlh1  Neil3 & Ercc1  
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3.2.3.  Analysis of the Expression Patterns of DNA Repair Genes in Different Colon 
Tumour Samples Relative to Gapdh. 
   
   
Figure 3.20. Gene expression levels of four DNA repair genes in biobank colon 
tumour tissue compared to normal colon tissue samples 
 
Table 3.4. Summary of the expression patterns of four selected DNA repair genes in 
colon tumours versus matched normal colon tissue (Biobank samples). 
Samples ≤ 1-fold 1-2 fold 2-10 fold ≥ 10 fold 
Pair 1573 Neil1, Neil3 & 
Nthl1 
  Ercc1 
Pair 1581 Neil3 Neil1 Ercc1 Nthl1 
Pair 1597 Neil1 & Nthl1 Neil3 Ercc1  
Pair 1604 Neil1, Neil3, 
Ercc1 & Nthl1 
   
 
Figure 3.20 and Table 3.4 shows the expression of the DNA repair genes, Neil1, Neil3, Ercc1 
and Nthl1 in colon tumour samples when compared with matched normal colon tissues. It 
should be noted that tissue sample pair 1581 exhibited abnormally high levels of Nthl1 (a 
3436-fold increase) that masks the behaviour of the other genes tested. The results show that 
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the expression of Neil1 did not change substantially between normal and tumour samples, 
with the highest fold difference occurring in tissue pair 1581 (1.3 fold). Similarly, the change 
in Neil3 expression was less than 2-fold in all tissue pairs (0.03 fold in pair 1581). However, 
higher levels of Ercc1 were observed in three out of the four tissue pairs, with a 3.4-fold 
increase being observed for pair 1581, compared with 15.8-fold for 1573 and 4.4-fold for 
pair 1597. With the exception of pair 1581, the expression of Nthl1 did not change 
substantially in the tumour samples. As no obvious pattern is evident, and the scale of fold 
change also differs markedly between samples, Figure 3.23 to Figure 3.26 present the data 
by gene and also where necessary using different scales on the y-axis to present the data 
more clearly. 
   
 
Figure 3.21. Gene expression levels of four DNA repair genes in biobank normal 
colon tissue samples. 
 
In Figure 3.21, three normal colon tissues were examined for the expression of the DNA 
repair genes. Neil1, Neil3, Ercc1 and Nthl1 in comparison with Gapdh. The results show 
that most of the genes were not highly expressed in comparison with Gapdh in the three 
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normal colon tissue samples. The exception was sample 1580 that showed high expression 
of Nthl1 (28-fold). Low level of Ercc1 was also observed in majority of the samples, the 
exception being sample 1580, where expression was 6-fold greater than that of Gapdh. 
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Figure 3.22. Gene expression levels of four DNA repair genes in biobank  colon 
tumour tissue samples. 
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In Figure 3.22, five colon tumour tissues were examined for the expression of the DNA 
repair genes, Neil1, Neil3, Ercc1 and Nthl1 in comparison with Gapdh. The results show 
that, similar to the normal tissue samples, most of the genes were not highly expressed 
relative to Gapdh in most of the five colon tumour samples. The exception is Nthl1, which 
was highly expressed (more than 4-fold) in four out of the five tumour samples and 
abnormally highly expressed in sample 1630. 
 
 
 
 
Figure 3.23. Gene expression levels of Neil1 in sixteen colon tissue samples. 
  Normal tissue samples are shown in blue and tumour samples in red. 
In Figure 3.23, the sixteen colon tissue samples were examined for the comparative 
expression of the DNA repair gene Neil1. In this instance, all of the samples showed higher 
expression levels of Neil1 when compared with Gapdh. However, the range of gene 
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expression varied from 0.0006-fold in sample 1620 (tumour) to 6.2-fold in sample 1573 
(normal). 
 
 
 
Figure 3.24. Gene expression levels of Neil3 in sixteen colon tissue samples. 
  Normal tissue samples are shown in blue and tumour samples in red. 
Figure 3.24 is a representation of the expression of Neil3 DNA repair gene for the sixteen 
colon tissue samples following qPCR analysis. Evidently, the expression of Neil3 gene were 
very low in virtually all the samples except samples 1573 (normal), 1581 (normal) and 1630 
(tumour; 4.3-fold, 36.4-fold and 29.1-fold respectively) which showed high expression of 
Neil3 relative to Gapdh. Clearly there seems to be no substantial increase in the gene 
expression of Neil3 in the colon tumour samples compared with the normal colon tissue. 
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Figure 3.25. Gene expression levels of Ercc1 in sixteen colon tissue samples. 
  Normal tissue samples are shown in blue and tumour samples in red. 
 
The gene expression of Ercc1 was assessed in the sixteen colon tissue samples and is shown 
in Figure 3.25A & B. In all samples, the expression of Ercc1 was higher than that of Gapdh, 
however Figure 3.25A indicates that in ten of the samples the level of expression was less 
than 1-fold greater than Gapdh, and in two others (1597T and 1604), just over one-fold 
greater than Gapdh. On the other hand, Figure 3.25B shows that three samples showed 
relatively high (3 – 6-fold) levels of Ercc1 expression, while one (1573T) had abnormally 
high levels of expression (84-fold). Interestingly, the matched normal colon tissue sample 
of the latter, 1573, had a high expression basal level of Ercc1 (5.3-fold over Gapdh) 
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indicating that expression levels of Nthl1 in this patient were elevated compared with the 
majority of patient samples. 
 
 
Figure 3.26. Gene expression levels of Nthl1 in sixteen colon tissue samples. 
  Normal tissue samples are shown in blue and tumour samples in red. 
 
In Figure 3.26, sixteen colon tissue samples were examined for the comparative expression 
of the DNA damage repair gene, Nthl1. Again, gene expression of Nthl1 is very 
heterogeneous across samples and, with the exception of 1630 (tumour), higher expression 
levels are observed in both normal and tumour samples. 
 
The gene expression data for the sixteen colon tissue samples is summarized in Table 3.5. 
From Table 3.5 it can be seen that the expression of Nthl1 is most frequently highly 
expressed in cells of the colon, but that this can occur in normal cells as well as tumour cells. 
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Similarly, Ercc1 was moderately highly expressed (>2 fold) in four tissue samples, but this 
was split 50:50 between normal and tumour samples. Thus overall, the data in Table 3.5 
does not indicate any increased expression of any of the four DNA repair genes tested in a 
tumour – specific manner. 
Table 3.5 Summary of the expression patterns of DNA repair genes for the sixteen 
colon tissue samples obtained from the biobank. Figures represent fold difference to 
the expression of Gapdh. 
Sample 
No. 
Status ≤1-fold 1-2 fold  2-10 fold ≥ 10 fold 
1538 Normal Neil1, 
Neil3 & 
Ercc1 
   Nthl1 
1545 Normal Neil1, 
Neil3 & 
Ercc1 
Nthl1    
1573 Normal    Neil1, Neil3 
& Ercc1 
Nthl1 
1580 Normal Neil3 Neil1  Ercc1 Nthl1 
1581 Normal Neil1, 
Ercc1 & 
Nthl1 
   Neil3 
1597 Normal Neil1, 
Neil3 & 
Ercc1 
   Nthl1 
1604 Normal Neil1 & 
Neil3 
Ercc1  Nthl1  
1573T Tumour Neil3 Neil1   Ercc1 & 
Nthl1 
1581T Tumour Neil1 & 
Neil3 
  Ercc1 Nthl1 
1597T Tumour Neil1 & 
Neil3 
Ercc1  Nthl1  
1604T Tumour Neil1, 
Neil3 & 
Ercc1 
Nthl1    
1610 Tumour Neil1, 
Neil3 & 
Ercc1 
   Nthl1 
1620 Tumour Neil1, 
Neil3, 
Ercc1 & 
Nthl1 
    
1626 Tumour Neil3 & 
Ercc1 
  Neil1 Nthl1 
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1627 Tumour Neil1, 
Neil3 & 
Ercc1 
  Nthl1  
1630 Tumour Neil1 & 
Ercc1 
   Neil3 & 
Nthl1   
 
3.3. Medulloblastoma: DAOY Normal and Cisplatin-Resistant Cell Lines. 
Medulloblastoma SHH group DAOY cells were grown in cisplatin as described in 
Section 2.3.2 and the surviving resistant cells used in the following experiments and 
compared with the parental cells. 
 
3.4. Cell Viability Assay on Medulloblastoma cell lines. 
To check that the surviving cells were in fact more resistant to cisplatin than the parental 
cell line, MTT assays were carried out to determine the IC50 values of each cell line for 
cisplatin, oxaliplatin and tert-butyl hydroperoxide, a chemical that induces ROS and 
therefore oxidative DNA damage in the cells. Figure 3.27 shows that the cisplatin-treated 
cells were more resistant to the genotoxic effects of cisplatin, with an IC50 value of 11.6 
µM compared with 3.8 µM for the parental cells (Table 3.6). The result of the MTT assay 
with oxaliplatin was not clear cut and no difference between the cell lines was observed ( 
Figure 3.28). Lastly, the cells were treated with an agent known to induce oxidative stress 
within cells. As NEIL3 has DNA glycosylase activity and is known to be active on oxidized 
pyrimidines (Albelazi et al., 2019), it was thought that if NEIL3 was induced in response 
to cisplatin, the cells may also be more resistant to tert-butyl hydroperoxide, an agent 
known to induce oxidative DNA damage in mammalian cells (Duweb, 2015). Figure 3.29 
shows that this hypothesis was correct and that the cisplatin – resistant cells were also more 
resistant to this oxidizing agent (4.9 and 3.9 µM respectively), giving circumstantial 
evidence at least, that the process of repairing cisplatin lesions in DNA also requires 
proteins involved in removing oxidised (base) damage from DNA. 
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Figure 3.27. Growth response of DAOY normal and cisplatin - resistant cell lines to 
cisplatin. 
 
 
Figure 3.28. Growth response of DAOY normal and cisplatin - resistant cell lines to 
oxaliplatin. 
 
In Figures 3.27 and 3.28, the orange line represents the normal, and the blue line the 
cisplatin - resistant DAOY cell line. 
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Figure 3.29. Growth response of DAOY normal and cisplatin - resistant cell lines to 
tert-butyl hydroperoxide. 
 
The orange line represents the normal, and the blue line the cisplatin - resistant DAOY cell 
line. 
 
Table 3.6. IC50 concentrations for three genotoxic agents used to treat the DAOY cell 
lines. 
Drug Normal (µM) Cisplatin - resistant  
(µM) 
oxaliplatin 25.74 27.34 
cisplatin 3.78 11.61 
tert-butyl hydroperoxide 3.97 4.93 
 
3.4.1. Assessment of Yield and Integrity of RNA Extracted from Medulloblastoma 
DAOY normal and cisplatin - resistant cell lines. 
RNA extraction was performed to assess the yield and integrity of RNA extracted from 
DAOY medulloblastoma cell (normal) & cisplatin-resistant DAOY cells. The aim was to 
establish the quality of the RNA purified from the cell lines. The RNA was extracted and 
separated by agarose gel electrophoresis producing two distinct bands of rRNA (Figure 
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3.30). This confirmed the presence of the intact ribosomal RNA bands (28S &18S) for total 
RNA extracted from the cells which indicated that the mRNA was most likely intact in the 
samples. 
                    
                    
Figure 3.30. Agarose gel electrophoresis of RNA extracted from DAOY 
medulloblastoma cells (Normal & cisplatin - resistant). 
 
Lane H, Hyperladder 1kb; lanes 1 - 4, RNA from DAOY cells; lanes 5 & 6, RNA from 
cisplatin - resistant DAOY cells. 
 
3.4.2. Confirmation of Target Product and Primer Specificity. 
RT-PCR was carried out on cDNA from the two medulloblastoma cell lines using specific 
primers for the target genes. To confirm the primer specificity and ensure that genes of 
interest were amplified, agarose gel electrophoresis of the RT-PCR products was conducted, 
with particular attention to the band size and to ensure only a single product was obtained 
(Figure 3.31). 
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Figure 3.31. Agarose gel electrophoresis of RT-PCR products for Gapdh, Neil3 and 
Ercc1 from DAOY normal and cisplatin-resistant cells. 
 
Lane H, Hyperladder 100 bp; G represents Gapdh (127 bp); N3 represents Neil3 (147 
bp); ER represents Ercc1 (146 bp). 
 
Figure 3.31 shows the PCR products for Gapdh, Neil3 and Ercc1 from four different RNA 
samples from DAOY cells and two different samples of RNA from cisplatin – resistant 
DAOY cells. Clearly, both cell lines express all three genes with inter-sample variation 
evident between the different RNA samples. However, as only one band of the correct size 
was obtained for each sample, the primer pairs and cDNA samples could now be assessed 
by qPCR.  
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3.4.3. Expression pattern of selected DNA repair genes in medulloblastoma DAOY 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32 shows the fold increase in the expression of Neil1, Neil3 and Ercc1 in the 
cisplatin –resistant DAOY cell lines. As the experiment was only performed once and the 
raw data shows a high level of variability, it was decided to present the data in two froms. 
In Figure 3.32A, the means were taken from all three replicates, the -Ct values obtained, 
and the fold change calculated. This clearly shows a more than 14-fold increase in Ercc1 
expression and only about a 2-fold increase in Neil3. However, when the outlying data was 
removed, and the means calculated from the remaining, consistent, figures, the results were 
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Figure 3.32. Increased gene expression levels of Neil1, Neil3 and Ercc1 in cisplatin 
resistant DAOY cell lines. (A) and (B) are representations of the same data, with 
outlyers removed in (B). 
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substantially different (Figure 3.32B). Now, the increase in gene expression for Ercc1 and 
Neil3 is similar, with both showing about a 4-fold increase over that in the control cells. 
However, in both scenarios, the expression of Neil1 is largely unaffected by the chronic 
cisplatin treatment (Figure 3.32). 
Of course, to be confident in the result, the qPCR experiment would have to be repeated, 
however, the results presented in Figure 3.32B do more reflect the western blot results shown 
below (Figure 3.33 and Figure 3.34), where NEIL3 protein does seem to be increased in the 
cisplatin – resistant cells. 
 
3.4.4. Protein Analyses 
Following separation by SDS-PAGE, the proteins were transferred onto PVDF membranes 
and probed with specific antibodies (Figure 3.33 and Figure 3.34). Figure 3.33 shows a 
western blot that has been probed with antibodies specific for NEIL3 and β-actin, as the 
loading control. It is clear that the amount of NEIL3 is greater in the protein samples 
extracted from the cisplatin treated DAOY cells. This correlates with induction of Neil3 gene 
expression observed in Figure 3.32B. However, an induction of ERCC1 was not observed 
by western blot (Figure 3.34) unlike the gene expression levels observed in Figure 3.32. Due 
to time constraints, these experiments were only performed once, and would need to be 
repeated to obtain a definitive answer.          
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Figure 3.33. Western blot analysis of NEIL3 and β-actin in DAOY normal (DAOY N) 
and cisplatin - resistant (DAOY R) cell lines. 
 
 
             
Figure 3.34. Western blot analysis of ERCC1 in DAOY normal and cisplatin - 
resistant (DAOY R) cell lines. 
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3.5. Mesothelioma 
3.5.1. Assessment of Integrity of RNA Extracted from Mesothelioma Cells. 
The Mero25 cell line was cultured as described in Section 2.3.2 and total RNA extracted 
using the Bioline Isolate II kit as described in Section 2.3.5. Figure 3.35 shows that the two 
rRNA bands were consistently obtained from both the Mero25 and putative Mero25 – 
derived cancer stem cells. 
 
Figure 3.35. Agarose gel electrophoresis of RNA extracted from Mero25 cells. 
 
H, Hyperladder (1kb); M25, Mero25 mesothelioma cell line; CS1, cancer stem cell pellet 
1; CS2, cancer stem cell pellet 2; CS3, cancer stem cell pellet 3. 
 
3.5.2. RT-PCR from Mero25 – derived RNA. 
Following first-strand synthesis, the cDNA was subjected to RT-PCR to detect Gapdh, 
Neil3 and Ercc1 gene expression in the Mero25 cells. Figure 3.36 shows that all three genes 
were detected in these cells, with Gapdh showing the highest level of expression (lane 1). 
Following this, RT-PCR was also carried out on cDNA prepared from RNA extracted from 
the putative Mero25 – derived cancer stem cells. Figure 3.37 shows that a very similar 
patteren of gene expression for these three genes was obtained from three independent cell 
pellets of these cells. Mlh1 was also tested for and the cell lines proved to be positive for 
expression of this MMR gene (Figure 3.37, lanes 4, 8 and 12). 
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Figure 3.36. RT-PCR of Gapdh, Neil3, and Ercc1 from Mero25 mesothelioma cells. 
Lane H, Hyperladder 1kb; lane 1, Gapdh, lane 2, Neil3, lane 3 Ercc1. 
 
Figure 3.37. RT-PCR of putative cancer stem cells from Mero25 mesothelioma cells. 
 
Lane H, Hyperladder 1kb; lanes 1, 5, 9, Gapdh, lanes 2, 6, 10, Neil3; lanes 3, 7, 11, 
Ercc1; lanes 4, 8, 12, Mlh1. 
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As the RT-PCR results showed little or no difference in the gene expression of the target 
genes between the parental Mero25 cells and the Mero25 – derived cancer stem cells, it was 
decided to analyse the putative cancer stem cells for their ‘stem cellness’ based on the 
expression of aldehyde dehydrogenase, a well known cancer stem cell marker (Tomita et 
al., 2016). Using a commercial kit and flow cytometry, the results shown in Figure 3.38 
indicate that while cancer stem cells were produced as described in Section 2.3.7, they still 
made up less than 10% (7.4%) of the cell population being analysed. As it was beyond the 
scope of the project to improve the yield of stem cells in the population, or to attempt to 
purify the aldehyde dehydrogenase – expressing cells from the cell population, it was 
decided not to proceed further with this analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38. Flow cytometry analysis of (A) Mero25 and (B) Mero25 - derived cancer 
stem cells. 
 Cells expressing aldehyde dehydrogenase are delimited and shown in blue. 
A 
B 
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3.6. Human Embryonic Stem Cells  
3.6.1. Assessment of RNA Integrity 
An RNA extraction experiment was performed to assess the yield and integrity of RNA 
extracted from human ES cells. The aim was to establish the quality of the RNA purified 
from the cell. The RNA was extracted and analysed by agarose gel electrophoresis. The 
results shown in Figure 3.39 reveal that all extractions produced two distinct bands 
confirming the presence of intact ribosomal RNA (28S and 18S) in the total RNA extracted 
from the cells and indicating that the mRNA component is most likely intact in the samples. 
                
 
Figure 3.39. Agarose gel electrophoresis of RNA extracted from human ES cells. 
 
Lane H, Hyperladder 1kb; lanes 1a - 3b contain RNA purified from three different 
human ES cell pellets, with each sample in duplicate (a and b). 
 
3.6.2. Reverse-transcription PCR. 
RT-PCR was carried out on cDNA prepared from human ES cells using specific primers for 
the target genes. To confirm the primer specificity and ensure that genes of interest were 
amplified, agarose gel electrophoresis of the RT-PCR products was conducted. Five separate 
ES cell pellets were processed and the RT-PCR results for Gapdh, Neil3 and Ercc1 are 
shown in Figure 3.40. The results are extremely consistent and indicate that all three genes 
are expressed by human ES cells. 
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It had been hoped to extend this work to human oocytes as little is known about the DNA 
repair capacity of of these female germ cells (Stringer et al., 2018) and it is becoming 
increasingly important to determine the ability of germ cells to maintain genetic integrity 
and mainitaing fertility as the use of in vitro fertilization continues to rise (IVF more 
popular…., 2019). However, as this was essentially outwith the scope of the project, it was 
decided to focus on the other cancer – related topics described earlier. 
 
          
Figure 3.40. Agarose gel electrophoresis of RT-PCR products of Gapdh, Neil3 and 
Ercc1 from human ES cells. 
 
Lane H, Hyperladder 100 bp; lanes 1, 4, 7, 10 & 13 Gapdh; lanes 2, 5, 8, 11 & 14 Neil3; 
lanes 3, 6, 9, 12 & 15, Ercc1. 
 
 
  
H 
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4.1.  DISCUSSION 
The molecular mechanisms of cancer development, progression, metastasis and resistance 
to therapy revolve around genetic instability. Consequently, sustained DNA damage 
affecting key genes coding for proliferation supporting proteins (oncogenes), anti-
proliferative proteins (tumour suppressor genes) and DNA repair proteins, could enhance 
the acquisition of immortal characteristics leading to tumour development and subsequently 
facilitate chemotherapeutic resistance. Essentially, damage to the DNA molecule that results 
in the loss of function of tumour suppressor genes and the gain of function by proto-
oncogenes is exacerbated by the ablation or dysregulation of DNA repair genes that code 
for proteins to restore the damaged DNA. Ultimately, this results in the development of 
mutant cell clones and the subsequent acquisition of the various hallmarks of cancer 
(Hanahan & Weinberg, 2000; Loeb, 2001). Accordingly, many genes have been identified 
that encode proteins that are directly or indirectly involved in the repair of damaged DNA 
and they have been classified into the major repair pathways previously reviewed (Section 
1.3). Additionally, some of the genes that are responsible for the repair of damaged DNA 
have been further implicated in tumour development and drug resistance in different cancer 
types. For instance, high levels of Ercc1 expression have been reported to result in poor 
survival of CRC patients receiving a combination of oxaliplatin and 5-fluorouracil (Shirota 
et al., 2001). Similarly, high levels of Neil3 have been found in melanoma tumour and 
various cancer cell lines and may also be a resistance factor against oxaliplatin 
chemotherapy (Shinmura et al., 2016; Taylor et al., 2015). 
 
Thus, the primary objective of this project was to determine the gene expression levels of 
specific DNA repair genes in colon cancer tissues. Initially, the focus was on a set of CRC 
tissue and matched normal colon tissue samples that had been stored for some years at -80°C 
at the University of Manchester. However, it soon became clear that despite employing 
several different methods to extract and purify the RNA and the addition of RNase inhibitors 
to the buffers, it was not possible to obtain non-degraded RNA from these samples, as 
determined by the presence of the 28S and 18S rRNA bands (Figure 3.4). The question then 
was, was the RNA already degraded in the frozen tissue samples, either through length of 
storage at -80°C, or inappropriate handling and length of time to freezing at the time of 
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surgery? A further problem with these samples was the lack of information on the patients 
and site of the tumour. Had the results of the gene expression analyses between the tumour 
and normal samples been significantly and reproducibly different, the analysis of the 
samples would still have been worthwhile, but with no clear pattern emerging, a full analysis 
of the data was not possible. 
For these reasons, it was decided to obtain fresh tumour samples from a biobank at a hospital 
in Manchester. These samples had the benefit of not being stored for an extended period 
before RNA extraction and came with some basic patient information (Table 3.2). However, 
these samples were also refractory to RNA extraction and few of the samples showed intact 
28S and 18S rRNA (Figure 3.5A - Figure 3.5D). This was in marked contrast to the RNA 
extraction from cells, where the ribosomal RNA bands were routinely seen following RNA 
extraction (Figure 3.1). Therefore, either much greater care is needed at the point of 
collection at surgery, with rapid snap-freezing of the samples along with the use of reagents 
such as RNase AWAY (Sigma-Aldrich) to pre-treat plasticware and/or more modifications 
need to be made to the RNA extraction procedure in the investigating laboratory. 
In the majority of CRC tissue samples, gene expression levels of the BER DNA glycosylase 
genes Neil1, Neil3, Nthl1, and Ercc1 one part of the XPF/ERCC1 lesion specific 
endonuclease in NER were analysed. These particular DNA repair genes were chosen for 
the following reasons: (i) Neil3 gene expression has been found to be increased in cancer 
cells and in certain metastatic tumours, (ii) Ercc1 expression has been shown to be increased 
following oxaliplatin treatment, a clinically relevant agent used to treat CRC, and (iii) 
ERCC1 and NER are involved in the repair of platinum-based drug – induced DNA damage. 
A lack of NEIL3 has been shown to sensitize mouse cells to the related agent cisplatin 
(Rolseth et al., 2013) and recent reports from two independent laboratories indicate that 
NEIL3 (and NEIL1) can repair ICLs in DNA (Semlow et al., 2016; Martin et al., 2017). As 
the tissue samples were from patients who had not been exposed to oxaliplatin, it was hoped 
that the expression levels of these genes would give some indication of the likely success of 
oxaliplatin treatment with the chance that more than one subset of tumours could be 
identified, albeit with a small number of samples. Nthl1 was also included because high 
expression has also been linked to cisplatin resistance (Guay et al., 2008) and deletion 
mutations lead to a CRC prone syndrome (Weren et al., 2015). 
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Analysis of the results from the matched tissue samples given in Table 3.3 show that most 
of the tumour tissues did not show high increases (< 1-fold increase) in any of the DNA 
repair genes tested. However, there were exceptions and Ercc1 was moderately increased in 
five out of the twelve tissue pairs tested and Neil3 in three. In one tissue pair, Ogg1 was 
highly expressed in the tumour sample (one of three samples tested) and the MMR gene 
Mlh1 in another (one of eight samples tested). Thus, there is no clear pattern of gene 
expression of the target genes and instead the results indicate the heterogeneous nature of 
different tumours and the random nature of mutation accumulation (Loeb, 2001). 
For the sixteen biobank tissue samples, expression of the target genes was based on the 
expression of the housekeeping gene Gapdh (Table 3.5). These tissues were categorized into 
three groups. (i) Four colon tumour tissues with corresponding matched normal colon tissue 
samples (sample pairs 1573, 1581, 1597 and 1604), (ii) Three normal colon tissue samples 
(samples 1538, 1545 and 1580) and, (iii) Five colon tumour samples with no matched 
controls (samples 1610, 1620, 1626, 1627 and 1630). Therefore, it must be assumed that the 
expression of Gapdh was constant between the different tumour samples. Accepting this, 
Table 3.5 and Figure 3.20 – Figure 3.26 again indicate a wide range of gene expression of 
the different DNA repair genes. However, Nthl1 stands out, as it is highly expressed (>10-
fold) in both normal (four out of seven samples) and tumour tissue (five out of nine samples; 
Table 3.5) and moderately expressed (2 – 10-fold) in tumour sample 1627. In contrast, Ercc1 
is highly expressed in only one tumour sample pair (1573) and moderately expressed in 
sample pairs 1581 and 1604 and sample 1580, while Neil3 is highly expressed only in sample 
1630. The expression of Neil1, which has also been shown to resolve ICLs in DNA was also 
analysed in these samples but was the least highly expressed of the four target genes and its 
expression was not substantially increased (>2-fold) in the match paired tumour samples 
analysed (Table 3.3 and Table 3.4). 
These results again indicate the heterogenous nature of CRC with no obvious pattern of gene 
expression emerging. However, the exceptionally high level of Ercc1 expression observed 
in sample pair 1573 (Table 3.4) and perhaps the high level of Neil3 in sample 1630 (Table 
3.5) would suggest a poor response to oxaliplatin treatment. There does not appear to be any 
correlation with site of tumour, or sex and age of patient. However, from another 
perspective, the predominant over-expression of the Nthl1 and to a lesser extent  Neil3 may 
not be unconnected to high levels of ROS, which has been reported to potentiate mutation 
and accumulation of genetic instability in different cancer types including, pancreatic 
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(Vaquero et al., 2004), prostate (Kumar et al., 2008), breast (Hecht et al., 2016) and colon 
(Acharya et al., 2010). 
While the RT-PCR and qPCR results show the expected results, it must be remembered that 
most of the RNA samples appeared degraded, with the exception of samples 1581T and 
1604 (Figure 3.5A and Figure 3.5D), both of which show high Nthl1 expression (Table 3.5). 
Thus, this perhaps does give credence to the overall results and that while overall the mRNA 
pool may be reduced by degradation, the ratio of individual mRNA species has not been 
altered. Therefore, basing the expression levels on an internal control, Gapdh, should give a 
true reflection of the relative amounts of each target gene in the mRNA pool. Going forward, 
it would be interesting to compare the expression of these genes before and after treatment 
with oxaliplatin and to extend the gene expression studies to proteomics and determine the 
level of protein by western blotting. 
The experiments on medulloblastoma cells that had acquired resistance to cisplatin further 
indicated that NEIL3 is involved in the repair of cisplatin and oxidative lesions in DNA 
(Section 3.4). Although the cisplatin – treated cells were indeed more resistant to cisplatin 
and an ROS inducing agent (Figure 3.27& Figure 3.29), it was nevertheless surprising that 
a similar resistance was not observed after treatment with oxaliplatin ( 
Figure 3.28). Good quality RNA was obtained from both DAOY cell lines (Figure 3.30) and 
reproducible results obtained from RT-PCR (Figure 3.31). Unfortunately, however, the data 
obtained from the qPCR experiment for the normal DAOY cells in particular was not of the 
expected quality and there was no time to repeat the experiment as required. Therefore, two 
possible outcomes are given in this thesis (Figure 3.32). In Figure 3.32A, all the triplicates 
were used to calculate a mean and the -Ct values plotted, using Gapdh as the control. 
However, in Figure 3.32B, obvious outliers were removed from the data set before 
calculating the -Ct values. From both calculations, Ercc1 gene expression is induced 
following cisplatin treatment, however, Figure 3.32B shows that Neil3 gene expression is 
also increased following cisplatin treatment. While the experiment would need to be 
repeated to determine which of these outcomes is correct, Figure 3.33 does show an increase 
in NEIL3 protein in the cisplatin – resistant cells. While this could be the result of an increase 
in the stability of the protein, it is likely that even if this is correct, it occurs in conjunction 
with increased gene expression, suggesting that the result shown in Figure 3.32B is likely to 
be correct. However, rather surprisingly, no similar increase in ERCC1 protein was observed 
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in these experiments (Figure 3.32) and therefore this set of experiments needs to be repeated 
to obtain reproducible data. 
Cancer stem cells (CSC) are a slow growing sub-population of a tumour that are intrinsically 
resistant to conventional chemotherapy regimen (Pattabiraman and Weinberg, 2014). Like 
ES cells, CSC are characterized by a capability of self-renewal, i.e. one of the daughter cells 
remains a stem cell. While resistance to radiotherapy and chemotherapy appears to be related 
to the induction of an epithelial-mesenchymal transition that leads to chemoresistance, a 
lower proliferation rate and higher quiescence and an increase in anti-apoptotic signalling 
(Pattabiraman and Weinberg, 2014), in the context of this project, it was thought worthwhile 
to study the gene expression of the DNA repair genes of interest. For these experiments it 
was decided to use a cell line derived from a mesothelioma patient as the model, as these 
were being studied by another group at the University of Salford. 
However, when the initial results of the RT-PCR experiments showed no difference between 
the parental Mero25 cells and the putative CSC population (Figure 3.36 & Figure 3.37), it 
was decided to check the percentage of the latter cell population that showed CSC 
characteristics. This was achieved using a commercial kit to analyse the amount of aldehyde 
dehydrogenase, a well-known CSC marker, in the cell population (Figure 3.38). The results 
indicated that the CSC population was only a minor fraction (7.4%) of the total cell 
population. Therefore, to obtain useful data from this set of experiments would take much 
longer than the time available to obtain the correct conditions to achieve a cell population 
predominantly made up of CSC and this particular project was not taken further. 
As part of a larger project studying the underlying causes of infertility, human ES cells were 
obtained as the first step to studying gene expression of DNA repair genes in human. 
oocytes. As with CSC, ES cells have an unlimited proliferation potential and exhibit a rapid 
cell cycle, due to a shortened G1 phase compared to differentiated cells (Jang et al., 2017). 
Due to their rapid proliferation and role in carrying the genetic information to the next 
generation, it would be assumed that these cells had a generally high expression of DNA 
repair genes to correct DNA damage quickly along with an efficient DNA damage response 
network to remove genetically vulnerable cells from the population. Figure 3.40 shows that 
the expression of Neil3 and Ercc1 was observed in human ES cells. Had time allowed, this 
work would have been extended to study the expression of a larger panel of DNA repair 
genes. However, the ultimate aim of the work was to compare the expression of DNA repair 
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genes in different populations of oocytes, some known to be fertile and some infertile and 
to see if DNA repair capacity could be a useful biomarker of female fertility with regard to 
IVF treatment. 
 
4.2. CONCLUSIONS 
From the results presented in this report, there is no clear pattern of gene expression of the 
target genes and instead the results indicate both the apparent varied basal expression levels 
in normal colon tissue of the DNA repair genes analysed and the heterogeneous nature of 
different tumours, presumably due to the random nature of mutation accumulation (Loeb, 
2001). However, it would still be most interesting to compare the expression of these genes 
before and after treatment with oxaliplatin. If initial results were promising, a whole 
transcriptome approach using RNA-seq would be appropriate, to determine global changes 
in gene expression occurring following chemotherapy. Suitable target genes could then be 
chosen, and the analysis extended to proteomics to determine the level of specific proteins 
by western blotting. 
There is need for the future research to focus on the relationship between the DNA repair 
genes and stage of tumour development. Furthermore, there is a need to analyze the 
expression patterns of DNA repair genes in other tumour types and their characterization as 
a common feature in different cancer types for potential use as biomarkers for cancer 
diagnosis.  
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APPENDIX 
 cDNA of genes showing sites of PCR primers 
1. NEIL1 gene qPCR primers (NM_001256552.1) 
                                                                                                         PCR product size 
                                                                                                                   212bp  
Primers from published work: Shinmura et al., (2004). 
 
RT 1071 S:  AGA AGA TAA GGA CCA AGC TGC  
 
RT 1283 AS: GAT CCC CCT GGA ACC AGA TG  
 
        1 cctttagtgg ctgcagtggc gacgagcgga acggagtgcg ggttcccggg gagggggcgt 
       61 gcaggatcgg gttgtggggg gtgcgctgta gggctaagga gaagatgagc tttggggggc 
      121 cctgaggagg aggggagtca ggattaaccg aggacagggt cgcagcgggg gcatggggag 
      181 gacgggcccg agagcgccgc tcctccccaa aactaggatt tggagcctca cgttctcccg 
      241 caaaacgagc cctgtgggtg ccaggccagg ggcggctccc aggtgtggag ggggcaaggt 
      301 acgggcgtct gccgtcgcta agtgccccct tccacttaag gcacaccttc gcctccgatt 
      361 ccgaaccgcc cggggacaga ggcaagtggc aaagcaggga gggcggagga ctctgccacc 
      421 ctccctcagg atgcctgagg gccccgagct gcacctggcc agccagtttg tgaatgaggc 
      481 ctgcagggcg ctggtgttcg gcggctgcgt ggagaagtcc tctgtcagcc gcaaccctga 
      541 ggtgcccttt gagagcagtg cctaccgcat ctcagcttca gcccgcggca aggagctgcg 
      601 cctgatactg agccctctgc ctggggccca gccccaacag gagccactgg ccctggtctt 
      661 ccgcttcggc atgtccggct cttttcagct ggtgccccgc gaggagctgc cacgccatgc 
      721 ccacctgcgc ttttacacgg ccccgcctgg cccccggctc gccctatgtt tcgtggacat 
      781 ccgccggttc ggccgctggg accttggggg aaagtggcag ccgggccgcg ggccctgtgt 
      841 cttgcaggag taccagcagt tcagggagaa tgtgctacga aacctagcgg ataaggcctt 
      901 tgaccggccc atctgcgagg ccctcctgga ccagaggttc ttcaatggca ttggcaacta 
      961 tctgcgggca gagatcctgt accggctgaa gatccccccc tttgagaagg cccgctcggt 
     1021 cctggaggcc ctgcagcagc acaggccgag cccggagctg accctgagcc agaagataag 
     1081 gaccaagctg cagaatccag acctgctgga gctatgtcac tcagtgccca aggaagtggt 
     1141 ccagttgggg ggcaaaggct acgggtcaga gagcggggag gaggactttg ctgcctttcg 
     1201 agcctggctg cgctgctatg gcatgccagg catgagctcc ctgcaggacc ggcatggccg 
181 
 
     1261 taccatctgg ttccaggggg atcctggacc gttggcaccc aaagggcgca agtcccgcaa 
     1321 aaagaaatcc aaggccacac agctgagtcc tgaggacaga gtggaggacg ctttgcctcc 
     1381 aagcaaggcc ccttccagga cacgaagggc aaagagagac cttcctaaga ggactgcaac 
     1441 ccagcggcct gaggggacca gcctccagca ggacccagaa gctcccacag tgcccaagaa 
     1501 ggggaggagg aaggggcgac aggcagcctc tggccactgc agaccccgga aggtcaaggc 
     1561 tgacatccca tccttggaac cagaggggac ctcagcctct tagcaggagg ctctccttgc 
     1621 ttgcactcac cctttcttat tgtcttgccc tgcatctggg ggtctgaatt tttgggagca 
     1681 ggcaatatct gaaggtgcaa acaggcccta cggctgttcc ctgcacaact ctcatggttt 
     1741 taattgtacc ccatcttcca catctttaaa gctcatgtga aaaatgctgc atttttaata 
     1801 aactgataca tttgaacttc 
 
2. human NEIL2 
                                                                                                    PCR product size 
                                                                                                            145bp 
Primers from published work: Mandal et al., (2012) 
1291 S: GCCTTAGAAGCTCTAGGCCA 
1436 AS: GCACTCAGGACTGAACCGAG 
 
1 ggggcgtcccctaaggggacggaggccgcatgggccgccgagccgggaaatctccgcccc 
       61 cagctggagcggctgtgcgggctgcgtagcggtgctgggtcgggccgacgtgccacccac 
      121 ccggagccggtgagtgcagccgcccgccctccggtagatctgcggcctggcggagaagtc 
      181 gggaggggacaggaagggagggcgggccccgggccctcctccgtctcagccgcctgcgga 
      241 ggtgctgcccacgcctggaggcccccactgaccctcagacccgcgtctgcgcccctctcc 
      301 ccgcaccccgaggcagagttgggaaagcagtggtcttagaccccccacctcgggcactcg 
      361 gaagagaacggcggagacaacccctcctcttccctggctggcgcagcgccagcctcgagc 
      421 tcctcggtagcccccgggcagggagggccggagggtgggcgcggcatcttcagcgactct 
      481 tcgaagtcccttccgcgtctcatctttcaaggctgttgcagaggcggcttgcttcccacc 
      541 tgtccatctccataaaaatccctaaacgaaacatgcccacgtgtccggagattttcagga 
      601 cttggtgcatttcagatgaaggcttttccagaagcttccccgtagaagaggatcaggcat 
      661 ccaactggttaagggatgccagaagggccgttggtgaggaaatttcaccatttggtctcc 
      721 ccctttgtgggtcagcaggtggtcaagacagggggcagcagtaagaagctacagcccgcc 
182 
 
      781 agcctgcagtctctgtggctccaggacacccaggtccatggaaagaaattattccttaga 
      841 tttgatctagatgaagaaatggggccccctggcagcagcccaacaccagagcctccacaa 
      901 aaagaagtgcagaaggaaggggctgcggacccaaagcaggtcggggagcccagcgggcag 
      961 aagacccttgatggatcctcacggtctgcagagctcgtcccccagggcgaggatgattct 
     1021 gagtatttggagagagacgcccctgcaggagatgctgggaggtggctgcgtgtcagcttt 
     1081 ggtttgtttggcagcgtttgggtgaacgatttctccagagccaagaaagccaacaagagg 
     1141 ggggactggagggacccttccccgaggttggtcctgcactttggtggtggtggcttcctg 
     1201 gcattttataattgtcagttgtcttggagctcttccccagtggtcacacccacctgtgac 
     1261 atcctgtctgagaagttccatcgaggacaagccttagaagctctaggccaggctcagcct 
     1321 gtctgctatacactgctggaccagagatacttctcagggctagggaacatcattaagaat 
     1381 gaagccttgtacagagctgggatccatcccctttctctcggttcagtcctgagtgcctcg 
     1441 cgtcgggaggtcctggtggatcacgtggtggagttcagtacagcctggctgcagggcaag 
     1501 ttccaaggcagaccgcagcacacacaggtctaccagaaagaacagtgccctgctggccac 
     1561 caggtcatgaaggaggcgtttgggcccgaagatgggttacagaggctcacctggtggtgc 
     1621 ccgcagtgccagccccagttgtcagaggagccagagcagtgccagttctcctaaggagct 
     1681 ggtggtgctcctcacggaaccttgccgcttggggaacctgacgtctaagtgtccagaaag 
     1741 gaggatgtgggcagggacggggtacagaggatagtgtgggtcagaggtgccagtagtata 
     1801 atattcgtctccctggagttatgttgaaggcagagttttcatagggttagatttttttta 
     1861 tccttttctagttcagttaattcatcctgttgaattgcaccatcgtgaaagatgggaaaa 
     1921 atcgtgatgatgggtaaggggaaaacttcccggaaggcaatggggcaaggaaaaagaaag 
     1981 cctatgggaaatggctgtgctcccaacatagctttgcagatgatgtgggttttttttttt 
     2041 tttttggttgtttgttttgagagagagtcttgctctgtctccctggctagggtgtggtgg 
     2101 tgtgatcttggctcacggcagccttgccctccctggctcaagcagtcttcatctcagcct 
     2161 ccagagtagctgggactacaggcatgtgatatgatgctcggctgatttttgtttactttt 
     2221 tagagagatggggtcttgccatatttgccaggctggtttgaactcctacaactcaagcat 
     2281 tcctcccaccttggtctcccaaaatgttgggaccacgggtgtgagccaccgcgcccagct 
     2341 agctcctgtgttttgtttttgttttgtaactttggttgatgttaaggccctccattttgg 
     2401 aaagcaggaaaacaggatttttttttttttatcttgttccctggaggatccagggatgag 
     2461 gatagagtggcctgagagcagtgcttggattcagcctcctgctgggtccttctgctggat 
     2521 acaggcaccaagaggcggtcgtggagcagggagctgcgccttcctggggtgcccggtggt 
     2581 gtgtagagaaaagctgcttgtttactccttaagtcaatgtattggtgactgttgatttgt 
     2641 tgaacaattcaggaatcaagggctgtggagaaactccctcatgttgttggcaacaggtga 
2701aacctagagcggtgacatgaaaataaagctcactgttactcgc 
 
183 
 
3. ERCC1 gene qPCR primers (NM_001983.3) 
                                                                                    PCR product size 
 
ERCC1:  884S: CAAAACGGACAGTCAGACCCT      146 
bp 
ERCC1: 1029AS:  TCAAGAAGGGCTCGTGCAG 
Primers from published work:  Seetharam et al., (2010). 
 
1 ccggaagtgc tgcgagccct gggccacgct ggccgtgctg gcagtgggcc gcctcgatcc 
       61 ctctgcagtc tttcccttga ggctccaaga ccagcaggtg aggcctcgcg gcgctgaaac 
      121 cgtgaggccc ggaccacagg ctccagatgg accctgggaa ggacaaagag ggggtgcccc 
      181 agccctcagg gccgccagca aggaagaaat ttgtgatacc cctcgacgag gatgaggtcc 
      241 ctcctggagt ggccaagccc ttattccgat ctacacagag ccttcccact gtggacacct 
      301 cggcccaggc ggcccctcag acctacgccg aatatgccat ctcacagcct ctggaagggg 
      361 ctggggccac gtgccccaca gggtcagagc ccctggcagg agagacgccc aaccaggccc 
      421 tgaaacccgg ggcaaaatcc aacagcatca ttgtgagccc tcggcagagg ggcaatcccg 
      481 tactgaagtt cgtgcgcaat gtgccctggg aatttggcga cgtaattccc gactatgtgc 
      541 tgggccagag cacctgtgcc ctgttcctca gcctccgcta ccacaacctg cacccagact 
      601 acatccatgg gcggctgcag agcctgggga agaacttcgc cttgcgggtc ctgcttgtcc 
      661 aggtggatgt gaaagatccc cagcaggccc tcaaggagct ggctaagatg tgtatcctgg 
      721 ccgactgcac attgatcctc gcctggagcc ccgaggaagc tgggcggtac ctggagacct 
      781 acaaggccta tgagcagaaa ccagcggacc tcctgatgga gaagctagag caggacttcg 
      841 tctcccgggt gactgaatgt ctgaccaccg tgaagtcagt caacaaaacg gacagtcaga 
      901 ccctcctgac cacatttggatctctggaac agctcatcgc cgcatcaaga gaagatctgg 
      961 ccttatgccc aggcctgggc cctcagaaag cccggaggct gtttgatgtc ctgcacgagc 
     1021 ccttcttgaa agtaccctga tgaccccagc tgccaaggaa acccccagtg taataataaa 
     1081 tcgtcctccc aggccaggct cctgctggct gcgctggtgc agtctctggg gagggattct 
     1141 gggggtgtca ccttctggtg gcccaggtgg gcaccttcag ctttctttag ttcctcagtt 
     1201 tcccgggggc agactacaca ggctgctgct gctgctgctt ccgcttcttg tcccggcctg 
     1261 tgggagcctc ctccccagac tctgaattca gtggcggccc tggcatctcc tcttggggca 
     1321 ctgtctctgg catccggctt tcctgactct gcttcttcct cttcttggtg gatcccggag 
     1381 ttgccctggc ttcaggctgt ccctcccctg gcagttcagg ctctagtggc tgaattggct 
     1441 cagtcactgt gtgacctctc tctttcttct tcttcttctt cttggtggat gtgggagctg 
184 
 
     1501 cctgaggctc aaggtcatcc ggcagctcag gccccaccac ctctgtctct ggctccactg 
     1561 tggcatcttg ctgtttttct ttcttcgtct tctttttggg agctgccaga gctgcctggg 
     1621 cctgaggctt cgctccttct ggctgttgag gcgccatggt cccccctggg gactccagag 
     1681 gcttcatctc cggctccact ggctccatcg cctccgtccc tggctccatc attgccatct 
     1741 gtcccttttc ttttttcctc ttcttcgtag ggggcagagg gatggcttcc tccagtggct 
     1801 ccaccttcac ctgtggctga gactcaactg tcaccccctc ctctggctcc atcccttccg 
     1861 tccccttttg cctctttctc tttttggtcg gggacaggac tgtgtcttct agaggctcag 
     1921 tgttaatctg ttcctgcttc actgtcttgt cttctggctc gaaggtttct ttccctttgg 
     1981 gcttcttcct cttcttggtg gtggacggga acagcactcc cagaggctcc agtgtctcca 
     2041 ctgtgggctc tgtccccaca ggccctgctg cctctggttc tttcagctgc tgattttttt 
     2101 tcttcttctt cttccgcaca tccatttctg gcgaccccaa agccatgtcc acctccaggg 
     2161 ccccgtgccc attcactgcc tcctgagtga ctggggcctc tgtcacctgc atctcctttt 
     2221 tcttcttccc tgaggtgagc aggttggggg ccaaggctga cctaggccct gtgactggtg 
     2281 ggttgccccc aaaggcacag aaccgaggcc tcaggccagg agggatctgt ggtgggggac 
     2341 ttgctgggat gggctgcaga gggctccctg acagggattg ctggggaccc tcaaggatcc 
     2401 ttagggtgcc ctggggggct gaggcacagg tgagtccacc tcctgcctcc gttgaggggg 
     2461 ccagcagggt cgcttctcca gcttggggac agctgctgag gactcgatag cggtgccgct 
     2521 tgcctgccaa tttgcccttg acgatctggg agccagagag aggcacatgc cgcccattga 
     2581 agctacagag agaaacaggg agggcagagg cttaagtgga acaggagagg gaaggttttt 
     2641 tgattttttt tttgtttttt tttgagagag tcttgctctg ttgcctaggc tggagtgcag 
     2701 tggcatgatc tcggctcact gcaatgtcca cctcctgggt tcaagcgatt ctcctgcctc 
     2761 agcctctcaa gtagctggga ttacaggcac ctgccaccac gcccagccaa tttttgtatt 
     2821 tttagtagag acaatttcac tatgttggcc aggctggtct tgaactcctg acctcaagtg 
     2881 atctgctcgc ctcggcctcc caaaggatgg gattacaggc accagccact gcgcctggct 
     2941 ggcctctggt ttttaataaa acatgactag agtgactcca tcttaaagtg agtagctagg 
     3001 cacttacaag gttcatgctt atggcctgaa aataaccaca tcccaggctg accaccaatt 
     3061 ataattacag aatatttatg gccatacaga acatgttcca ccaagcctgc agaatgtcca 
     3121 aatgtcctaa gaatgcagcc cccattactt aaatataaca taaatgagca agcttaggtt 
     3181 gcaggattaa tggtcgtgga taacaccaat agcccctacc tttagtgagc ttatctgcac 
     3241 actccaagtt taactatagt tccttatagt ttcttataag tagaaatact aacaaagggc 
     3301 tgtgggtttc tccccctgct ttctgaggac actctctct gtaaaggagt agtttccaat 
     3361 aaacttgttt ctttcactgt gcaaaaaaaa aaaaaaaaaa 
 
 
185 
 
 
4. NTH1 gene qPCR primers (NM_002528.5)                                                                                  
 
                                                                                            PCR product size 
                                                                                            165 bp 
Primers from published work: Goto et al., (2009). 
 
RT        679 S: GATGGCACACCTGGCTATG 
RT        844AS:  CCACAGCTCCCTAGGCAG 
 
1 ggccgcatgg gccgccggga tgtgtagtcc gcaggagtcc ggcatgaccg ccttgagcgc 
       61 gaggatgctg acccggagcc ggagcctggg acccggggct gggccgcggg ggtgtaggga 
      121 ggagcccggg cctctccgga gaagagaggc tgcagcagaa gcgaggaaaa gccacagccc 
      181 cgtgaagcgt ccgcggaaag cacagagact gcgtgtggcc tatgagggct cggacagtga 
      241 gaaaggtgag ggggctgagc ccctcaaggt gccagtctgg gagccccagg actggcagca 
      301 acagctggtc aacatccgtg ccatgaggaa caaaaaggat gcacctgtgg accatctggg 
      361 gactgagcac tgctatgact ccagtgcccc cccaaaggta cgcaggtacc aggtgctgct 
      421 gtcactgatg ctctccagcc aaaccaaaga ccaggtgacg gcgggcgcca tgcagcgact 
      481 gcgggcgcgg ggcctgacgg tggacagcat cctgcagaca gatgatgcca cgctgggcaa 
      541 gctcatctac cccgtcggtt tctggaggag caaggtgaaa tacatcaagc agaccagcgc 
      601 catcctgcag cagcactacg gtggggacat cccagcctct gtggccgagc tggtggcgct 
      661 gccgggtgtt gggcccaaga tggcacacct ggctatggct gtggcctggg gcactgtgtc 
      721 aggcattgca gtggacacgc atgtgcacag aatcgccaac aggctgaggt ggaccaagaa 
      781 ggcaaccaag tccccagagg agacccgcgc cgccctggag gagtggctgc ctagggagct 
      841 gtggcacgag atcaatggac tcttggtggg cttcggccag cagacctgtc tgcctgtgca 
      901 ccctcgctgc cacgcctgcc tcaaccaagc cctctgcccg gccgcccagg gtctctgatg 
      961 gccgcatggc tctggccgag gtgccgctgt ggccaccgtc tgtgaagtgg ctttacgctt 
     1021 caggaagcca cgcctgttga ataaagcttt ggtgtgtttg cagatgg 
 
5. MLH1 gene qPCR primers (NM_000249) 
                    PCR product size 
                                                                                                              66 bp 
Primers from published work: Jensen et al., (2013). 
186 
 
 
RT 2276 S: AGGAGTCGACCCTCTCAGG  
RT 2342 AS: GTCCACTTCCAGGAGTTTGG 
 
1 gaagagaccc agcaacccac agagttgaga aatttgactg gcattcaagc tgtccaatca 
       61 atagctgccg ctgaagggtg gggctggatg gcgtaagcta cagctgaagg aagaacgtga 
      121 gcacgaggca ctgaggtgat tggctgaagg cacttccgtt gagcatctag acgtttcctt 
      181 ggctcttctg gcgccaaaat gtcgttcgtg gcaggggtta ttcggcggct ggacgagaca 
      241 gtggtgaacc gcatcgcggc gggggaagtt atccagcggc cagctaatgc tatcaaagag 
      301 atgattgaga actgtttaga tgcaaaatcc acaagtattc aagtgattgt taaagaggga 
      361 ggcctgaagt tgattcagat ccaagacaat ggcaccggga tcaggaaaga agatctggat 
      421 attgtatgtg aaaggttcac tactagtaaa ctgcagtcct ttgaggattt agccagtatt 
      481 tctacctatg gctttcgagg tgaggctttg gccagcataa gccatgtggc tcatgttact 
      541 attacaacga aaacagctga tggaaagtgt gcatacagag caagttactc agatggaaaa 
      601 ctgaaagccc ctcctaaacc atgtgctggc aatcaaggga cccagatcac gtggaggac 
      661 cttttttaca acatagccac gaggagaaaa gctttaaaaa atccaagtga agaatatggg 
      721 aaaattttgg aagttgttgg caggtattca gtacacaatg caggcattag tttctcagtt 
      781 aaaaaacaag gagagacagt agctgatgtt aggacactac ccaatgcctc aaccgtggac 
      841 aatattcgct ccatctttgg aaatgctgtt agtcgagaac tgatagaaat tggatgtgag 
      901 gataaaaccc tagccttcaa aatgaatggt tacatatcca atgcaaacta ctcagtgaag 
      961 aagtgcatct tcttactctt catcaaccat cgtctggtag aatcaacttc cttgagaaaa 
     1021 gccatagaaa cagtgtatgc agcctatttg cccaaaaaca cacacccatt cctgtacctc 
     1081 agtttagaaa tcagtcccca gaatgtggat gttaatgtgc accccacaaa gcatgaagtt 
     1141 cacttcctgc acgaggagag catcctggag cgggtgcagc agcacatcga gagcaagctc 
     1201 ctgggctcca attcctccag gatgtacttc acccagactt tgctaccagg acttgctggc 
     1261 ccctctgggg agatggttaa atccacaaca agtctgacct cgtcttctac ttctggaagt 
     1321 agtgataagg tctatgccca ccagatggtt cgtacagatt cccgggaaca gaagcttgat 
     1381 gcatttctgc agcctctgag caaacccctg tccagtcagc cccaggccat tgtcacagag 
     1441 gataagacag atatttctag tggcagggct aggcagcaag atgaggagat gcttgaactc 
     1501 ccagcccctg ctgaagtggc tgccaaaaat cagagcttgg agggggatac aacaaagggg 
     1561 acttcagaaa tgtcagagaa gagaggacct acttccagca accccagaaa gagacatcgg 
     1621 gaagattctg atgtggaaat ggtggaagat gattcccgaa aggaaatgac tgcagcttgt 
     1681 accccccgga gaaggatcat taacctcact agtgttttga gtctccagga agaaattaat 
     1741 gagcagggac atgaggttct ccgggagatg ttgcataacc actccttcgt gggctgtgtg 
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     1801 aatcctcagt gggccttggc acagcatcaa accaagttat accttctcaa caccaccaag 
     1861 cttagtgaag aactgttcta ccagatactc atttatgatt ttgccaattt tggtgttctc 
     1921 aggttatcgg agccagcacc gctctttgac cttgccatgc ttgccttaga tagtccagag 
     1981 agtggctgga cagaggaaga tggtcccaaa gaaggacttg ctgaatacat tgttgagttt 
     2041 ctgaagaaga aggctgagat gcttgcagac tatttctctt tggaaattga tgaggaaggg 
     2101 aacctgattg gattacccct tctgattgac aactatgtgc cccctttgga gggactgcct 
     2161 atcttcattc ttcgactagc cactgaggtg aattgggacg aagaaaagga atgttttgaa 
     2221 agcctcagta aagaatgcgc tatgttctat tccatccgga agcagtacat atctgaggag 
     2281 tcgaccctct caggccagca gagtgaagtg cctggctcca ttccaaactc ctggaagtgg 
     2341 actgtggaac acattgtcta taaagccttg cgctcacaca ttctgcctcc taaacatttc 
     2401 acagaagatg gaaatatcct gcagcttgct aacctgcctg atctatacaa agtctttgag 
     2461 aggtgttaaa tatggttatt tatgcactgt gggatgtgtt cttctttctc tgtattccga 
     2521 tacaaagtgt tgtatcaaag tgtgatatac aaagtgtacc aacataagtg ttggtagcac 
     2581 ttaagactta tacttgcctt ctgatagtat tcctttatac acagtggatt gattataaat 
     2641 aaatagatgt gtcttaacat aa 
 
6. OGG1 gene qPCR primers (NM_002542) 
                                                                                                   PCR product size 
RT   1020 S:       AGCAGCTACGAGAGTCCTCA                  137 bp 
 
RT    1156 AS:   CATATGGACATCCACGGGCA   
 
Primers from published work: Santos et al., (2014). 
1 ctacttccgg tggtgctgtg gtctgcccct ggagaaccca gaagaacaca gctgtgcgcg 
       61 cccacaggct ctgggggcgg gagaagataa gtcgcaagga gggggcggga cctacacctc 
      121 aggaaagccg gagaattggg gcacgaagcg gggctttgat gacccgcaaa gggcgaggca 
      181 tgcaggaggt ggaggaatta agtgaaacag ggaaggttgt taaacagcac cgtgtgggcg 
      241 aggccttaag ggtcgtggtc cttgtctggg cggggtcttt gggcgtcgac gaggcctggt 
      301 tctgggtagg cggggctact acggggcggt gcctgctgtg gaaatgcctg cccgcgcgct 
      361 tctgcccagg cgcatggggc atcgtactct agcctccact cctgccctgt gggcctccat 
      421 cccgtgccct cgctctgagc tgcgcctgga cctggttctg ccttctggac aatctttccg 
481 gtggagggag caaagtcctg cacactggag tggtgtacta gcggatcaag tatggacact 
      541 gactcagact gaggagcagc tccactgcac tgtgtaccga ggagacaaga gccaggctag 
      601 caggcccaca ccagacgagc tggaggccgt gcgcaagtac ttccagctag atgttaccct 
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      661 ggctcaactg tatcaccact ggggttccgt ggactcccac ttccaagagg tggctcagaa 
      721 attccaaggt gtgcgactgc tgcgacaaga ccccatcgaa tgccttttct cttttatctg 
      781 ttcctccaac aacaacatcg cccgcatcac tggcatggtg gagcggctgt gccaggcttt 
      841 tggacctcgg ctcatccagc ttgatgatgt cacctaccat ggcttcccca gcctgcaggc 
      901 cctggctggg ccagaggtgg aggctcatct caggaagctg ggcctgggct atcgtgcccg 
      961 ttacgtgagt gccagtgccc gagccatcct ggaagaacag ggcgggctag cctggctgca 
     1021 gcagctacga gagtcctcat atgaggaggc ccacaaggcc ctctgcatcc tgcctggagt 
     1081 gggcaccaaggtggctgact gcatctgcct gatggcccta gacaagcccc aggctgtgcc 
     1141 cgtggatgtc catatgtggc acattgccca acgtgactac agctggcacc ctaccacgtc 
     1201 ccaggcgaag ggaccgagcc cccagaccaa caaggaactg ggaaactttt tccggagcct 
     1261 gtggggacct tatgctggct gggcccaagc ggtgctgttc agtgccgacc tgcgccaatc 
     1321 ccgccatgct caggagccac cagcaaagcg cagaaagggt tccaaagggc cggaaggcta 
     1381 gatggggcac cctggacaaa gaaattcccc aagcaccttc ccctccattc cccacttctc 
     1441 tctccccatc cccacccagt ctcatgttgg ggaggggcct ccctgtgact acctcaaagg 
     1501 ccaggcaccc ccaaatcaag cagtcagttt gcacaacaag atggggtggg ggatattgag 
     1561 ggagacagcg ctaaggatgg ttttatcttc cctttattac aagaaggaac aataaaatag 
     1621 aaacatttgt atggaaaaaa aaaaaaaaaa aa 
 
 
 
 
 
 
 
 
 
 
 
